',6&/2685(
5('$&7('35272&2/

0(',00
08/7,&(17(56,1*/($503+$6(67 8'<72'(7(50,1(7+(()),&$& <)25
7+(&20%,1$7,212)'$5$ 78080$%'$5$3/86'859$/80$%'859$ ',1
68%-(&76:,7+5(/$36('$1'5()5$&725<08/7,3/(0<(/20$5500: +2
+$9(352*5(66('21'$5$:+, /(21$'$5$&217$,1 ,1*5(*,0(1$67 +(
02675(&(1708/7,3/(0<(/20$ 7+(5$3<Â³)86,2100Â´
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 

&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV
7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW
,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

CELGENE PROPRILILILRIETARY INFORMATION,11
:+2+2
+(+(
QRWEHVKDUHGQRWEHVKDUH
FKHUVDQGSDKHUVDQ
HJXOHJXODWLRQVUHDWLRQVU
DORUFDORUFRQWUDRQW
WRFHUWDLQSFHUWDLQS
DLQLQIRUPDLQLQIRUP
W&HOJHQHÂ¶VW&HOJHQHÂ¶V
SULQFLSOHVSULQFLSOHV
H\\VSDFHPVSDFHP
FDWLRQRIFDWLRQRI
QFRQILGHQQFRQILG WLL
DLQLGHQWLILLQLGHQWLI
OVRPD\FRQOVRPD\FR
VLVJHQHUDWLQVLVJHQHUDWL
DWWDFKPHQWVWWDFKPHQ
\RIWKHUHSR\RIWKHUH
XW&HOJHQHYXW&HOJHQHY
WKDWLQIRUPDKDWLQIRUP
DERXWRXUYDERXWRXU
RQDERXW&HDERXW&
QGDWKWWSZQGDWKWWSZ
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 1 MEDI4736-MM- 005 Final: 03 Oct 2016TITLE PAGE
MULTICENTER, SINGLE-ARM, PHASE 2 STUDY TO 
DETERMINE THE EFFICACY FOR THE 
COMBINATION OF DARATUMUMAB (DARA) PLUS 
DURVALUMAB (DURVA) (D2) IN SUBJECTS WITH 
RELAPSED AND REFRACTORY MULTIPLE 
MYELOMA (RRMM) WHO HAVE PROGRESSED ON 
DARA WHILE ON A DARA-CONTAINING REGIMEN 
AS THE MOST RECENT MULTIPLE MYELOMA 
THERAPY. â€œFUSION MM-005â€
PROTOCOL NUMBER: MEDI4736-MM-005
DATE FINAL: 03 Oct 2016
EudraCT NUMBER: 2016-003801-32
IND NUMBER: 127058
SPONSOR NAME/ ADDRESS: Celgene International II SÃ rl
Rue des Moulins 4 2108 Couvet
Switzerland
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or 
consultant for review by you, your staff, and ethics committee/institutional 
review board.  The information contained in this document is regarded as 
confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by 
law or regulations.  Persons to whom the information is disclosed must be 
informed that the information is confidential and may not be further 
disclosed by them.
CCICELGENE PROCOCO
ovided to yovided to y
review by yview by yOPRIETARY INFORMATIONON ON 
IMEN IMEN 
LOMA LOMA 
66-MMMM-005-00
20162016
16-0038016-00380
127058127058
CelgeCelge
RuR
d.  The infd.  The inf
ial and, excl and, ex
ot be discloot be disclo
w or regulator regula
informedinformedOPO
LEELELELELG
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 2 MEDI4736-MM- 005 Final: 03 Oct 2016MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION 
Contact Information: US/Canada/Europe
Name:
Title:
Address: 86 Morris Avenue Summit, NJ 07052
Phone:
E-mail:
Note: The back-up 24-hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for emergency calls.
Back-up 24-hour Global Emergency Contact Call Center: 
CCIPPD
PPD
PPD
PPD
PPD
CELGENE PROPRIETARY INFORMATIONMAMAMARMMAM
bbe used if  used if 
r designee r designee 
INYYI N
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 3 MEDI4736-MM- 005 Final: 03 Oct 2016CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE
{See appended electronic signature page}
Signature of Celgene Therapeutic Area Head dd mmm yyyy
Printed Name of Celgene Therapeutic Area Head and Title
By my signature, I indicate I ha ve reviewed this protocol and find its content to be 
acceptable.  
{See appended electronic signature page}
Signature of Celgene Therapeutic Area Head dd mmm yyyy
Printed Name of Celgene Therapeutic Area Head and Title
By my signature, I indicate I have reviewed this protocol and find its content to be 
acceptable.  
CCIPPD
PPD
CELGENE PROPe Therapeue TherapeOP
, I i, I indicate ndicateiiPRIETARY INFORMATIONMAMARMMMMM
its content tconte
YI NYI NRRRYRYRYRY
a HeadHeadET
NNM
OPR
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 4 MEDI4736-MM- 005 Final: 03 Oct 2016SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator dd mmm yyyy
Printed Name of Site Principal Investigator
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from
Celgene representatives, the Declaratio n of Helsinki, International Council on 
Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations governing the conduct of clinical studies.
CCICELGENE PROPRIETARY INFORMATIONMAMARMMM
s studys study at matyy
, informed nformed
ocedures, iedures, i
national Cnationa
nes, and locs, and lo
TATA
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 5 MEDI4736-MM- 005 Final: 03 Oct 2016COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator dd mmm yyyy
Printed Name of Coordinating Principal Investigator
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
CCICELGENE PROPRIETARARARY INFORMATIONAAMAMA
OR_
plyplwiwiy ththiiiICI
roughout throughout th
AR
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 6 MEDI4736-MM- 005 Final: 03 Oct 2016PROTOCOL SUMMARY
Study Title
MEDI4736-MM-005 (FUSION MM-005):  A Multicenter, Single-arm, Phase 2 Study to 
Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab
(DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) who 
have Progressed on DARA While on a DARA-containing Regimen as the Most Recent MM 
Therapy.
Indication
Relapsed and refractory multiple myeloma (RRMM) after treatment with at least 3 prior anti-
myeloma therapies, including a proteasome inhibitor (PI) and an immunomodulatory drug 
(IMiDÂ®) or after development of double-refractoriness to a both a PI and an IMiD.
!The most recent multiple myeloma (MM) treatment regimen should contain 
daratumumab (DARA) and subjects must have progr essed on DARA while on this 
regimen.
!Induction, bone marrow transplant with or without maintenance therapy is 
considered one regimen
!Refractory is defined as disease that is nonresponsive on therapy, or progresses 
within 60 days of last therapy. Nonresponsive disease is defined as either failure to achieve minimal response or development of progressive disease while on therapy.
!For subjects who received more than 1 regimen containing a PI their disease must be 
refractory to the most recent PI containing regimen.
!For subjects who received more than 1 regimen containing a IMiD their disease must 
be refractory to the most recent IMiD containing regimen
Objectives
Primary: 
!To determine the efficacy of DARA plus durvalumab (DURVA) in subjects with 
RRMM who have progressed on DARA while on a DARA-containing regimen as themost recent MM treatment.
Secondary:
!Determine the safety of DARA plus DURVA in subjects with RRMM who have 
progressed on DARA while on a DARA-containing regimen as the most recent MM treatment.
!Further evaluate the efficacy of the combination of DARA plus DURVA in subjects 
with RRMM who have progressed on DARA while on a DARA-containing regimenas the most recent MM treatment. Key eff icacy measures include  time-to-response
[TTR], duration of response [DOR], progression-free survival [PFS], and overall 
survival [OS].
CCICELGENE PROPRIETARY INFORMATIONantinti--
ydrug drug 
.
d contain d contain 
ARAARA whwhileileFO
ntenance thntenance 
nsive nsive on thth
disease is disease is 
of progressof progress
 regimen cregimen c
taining regaining re
e than 1 regthan 1 re
ent ent IMiDIMiD c
e efficacy oefficacy
have ha pprogrro
nt MM treat MM tr
etermine etermine thth
pprogresserogresse
treatmreatm
!!FuFu
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 7 MEDI4736-MM- 005 Final: 03 Oct 2016!Evaluate the pharmacokinetics (PK) of DARA and DURVA in subjects with RRMM
who have progressed on DARA while on a DARA-containing regimen as the most recent MM treatment.
 
 
 
 
 
 
Study Design
This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the 
combination regimen of DARA plus DURVA (D
2) in subjects with relapsed and refractory 
multiple myeloma after failure of prior therapies containing a PI, immunomodulatory drug and 
DARA. The study will be conducted in 2 parts: Pa rt 1 and Part 2. Part 1 has a 2-stage design 
while Part 2 consists of an expansion phase. Subjects will receive intravenous (IV) DARA at 16 
mg/kg on the same dosing schedule (weekly [Q W], every 2 weeks [Q2W], or every 4 weeks 
[Q4W] of each 28-day treatment cycle) receive d during their last prior therapy containing DARA
at the time of DARA progression.  Dosi ng schedules, for the administration of DARA, may be 
adjusted during the course of the study, as detailed in Section 7.2, provided that the subject has a 
response of stable disease (SD) or better. Subjects will also receive IV DURVA at 1500 mg on Day 2 (Cycle 1) and on Day 1 (Cycles â‰¥ 2) of each 28-day treatment cycle. 
Part 1:
Stage 1
A cohort of 18 subjects will be enrolled to deter mine the safety and preliminary efficacy of
DARA plus DURVA. Once 6 subjects have been enro lled in MEDI4736-MM-005 and 
completed the first treatment cycle in Stage 1 of this study, the enrollment continuity would depend on the availability of additional safety data from the ongoing Phase 2 study 
(MEDI4736-MM-003) of DARA and DURVA in previously DARA-naÃ¯ve subjects.
!If MEDI4736-MM-003 safety data are available and the tolerability profile of DARA 
plus DURVA is determined to be adequate, th en enrollment will continue as planned 
in Stage 1 of MEDI4736-MM-005.
!If safety data are not available in MED I4736-MM-003, enrollment in MEDI4736-
MM-005 will be paused for a review of the safety profile of DARA plus DURVA by 
CCICCI
CELGENE PROPRIETARY INhe efficacyhe efficacy
jects wiects wi ththiir
ning a PI, iing a PI, i mm
11and Partand Pa
jects will reects will r
QQW]W], , everyever
eivivededdurinduri
ng schedulng schedu
dydy, as detail, as de
better. bette SubSub
(Cycles Cycles â‰¥ 2â‰¥ 2
subjects wsubjects w
DURVA. DURVA. 
d the first td the first tFORMATION
d on the avon the av
EDIED4736-736-MM
!!If IfAT
RMAORFONFO
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 8 MEDI4736-MM- 005 Final: 03 Oct 2016a Dose Review Team (DRT), using the data from the first 6 patients. See Section
3.1.1.1.1.
Once the 18 subjects have been enrolled in ME DI4736-MM-005 (end of St age 1), an interim 
analysis for futility purpose will be conducted to determine if the study can proceed to Stage 2.
Stage 2
If 3 or more subjects achieved a response (partial response [PR] or better) out of the 18 
subjects at the end of Stage 1, an additional 32 subjects will be enrolled to evaluate the safety 
and efficacy of DARA plus DURVA.
Part 2: 
Expansion
Upon completion of Part 1, if there are at least 9 subjects who achieved a response (PR or 
better) out of a total of 50 subjects and it is determined by the Sponsor to further confirm the efficacy and safety of DARA plus DURVA, an additional 70 subjects may be enrolled.
An Independent Response Adjudication Committee (IRAC) will be set up for this trial to 
perform an independent assessment of the efficacy data. The IRAC will determine tumor response to therapy and to confirm the time of disease progression (PD) (if disease progressed) at 
scheduled or unscheduled visits for each subject. 
The safety and efficacy of the study will be monitored by an independent Data Monitoring 
Committee (DMC) who are not involved in the trial conduct. The DMC will meet up and review 
study data at pre-specified intervals throughout the tr ial.  At time of the interim analysis, the 
DMC will assess the study data for fut ility. In addition to the DMC review, safety d ata will be 
monitored by the Celgene Medical Monitor and Safety Physician on an ongoing basis throughout 
the study. Should a significant safety issue be identified, the DMC will be convened to make a 
recommendation as to the future conduct of the study.
The study will be conducted globally and in compliance with the International Council on 
Harmonisation (ICH) Good Clinical Practices (GCPs).
Study Population
The study population w ill include subjects with multiple myeloma who have received at least 
3 prior lines of anti-myeloma regimens including a PI and an IMiD, or who are double-refractory 
to a PI and an IMiD. In additi on, eligible subjects must have had progressive disease while on a 
DARA-containing regimen as the most recent MM therapy.
Approximately 120 subjects will be enro lled into this study.
!Part 1, Stage 1: ~18 subjects
!Part 1, Stage 2: ~32 subjects
!Part 2, Expansion: ~70 subjects 
CCIafetafety 
response (response (
toofurther further 
cts mcts m aay y be b
e set up for e set up fo
AC will deAC will de
essission on(PD)(PD
d bybyan indean indey
l conduct. Tl conduct. 
the trial.  Athe trial.  A
additiadditi on ton t
or and Safetr and Safet
sue uebebeidenide
nduct of theduct of th
ballybally andandini
Clinical PraClinical Pra
will will includinclu
i--myelomyelo mama
MiMiDD..In adIn 
aining regiaining regi
imatelymately 12012y
!!ParPar
!!
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 9 MEDI4736-MM- 005 Final: 03 Oct 2016Length of Study
The study will consist of the following consecutive phases: Screening, Treatment, and Follow-
up. The Screening Phase may not exceed a 28-day window prior to start of study treatment 
(Cycle 1 Day 1). Subjects may continue on study  treatment until PD or unacceptable toxicity. All 
subjects will have an End of Treatment (EOT) visit within 7 days after discontinuation of all 
study treatment. Subjects are to return to the study site 28 (+3) days after the EOT visit and 90 
(+3) days after the last dose of DURVA or DARA, whichever is later, for safety follow-up visits.
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol, 
whichever is the later date.
Study Treatments
All subjects will receive: 
!IV DARA at 16 mg/kg starting at the same dosing schedule as their immediate prior 
DARA regimen. (QW, Q2W, or Q4W of each 28-day cycle). The dosing schedule
may be adjusted during the course of the study as outlined in Section 7.2.  
!IV DURVA at 1500 mg on Cycle 1 Day 2/28-day cycle then â‰¥Cycle 2 on Day 1/28-
day cycle
Overview of Key Efficacy Assessments
!Myeloma paraprotein
!Serum immunoglobulins
!Serum free light chains
!Corrected serum calcium
!Percent of plasma cells in the bone marrow 
!Radiographic assessments of lytic bone lesions
!Extramedullary plasmacytoma (EMP) assessments
!Response per the International Myeloma Working Group (IMWG) criteria
Overview of Key Safety Assessments
!Complete physical examination including vital signs
!Clinical laboratory evaluations
!Pregnancy testing (FCBP only; see 
!Electrocardiogram (ECG)
!Concomitant medications and procedures
!Adverse events (AEs) 
CCICELGENE PROPRIETARY INFORMATIONe 
hat is hat is 
ocolocol, , 
s theitheir immr iiii
lee). ). The dThe d o
ned in ed in SectSec
cycycle then cle the
s in the bons in the bo
essments ofessments of
ryry plasmacasmy
e perperththeIntIn
eyeySafety Safety AA
ComCom plete pplete pm
ClinicaClinica
!!PrePre
!!
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 10 MEDI4736-MM- 005 Final: 03 Oct 2016Overview of Key Pharmacokinetic Assessments
!Serum samples will be collected to assay plasma concentrations of DURVA and 
DARA
 
 
 
 
 
 
Other
!
!Eastern Cooperative Oncology Group (ECOG) Performance Status
Statistical Methods
The study will be conducted in 2 parts. 
In Part 1, a 2-stage design is used with 1 interim analysis for futility at the end of Stage 1. 
In Stage 1, 18 subjects will be enrolled and if at least 3 subjects out of 18 achieve a response (PR 
or better) by end of Cycle 3, the study will continue to Stage 2. If there are 2 or less subjects 
who achieved a response out of 18 subjects in Stage 1, the study will be terminated for fut ility 
and will not proceed to Stage 2. 
In Stage 2, an additional 32 subjects will be en rolled.
If it is determined at the end of Part 1 to further evaluate the efficacy and safety of the 
combination regimen of DARA plus DURVA, then up to an additional 70 subjects will be enrolled in Part 2. In total, approximately 120 subjects will be included in this study. 
The primary statistical analysis  will be based on the full analysis set patient population, 
following the intent-to-treat (ITT) principle. For binary endpoints, the observed rate and 2-sided 
exact 95% confidence intervals (CIs) will be provi ded. For time-to-event type of endpoints, 
Kaplan-Meier method will be us ed. The Kaplan-Meier, as well as the median and its 95% CIs 
will be provided. Safety analysis will be based on all subjects who received at least 1 dose ofDARA plus DURVA.
CCICCI
CCI
CELGENE PROPRIETARY INFOformrmance Stan
nalysisnalysis fofor ff
at least 3at least 3 susu
ontontinue toinue to
cts in cts in SStagetage
cts will be cts will be
of Part 1 to of Part 1 to
ARA plus DRA plus D
ximately 12ximately 1
call analysianalysill
entent--toto-treattrea
nfidence infidence in
eier mer methodethod
provided.provided.
RA plRA plMATION
us DUus DUlllMAMARMAORMOR
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 11 MEDI4736-MM- 005 Final: 03 Oct 2016TABLE OF CONTENTS
TITLE PAGE .................................................................................................................1
PROTOCOL SUMMARY .............................................................................................6
1. INTRODUCTION ..................................................................................... 18
1.1. Disease Background .................................................................................. 18
1.2. Compound B ackground ............................................................................. 18
1.2.1. Durvalumab  (MED I4736) .......................................................................... 18
1.2.2. Daratumu mab............................................................................................ 19
1.3. Ration ale ................................................................................................... 21
1.3.1. Study Rationale and Purpos e ..................................................................... 21
1.3.2. Rationale for the Study De sign .................................................................. 23
1.3.3. Rationale for Dose, Schedule and Regimen Selectio n ................................ 24
1.3.3.1. Durvalu mab............................................................................................... 24
1.3.3.2. Daratumu mab............................................................................................ 24
1.3.3.3. Potential for S ynergistic Toxicities ............................................................ 25
2. STUDY OBJECTIVES AND ENDPOINTS .............................................. 27
3. OVERALL STUDY DESIGN ................................................................... 29
3.1. Study De sign............................................................................................. 29
3.1.1. Part 1: Selected  2-Stag e ............................................................................. 29
3.1.1.1. Stage 1....................................................................................................... 29
3.1.1.2. Stage 2....................................................................................................... 30
3.1.1.3. Part 2: E xpansion....................................................................................... 30
3.2. Study Duration for Subj ects....................................................................... 33
3.3. End of Trial ............................................................................................... 33
4. STUDY POPULATION ............................................................................ 34
4.1. Number of Subjects ................................................................................... 34
4.2. Inclusion Criteri a ....................................................................................... 34
4.3. Exclusion Criteri a...................................................................................... 36
5. TABLE OF EVENTS................................................................................ 39
6. PROCEDURES......................................................................................... 45
6.1. Screening P eriod........................................................................................ 45
CCICCI
CELGENE PROPRIETARY INFORMATION99
......2121
................... 212
.........................
..........................
............................
......................
.................
INTSINT ......
...........................
......................
......................
...........................
......................
nsionnsion .........
ratiration fon or Sorfff
of Trialf Trial .....
TUDY POTUDY PO
NumberNumb
InclInc
.3..3.TAR
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 12 MEDI4736-MM- 005 Final: 03 Oct 20166.2. Treatment Pe riod....................................................................................... 47
6.2.1. End of Tr eatment....................................................................................... 48
6.3. Follow-up Period ....................................................................................... 49
6.3.1. Safety Fo llow-up ....................................................................................... 49
6.4. Efficacy Assessments ................................................................................ 50
6.4.1. Laboratory Assessments for Efficacy Parameters ....................................... 50
6.4.2. Bone Marrow Aspiration and/or Biopsy ..................................................... 51
6.4.3. Bone Lesion Assessment ........................................................................... 51
6.4.4. Extramedullary Plasmacy toma Asse ssments .............................................. 52
6.4.5. Assessment of Response ............................................................................ 52
6.4.5.1. Inve stigator Assessment ............................................................................. 52
6.4.5.2. Independent Response Adjudication Committee Assessment ..................... 52
6.5. Pharmacokinetics ....................................................................................... 52
6.5.1. Pharmacokinetics of Durvalumab .............................................................. 53
6.5.2. Pharmacokinetics of Daratumumab ............................................................ 53
6.8. Blood Type, Rh and Indirect Antiglobulin Test (IAT)................................ 54
7. DESCRIPTION OF ST UDY TREATM ENTS........................................... 56
7.1. Description of Investigational Product(s) ................................................... 56
7.1.1. Durvalumab (MEDI4736) .......................................................................... 56
7.1.2. Daratumumab (Darzalex )........................................................................... 57
7.2. Treatment Administration and Schedule .................................................... 57
7.2.1. Treatment Admin istratio n.......................................................................... 57
7.2.1.1. Durvalumab (MEDI4736) .......................................................................... 57
7.2.1.2. Daratumumab (Darzalex )........................................................................... 58
7.2.2. Treatment Schedule ................................................................................... 60
7.2.2.1. Daratumumab Plus Durv alumab Treatment Schedul e ................................ 60
7.2.3. Overdose ................................................................................................... 60
7.2.4. Dose Modifications and Interruptions ........................................................ 60
7.2.4.1. Dose Modification Instructions for Durvalumab ........................................ 61
CCICCI
CELGENE PROPRIETARY INFORMATION1
......5252
.................... 525
..........................
tt............ ......
..........................
..................
.........................
ct Antt Ant iglo
TUDYUD TRT
estestigatigat ioionan
(MEDI4736MEDI4736
umab (Darzumab (Da
ment Admiment Admi
reatment Aatment A
DurvaluDurvalu
2.2. DarDa
.2.2..2.2.
7.2.2.1..2.2.1TARETARIETPRI
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 13 MEDI4736-MM- 005 Final: 03 Oct 20167.2.4.2. Dose Modification Instructions for Daratumumab ...................................... 61
7.3. Treatment Assignment ............................................................................... 62
7.4. Packaging and Labeling ............................................................................. 62
7.5. Investigational Product Accountability and Disposal ................................. 62
7.6. Investigational Product Compliance ........................................................... 62
8. CONCOMITANT MEDICATI ONS AND PROC EDURES ....................... 63
8.1. Permitted Concomitant Med ications and P rocedure s.................................. 63
8.2. Prohibited Concomitant Medications and Procedures ................................. 63
8.3. Required Concomitant Medications and Procedures ................................... 64
9. STATISTICAL CONSIDERATIONS ....................................................... 65
9.1. Overvi ew................................................................................................... 65
9.2. Study Population Definitions ..................................................................... 65
9.2.1. Full Analysis Set Population ...................................................................... 65
9.2.2. Efficacy Evaluable Population ................................................................... 65
9.2.3. Safety  Populat ion....................................................................................... 65
9.2.4. Pharmacokinetic Population ....................................................................... 65
9.3. Sample Size and Po wer Consider ations ...................................................... 65
9.4. Background and Demographic Characteristics ........................................... 66
9.5. Subject Disposition .................................................................................... 66
9.6. Efficacy Analysis ....................................................................................... 67
9.6.1. Primary Efficacy  Endpoi nt......................................................................... 67
9.6.2. Secondary Eff icacy Endpoi nts................................................................... 67
9.7. Safety An alysis.......................................................................................... 67
9.8. Interim An alysis ........................................................................................ 68
9.9. Other T opics.............................................................................................. 68
9.9.1. Pharmacokinetic Analysis .......................................................................... 68
9.10. Study Committees ..................................................................................... 69
9.10.1. Data Monit oring Co mmittee ...................................................................... 69
9.10.2. Independent Review Adjudication Co mmittee ........................................... 69
10. ADVERSE EV ENTS ................................................................................. 70
10.1. Monitoring, Recording and Re porting of Advers e Even ts .......................... 70
10.2. Evaluation of A dverse Events.................................................................... 70
CCICCI
CELGEStudStu
.10.1.10.1 ..GENE PROPRIETARY INFORMATION3
......6464
.................... 656
..........................
..........................
..........................
..................
.........................
..........................
s.........................
aracteristaracterist icic
.......................
.................
pointpoint .........
cycyEndpoinEndpoinyy
sis..............
nalysisnalysis ....
r TopiTopicscs....
harmacokinarmacoki
9.10.2..10.2.LGE
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 14 MEDI4736-MM- 005 Final: 03 Oct 201610.2.1. Se riousness................................................................................................ 70
10.2.2. Severity/I ntensi ty....................................................................................... 72
10.2.3. Caus ality ................................................................................................... 72
10.2.4. Durati on .................................................................................................... 73
10.2.5. Action Taken............................................................................................. 73
10.2.6. Outco me.................................................................................................... 73
10.3. Abnormal Laborat ory Valu es..................................................................... 73
10.4. Pregna ncy.................................................................................................. 73
10.4.1. Females of Childbear ing Potential: ............................................................ 74
10.4.2. Male Subjects ............................................................................................ 74
10.5. Reporting of Serious Adverse Ev ents......................................................... 74
10.5.1. Safety  Querie s ........................................................................................... 75
10.6. Expedited Reporting of Adverse Events ..................................................... 75
10.7. Adverse Events of Special Interest ............................................................. 76
11. DISCONTINUATIONS ............................................................................ 77
11.1. Treatment Discontinuation ......................................................................... 77
11.2. Study Discont inuation ............................................................................... 77
12. EMERGENCY PROCEDURES ................................................................ 78
12.1. Emergency Contact .................................................................................... 78
12.2. Emergency Identification of Investigational Products ................................ 78
13. REGULATORY CONSIDERATIONS ...................................................... 79
13.1. Good Clinical Practice ............................................................................... 79
13.2. Inve stigator Responsibilities ...................................................................... 79
13.3. Subject Information and Informed Consent ................................................ 80
13.4. Confidentiality ........................................................................................... 80
13.5. Protocol A mendments................................................................................ 80
13.6. Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................... 80
13.7. Ongoing Information for Institution al Review Board/ Ethics Co mmittee ... 81
13.8. Termination of the St udy........................................................................... 81
14. DATA HANDLING AND RECORDKEEPING ........................................ 82
14.1. Data/Docu ments ........................................................................................ 82
14.2. Data Management ...................................................................................... 82
CCICELGENE PROPRIETARY INFORMATION3
......7474
.................... 747
..........................
..........................
..........................
..................
.........................
..........................
.........................
.............. ..........
.......................
of InvestInvef ig
NSIDERADERA T
ctcticeice.......
ResponsibiliResponsibil
nformatnforma ioion
dentdent iaialitlityy
rotocoltocol  AmAml
CInstInst ititutiuti
ApprAppr
.7. OO
13.8.3
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 15 MEDI4736-MM- 005 Final: 03 Oct 201614.3. Record Retention ....................................................................................... 82
15. QUALITY CONTROL AND QUALITY ASSURANCE ........................... 84
15.1. Study Monitoring and S ource Data Veri ficatio n......................................... 84
15.2. Audits and Inspections............................................................................... 84
16. PUBLICATIONS ...................................................................................... 85
17. REFERENCES.......................................................................................... 86
18. APPENDICES ........................................................................................... 90
Appendix A: Table of Abbreviations ......................................................................... 90
Appendix B: International Myeloma Working Group Uniform Response Criteria ...... 95
Appendix C: ECOG Pe rformance S tatus .................................................................... 97
Appendix D: Staging Systems for Multiple Myeloma ................................................ 98
Appendix E: Durvalumab Treatment Modification and Toxicity Management 
Guidelines ................................................................................................. 99
Appendix E-1: Durvalumab Treatment Modification and Toxicity Management 
Guidelines for Immune-related Adverse Events ......................................... 99
Appendix E-2: Durvalumab Treatment Modification and Toxicity Management 
Guidelines for Infusion-related Reactions ................................................ 117
Appendix E-3: Durvalumab Treatment Modification and Toxicity Management 
Guidelines for Non- immune-mediated Reactions ..................................... 118
Appendix F: Guideline for Asthma Eligibility Criteria ............................................. 119
CCI0
......9595
.................... 979
..........................
agement agement 
....................
ity yManagManag
...........................
d Toxicitd Toxic y
.............................
tion and Toion and To
ted Reacted React io
ilitlity Criy Cri terteii
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 16 MEDI4736-MM- 005 Final: 03 Oct 2016LIST OF TABLES
Table 1: Study Objectives ........................................................................................ 27
Table 2: Study Endpoints ........................................................................................ 27
Table 3: Dosing Schedules ...................................................................................... 31
Table 4: Table of Events.......................................................................................... 39
Table 6: Daratumumab Pre Infusion and Post Infusion Medications ........................ 59
Table 7: Conversion Table for Glucocorticoid Dose ................................................ 59
Table 8: Daratumumab-related Toxicity Ma nagemen t ............................................. 61
Table 9: Estimated Overall Response Rate and 95% Confidence Interval Out of 120 
Subjects ..................................................................................................... 66
Table 10: Abbreviations and Specialist Terms ........................................................... 90
Table 11: Staging Systems for Multiple Myeloma ..................................................... 98
CCICCI
CELGENE PROPRIETARY INFORMATION5959
........616
ut of 120 t of 120 
............................
............. .......
.............. .......
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 17 MEDI4736-MM- 005 Final: 03 Oct 2016LIST OF FIGURES
Figure 1: Mechanism of Action for Durvalumab ....................................................... 19
Figure 2: Mechanisms of Daratumumab Activity ...................................................... 20
Figure 3: Overall Study Design ................................................................................. 32
Figure 4: Study Schematic ........................................................................................ 33
CCICELGENE PROPRIETARY INFORMATION
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 18 MEDI4736-MM- 005 Final: 03 Oct 20161. INTRODUCTION 
1.1. Disease Background 
Multiple myeloma (MM) is a rare and incura ble progressive neoplastic disease that accounts for 
10% of all hematological malignancies. It has been  estimated that 63,700 incident cases and 
79,410 deaths from MM occurred globally in 2013 ( GBD, 2015 ). 
Significant progress has been made in the treatment of MM with various combinations of 
melphalan, prednisone, dexamethasone, doxorubicin, cyclophosphamide, etoposide, cisplatin, 
immunomodulatory agents (thalidomide, lenalidomide and pomalidomide), and proteasome 
inhibitors (eg, bortezomib, carfilzomib, and ixazomab) or with autologous stem cell transplant following high-dose chemotherapy and more recently monoclonal antibodies (eg, daratumumab, 
elotuzumab) ( National Comprehensive Cancer Network [NCCN]-MM Guidelines, 2016 ). The 
main considerations for choosing an appropriate treatment for relapsed and refractory multiple myeloma (RRMM) are: risk level, prior therapy, dur ation of response to prior therapy, residual 
toxicity, age, physical condition, and whether the patient is a candidate for stem cell 
transplantation ( NCCN-MM Guidelines, 2016 ). 
Despite the progress in treatment options for MM, the disease follows a relapsing course in the 
majority of patients, regardless of treatment regimen or initial response to treatment. Multiple 
myeloma remains incurable using conventional treatments, with an overall 5-year relative survival rate of 48.5% ( Howlader, 2016 ). New therapies are needed to treat RRMM patients.
1.2. Compound Background 
1.2.1. Durvalumab (MEDI4736)
Durvalumab (MEDI4736; DURVA) is a human  immunoglobulin (Ig) G1 kappa monoclonal 
antibody (mAb) directed against human  programmed death ligand-1 (PD-L1) protein. 
Durvalumab is expressed in Chinese hamster ovary cells and has an overall molecular weight of approximately 149 kDa. Durvalumab selectively binds human PD-L1 with high affinity and 
blocks its ability to bind to programmed cell death 1 (PD-1) protein and cluster of differentiation 
(CD)80. The fragment crystallizable (Fc) domain of DURVA contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component 
C1q and the Fc gamma receptors responsible for mediating antibody-dependent cell-mediated 
cytotoxicity (ADCC) ( Oganesyan, 2008 ).
CCICELGENE PROPRIETARY INFORMATION,,
me me
nsplant nsplant 
ratumumabratumumab
s,20162016 ). Th). T
fractoryactory mmy um
or therapyor therapy
or stem cellr stem
ows a relapws a rela
response torespons
with an ovewith an ove
are neededre need
human immhuman imm
n programmn program
e hamster ohamster 
umab selectumab selec
ogrammed ogrammed
stallizable (allizable 
IgG1 heavyIgG1 heav
ma receptorma recepto
CC) C) ((OganeOgane
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 19 MEDI4736-MM- 005 Final: 03 Oct 2016Figure 1: Mechanism of Action for Durvalumab
Refer to the DURVA Investigatorâ€™s Brochure (IB) for detailed information concerning the 
available pharmacology, toxico logy, drug metabolism, clinical studies, and adverse event (AE) 
profile of the investigational product (IP).
1.2.2. Daratumumab
Daratumumab (DARA) is a human IgG1 kmonoclonal antibody that binds w ith high affinity to a 
unique epitope on CD38. It is a targeted immunotherapy that attacks tumor cells that overexpress CD38, a transmembrane glycoprotein, in a variety of hematological malignancies including 
multiple myeloma. Daratumumab was approved under the accelerated approval regulations in the 
United States (US) on 16 November 2015, and in the European Union (EU) on 24 May 2016, for 
the treatment of patients with multiple myeloma who have received at least three prior lines of 
therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are 
double-refractory to a PI and an immunomodulatory agent.
Daratumumab induces tumor cell death through diverse mechanisms of action, which include 
complement-dependent cytotoxicity (CDC), antibody dependent cell-mediated cytotoxicity
(ADCC), antibody-dependent cellular phagocytosis, and induction of apoptosis ( de Weers, 2011; 
Lammerts van Bueren, 2014; Overdijk, 2015; Jansen 2012 ).  
CCICELGENE PROPRIETARfor detailed or detaile
lism, clinilism, clini
gG1gG1 kkmomono
argeted immrgeted im
protein, in rotein, in 
mumab was umab wa
NovNovemberem
nts with munts with mu
a proteasomproteasom
ryyto a PI anto a PI ayy
ab induces ab induces
ment t--dedependpend
C)C), antibod, antibod
mmertsmmertNFORMATION
vanvan

EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 20 MEDI4736-MM- 005 Final: 03 Oct 2016Figure 2: Mechanisms of Daratumumab Activity
Krejcik, 2015
Daratumamab was shown as a single agent, in heavily pretreated patients with relapsed or
relapsed and refractory multiple myeloma, to have an overall response rate of 31% and a median overall survival of 20.1 months ( Usmani, 2016 ). In addition, daratumamab in combination with 
bortezomib and dexamethasone (Vd) as well as RevlimidÂ® and dexamethasone (Rd) have been 
shown to be effective.  The DARA plus Vd (DVd) combination was tested in the CASTOR trial, where 498 patients were randomized between Vd and DVd ( Palumbo, 2016 ). A prespecified 
interim analysis showed that the rate of progression-free survival (PFS) was significantly higher 
in the DVd group than in the control group; the 12-month rate of PFS was 60.7% in the DVdgroup versus 26.9% in Vd group. After a median follo w-up period of 7.4 months, the median 
PFS was not reached in the DVd group and was 7.2 months in the Vd group (hazard ratio for 
progression or death with daratumumab versus control, 0.39; 95% confidence interval (CI), 0.28 
to 0.53; p<0.001). The rate of overall response (ORR) was higher in the DVd group than in the 
Vd group (82.9% versus. 63.2%, p<0.001), as were the rates of very good partial response
(VGPR) or better (59.2% versus. 29.1%, p <0.001) and complete response (CR) or better (19.2% 
versus. 9.0%, p = 0.001).  In the POLLUX trial ( Dimopoulos, 2016 ), the DARA plus Rd (DRd) 
regimen was tested against Rd in a population of 569 patients with at least one prior therapy and 
maintaining sensitivity to RevlimidÂ®. After a median follow-up of 13.5 months, DRd 
significantly improved patientsâ€™ median PFS, with the median PFS in the DRd group being not 
reached, compared with 18.4 months in the Rd arm (p<0.0001), translating to a 63% reduced risk 
of disease progression or death compared with Rd (hazard ratio = 0.3 7; 95% CI 0.27-0.52; 
CCICELGENE PROPRIETARY INFORMATIONnt, int, in heaviln heavi
ma, ma, to haveto hav
manimani , 2016201
Vd)Vd)as welas we
ARA plus ARA plus V
ndomized bdomized
thatththhe rate r
n in the conn in the c
% in% in VdVdgrogr
ached in theched in th
or death wior death w
<0.001). Th0.001). T
oup (82.9%up (82.9%
GPR)GPR) or betor bet
ersusersus . 9.0%. 9.0%
regimen egimen 
aintit

EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 21 MEDI4736-MM- 005 Final: 03 Oct 2016p<0.0001). Similarly, overall survival at 18 months was higher for daratumumab-treated patients: 
86 % for DRd and 76 % for Rd. Daratumumab led to a higher ORR, more than doubling the rate 
of CRs or better: ORR: 93% versus. 76% (p<0.0001), â‰¥ VGPR: 76% versus. 44% (p<0.0001)
and â‰¥ CR: 43% versus. 19% (p<0.0001).  The median duration of response was longer in the 
DRd group (not reached versus. 17.4 months) and the median time to response was shorter (1 
month versus. 1.3 months), 
Refer to the DARA IB for detailed information concerning the available pharmacology, 
toxicology, drug metabolism, clin ical studies, and AE profile; as well as the current US label 
(Darzalexâ„¢Prescribing Information [PI], 2015 ) and Summary of Product Characteristics 
[SmPC] for the EU.
1.3. Rationale
1.3.1. Study Rationale and Purpose
The importance of the immune system in cancer development and progression has been 
recognized during the past decade (Hanahan, 2000 ). Failure of immune surveillance of pre-
neoplastic lesions and micro-metas tases is a key step in cancer development. Chronically 
immunosuppressed individuals show higher rates of cancer. This observation led to the hypothesis that sporadic cancers among immune-com petent individuals are likely to be 
minimally immunogenic, allowing for passive escape from immune surveillance. Recent data 
suggest that this may be an oversimplification. Some sporadic tumors are highly immunogenic, but actively suppress the local immune environment through production of immunosuppressive 
cytokines ( Shields, 2010 ). As such, the local tumor environment is likely a highly dynamic 
environment where most tumors grow and metastasize through adaptive responses that modulate antitumor immunity. The complexity and redundancy of the immune system offers multiple 
targets that may be manipulated to maximize the bodyâ€™s inherent immune response to a tumor. 
Immune response may be augmented by directly  stimulating effector cells, indirectly stimulating 
effectors by augmenting antigen presentation activity or costimulation, or by suppressing 
immunosuppressive factors, cells, or messages ( Monti, 2005 ).
DARA acts through multiple immune effector-medi ated mechanisms, including CDC, ADCC, 
and antibody-dependent cellular phagocytosis.  In addition to direct targeting of CD38+ 
myeloma cells, recently published data suggests an immune stimulating/modulatory role of 
DARA. Increases in CD8+, CD4+ T cell ratios, antiviral responses, and T cell clon ality were all 
observed after DARA treatment in a heavily pr etreated, relapsed, and refractory patient 
population not expect ed to have strong immune responses ( Krejcik, 2015 ). Improved clinical
responses were associated with changes in these parameters. In addition, DARA was shown to deplete regulatory T cells (Tregs) that express high levels of CD38. Reduction of these immune 
suppressive Tregs may promote expansion of cytotoxic CD8+ T cells which could have 
additional anti-tumor effects.  These data sugge st an immune modulatory role of DARA that may 
contribute to its efficacy. ( Krejcik, 2015 ).
The mechanism of resistance to DARA remains to be fully explained, but immune escape by 
upregulation of PD-L1 signaling through PD-1 is hypothesized to contribute to resistance. 
Adding durvalumab, while continuing daratumumab is hypothesized to potentially reverse this 
mechanism of resistance.
CCIssion has besion has b
e surveillansurveilla
lopment. Cpment. C
observatbservat ioi
ndividuals andividual
immune summune 
oradic tumooradic tum
through prothrough pro
r environmr environm
astasize thrstasize th
dundancy odundancy o
mize the bodmize the bo
bydirectdirecy ly y
esentation aentation
s, or messas, or messa
e immunee immun e
ellular phaellular pha
y publishedy publishe
CD8+CD8+ ,,CDCD
ARA treatmARA treatm
t expected expected
were associwere associ
regulregul atoryatory Ty
ressive Tregressive Tr
dititiionalona ananl
contributeontribute
he mhe m
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 22 MEDI4736-MM- 005 Final: 03 Oct 2016Durvalumab (MEDI4736; DURVA) is a human IgG1 kappa mAb directed against human PD-L1
protein. Durvalumab selectively binds human PD-L1 wi th high affinity and blocks its ability to 
bind to PD-1 protein and cluster of differentiation (CD) 80. PD-1 is highly expressed on MM 
patientâ€™s T cells and natural killer (NK) cells; and both plasmacytoid dendritic cells (pDCs) and MM cells express PD-L1. Dysfunctional T cells, NK cells, and functionally defective pDCs 
contribute to the immune suppression in MM ( Chauhan, 2009; Ray, 2015 ). It has been shown 
that pDCs produce T cell and NK cell immune suppression in the MM bone marrow (BM) milieu by engaging immune checkpoints via the PD-L1/PD-1 signaling axis ( Ray, 2015 ). Blockade of 
PD-L1/PD-1 using anti-PD-L1 antibody gener ates MM-specific CD8+ cytotoxic T lymphocyte 
activity, as well as enhances NK-cell-mediated MM cell cytolytic activity. 
As PD-L1-expressing pDCs are increased in MM bone marrow and localize with PD-L1-positive 
MM cells ( Chauhan, 2009 ), PD-L1 expression may c orrelate with progression of disease, with 
highest levels in relapsed or relapsed/refractory MM. Indeed, a recent study showed that PD-L1 expression positively correlates with increased proliferative potential of tumor cells and 
resistance to therapies in MM ( Tamura, 2013 ). Combination treatment of anti-PD-L1 mAb, like
DURVA, with other anti-MM therapies that modulate MM-host immune responses, like DARA 
will potentially enhance both host anti-MM immunity and clinical response and warrant further 
exploration in the relapsed/ refractory population being considered in this study.
The future of successful MM treatment lies in both the development of novel agents targeting the 
MM cells or the bone marrow microenvironment, and the development of rationally based 
combination therapies. As DARA use post approval, either alone, or in combination, increases, it 
is expected that patients who fail DARA-containing regimens will require new therapeutic options.
Targeted immunotherapy based on monoclonal antibodies against relevant tumor antigens has 
not only shown to be feasible, but also an effective approach in treating hematological malignancies. However, treatment options for heavily  treated patients are limited, especially for 
those with disease that is double refractory to a PI and an immunomodulatory drug (IMiDÂ®)
(Laubach, 2016 ). To date, targeting MM cells by a combination-therapy approach has 
demonstrated superior clinical response as compared with that of single agents ( Cavo, 2011 ). In 
theory, combination treatment of anti-PD-L1 mAb,  like DURVA, with other anti-MM therapies 
that modul ate MM-host immune responses, like DAR A, may enhance both host anti-MM 
immunity and clinical response and warrant further exploration in a relapsed/refractory 
population being cons idered in this study.  The impor tance of the PD-L1:PD-1 interaction has 
been recently further substantiated.  In a recen t study, PD-L1â€“expressing myeloma cells treated 
with PD-1 molecules were shown to have induction of drug resistance through activation of the
Akt signaling pathway ( Ishibashi, 2016 ). These results suggest that in the bone marrow
microenvironment, the interaction between PD-L1 on myeloma cells and PD-1 on tumor-specific 
CTLs not only inhibits CTL activity via the PD-1 signaling pathway but also induces drug 
resistance via PD-L1mediated reverse signals.
Current treatments may mitigate, but are unable to completely circumvent, the inherent genomic 
instability and clonal heterogeneity that leads to r ecurrent relapses and ultimately refractory MM.  
In addition, in the era of novel agents, where MM patients are surviving longer, physicians are 
encountering more resistant and atypical relapses . Salvaging such patients becomes particularly 
CCICELGENE PROPRIETARY INFORMATIONyyte 
L11--posipositivetiviii
sease, wisease, wi ththii
wed that PDwed that PD
r cells and r cells and 
ntntii-PDPD-L1L1
ne responsene respon
sponse andponse and
d in this stuin this stu
opment of nopment of
developmenvelopm
her alone, her alone,
regimens wregimens
al antibodieal antibodie
effectfective apive ap
ons for heavns for he
actoryactory to a toyy
ng MM cellg MM ce
response asesponse as
PRnt of ant
EP Rmmune
EPresponse a
NE onsidered in
ENEther subst
GENecules we
GEng pathwa
LGnvironment
ELGs not only
CELsistance vi
Current tCurren
tabb
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 23 MEDI4736-MM- 005 Final: 03 Oct 2016challenging and their prognosis often remains dismal ( Phipps, 2015 ).  There remains an unmet 
need for novel therapies that target different mechanisms of action. 
The principle of overcoming resistance to an agent through continuation of that agent alone or in 
conjunction with the addition of a second agent or combination has been explored more extensively in the area of solid tumors.  In lung cancer, discontinuation of epidermal growth 
factor receptor inhibitors (erlotinib and ge fitinib) for radiographic progression resulted in 
increased rapidity of radiographic progression and onset of symptomatic progression that could be controlled by reinstitution of the same agents ( Riely, 2007 ) with reduction in maximum 
standardized uptake value measurements. In melanoma,  withdrawal of  treatment after isolated 
progression of MAPK inhibitors in preparation for a new clinical trial sometimes led to rapid growth of remaining disease which had been controlled prior to that time point ( Carlino, 2013 ).  
Multiple retrospective and prospective reports have described the clinical benefit potentially 
accruing from continuing particular agents in terms of PFS or overall survival (OS) in breast and colorectal cancers.  Specific examples include continuation of bevacizumab or cetuximab wh ile 
switching to differing chemotherapy regimens in colon cancer ( Masi, 2015; Ciardiello, 2016 ), 
and continuation of trastuzumab beyond progression in breast cancer ( von Minckwitz, 2011; 
Jackish, 2014 ).  
Overcoming resistance and restoring a functional immune- surveillance system requires 
leveraging multiple, complementary mechanisms of action and agents that act in multiple phases of the cancer-immunity cycle. As such, combination immunotherapies that involve various 
phases of the cancerâ€“immunity cycle may enhance the ability to prevent immune escape by 
targeting multiple mechanisms by which tumor cells avoid elimination by the immune system and with synergistic effects that may offer improved efficacy in broader patient populations 
(Morrissey, 2016 ). As CD38 expression is tied to response in patients with prior DARA 
treatment, and loss of CD38 correlates with development of resistance ( Nijhof, 2016 ), it may be
the case that controlling disease after progression with DARA treatment may also require 
continuation of DARA to continue control of sensitive disease clones, with the addition of 
DURVA providing additional therapeutic benefit for control of remaining clones no longer expressing CD38.  
1.3.2. Rationale for the Study Design
The study will be conducted in 2 parts: Part 1 and Part 2. 
Part 1 has a selected 2-stage design, where a limited number of subjects will be enrolled in Stage 
1 to ensure a sufficient efficacy signal is seen prior to enrolling additional subjects in Stage 2.
While durvalumab has been dosed to over 1,910 patients and is currently being evaluated in over 
30 Phase 3 clinical trials and daratumumab has received marketing approval, the combination of
these two agents has not yet been extensively studied. An ongoing Phase 2 clinical study,
MEDI4736-MM-003, is evaluating this two drug combination and is expected to provideevidence of safety and tolerability prior to the init iation of this study. However, if these safety
data to clearly support the expected Phase 2 dose and schedule are not available prior to initiation
of this study, a safety run-in phase will be conducted prior to further enrollment of this study.
Once 6 subjects have been enrolled and completed the first treatment cycle in Stage 1 of this 
study, the enrollment continuity would depend on the availability of safety data from the ongoing 
CCICELGENE PROPRIETARY INFORMATIONed ed 
apid pid
oo, 2013, 2013 ).  ). 
otentially otentially 
OS) in breaOS) in brea
r cetuximar cetuxima
5; Ciardiello Ciardiell
on Minckwon Minck
eillance syseillance sys
nd agents thd agents 
unotherapieotherapi
bilitility y to prto p
avoavoid elimel
ved efficacyed efficac
to responso respons
develodevelo pmpm
gression wgression w
ntrol of senntrol of sen
apeutic beneutic ben
he Se Study tudy D
ducted in 2 pucted in 2 
d 2d 2-stage stage dd
fficient effifficient eff
alumab hasalumab has
e 3 clinical clinica
two agentstwo agents
EDI4736DI4736 --MM
evidence ovidence o
data tata to co 
h
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 24 MEDI4736-MM- 005 Final: 03 Oct 2016Phase 2 study (MEDI4736-MM-003) of DARA and DURVA in previously DARA-naÃ¯ve 
patients. Details are provided in Section 3.1. 
If data are available and the safety profile of DARA plus DURVA has been evaluated as 
tolerable, enrollment in Part 1 Stage 1 will not be paused.
Part 2 will consist of an expansion phase and will be initiated once Part 1 has been completed 
and if a sufficient efficacy signal has been determined by the Sponsor at the end of Part 1, Stage 
2. 
1.3.3. Rationale for Dose, Schedule and Regimen Selection1.3.3.1. Durval umab
Nonclinical safety of DURVA was assessed in  the pivotal Good Laboratory Practice (GLP) 13-
week intravenous (IV) repeat-dose toxicity study in sexually mature cynomolgus monkeys. 
Animals received an IV loading dose of 30, 60 or 200 mg/kg of DURVA on Day 1, followed by 13 weekly IV doses of 15, 30 or 100 mg/kg, resp ectively. Animals were euthanized 3 days after 
the final dose, or after an 8-week treatment-free period. In the majority of animals exposure to 
DURVA and pharmacodynamics (as assessed by serum levels of free soluble PD-L1) were maintained throughout the dosing period. The IV administration of DURVA was not associated 
with any treatment- related effects on any of the endpoints studied (including clinical signs, 
bodyweight s, ophthalmology, safety pharmacology endpoints (electrocardiograms [ECGs], 
respiratory rate, blood pressure and neurologi cal examinations), peripheral blood leukocyte 
counts, clinical pathology parameters or gross and microscopic histopathology). The no observed 
adverse effect level (NOAEL) for DURVA in this study was therefore considered to be the 200/100 mg/kg dose (area under the curve [AUC] = 34,900 Î¼gÂ·d/mL, maximum plasma 
concentration [C
max] of drug = 7,470 Î¼g/mL), the highest dose tested. 
Based on the data from the GLP 3-month toxicit y study in cynomolgus monkeys and the 
resultant safety margins, the Sponsor believes that the safety of these doses is supported by the 
existing nonclinical safety data.
As per the latest IB (Version 9), with data cut off dates of 15 April 2015 to 18 September 2015, 
1,910 subjects have been treated across 30 ongoing DURVA studies, including 20 sponsored 
(6 monotherapy and 14 combination therapy) and 10 collaborative studies. Of the 1,910 
subjects, 1,279 received DURVA monotherapy, 468 received DURVA in combination with other agents, and 163 have been treated with blinded investigational product. No studies have been 
completed or terminated prematurely due to toxicity.
The maximally administered dose of DURVA to humans in clinical trials conducted to date has 
been 20 mg/kg, which is equivalent to the 1500 mg every 4 weeks (Q4W) starting dose proposed 
in study MEDI4736-MM-003.  Doses of DURVA up to  20 mg/kg as monotherapy did not define 
a non tolerated dose.
1.3.3.2. Daratumumab
The DARA dose/schedule will be as per the current approved label in the US ( Darzalex PI ) and 
Summary of Product Characteristics [SmPC] for the EU.
CCICELGENE PROPRIETARY INFORMATIONice (ce (GLPGLP))
us us momonkeynke
n Dayn Day  1, f1, fyy olofff
euthanizeduthani
yyofofyanimalanimaff
ee soee so luluble bl
of oDURVADURV
udied (includied (incl
nts (electros (electr
natnatioions), pens), p
microscopicmicroscop
s study wass study wa
UCC]=]=34,934,9
L), the high), the high
h toxicith toxicit yy
r believes thbelieves
9)9),,wiwiththiiidatda
reated acroated acro
combinatcombinat io
ved ed DURVDURV
ave beenave been trtr
erminatedrminated
mally adminally admin
mg/kg, whmg/kg, w
udyudyMMyEDI4EDI
non tolnon tol erateerat
.3.3.2..3.3.2
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 25 MEDI4736-MM- 005 Final: 03 Oct 20161.3.3.3. Potential for Synergistic Toxicities
There are no completed studies of anti-CD38 combined with PD-1 or PD-L1 inhibitors. These 
molecular targets do not have known mechanistic synergies, although variation in the co-
expression of CD38/PD-1 has been studied as a marker of human immunodeficiency virus (HIV) infection, as a possible sign immune activation ( Vollbrecht, 2010 ).  Related cases of 
pneumonia or interstitial lung disease (ILD) have been reported with DARA (11%) ( Darzalex
PI), targeting CD38, and durvalumab (2%) (DURVA IB), targeting PD-L1. However, infections, 
and specifically pneumonias and ILDs, are well known clinical conditions in MM patients. With 
the exception of infusion-related reactions, the addition of DARA to standard MM treatment 
regimens did not seem to add toxicity to the safety profiles previously reported with these backbone regimens ( Darzalex PI ).  No other known synergistic toxicities are expected with 
DURVA and DARA.
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
CCICCI
PROPRIETARY INFORMATIONh h 
e
with with 
FORNFONFINYI NRY ARYARTAETARIETRIEPRIOPROPROPROEP REPNE ENEGENGELGELGCELCECC
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 26 MEDI4736-MM- 005 Final: 03 Oct 2016 
 
CCICCI
CELGENE PROPRIETARY INFORMATION
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 27 MEDI4736-MM- 005 Final: 03 Oct 20162. STUDY OBJECTIVES AND ENDPOINTS
Table 1: Study Objectives
Primary Objective
The primary objective of the study is to determine the efficacy of daratumumab (DARA) plus
durvalumab (DURVA) in subjects with relapsed and refractory multiple myeloma (RRMM) who have 
progressed on a current treatmen t regimen containing DARA.
Secondary Objective(s)
The secondary objectives are to:
!Determine the safety of DARA plus DURVA in subjects with RRMM who have progressed 
while on a current treatment regimen containing DARA.
!Evaluate additional measures of efficacy of DARA plus DURVA in subjects with RRMM who 
have progressed on a current treatment regimen containing DARA.
!Evaluate the pharmacokinetics (PK) of DARA plus DURVA in subjects with RRMM who
have progressed on a current treatment regimen containing DARA.
 
 
 
 
 
Table 2: Study Endpoints
Endpoint Name Description
Primary Overall response rate (ORR) Tumor response (partial response [PR] or better), and the 
rate of progressive disease (PD) according to the
International Myeloma Working Group (IMWG) UniformResponse Criteria ( Rajkumar, 2011 ).
Secondary Safety Type, frequency, seriousness and severity of adverse
events (AEs), and relationship of AEs to study
treatment
Secondary Time-to-response (TTR) Time from treatment initiation to the first 
documentation of response (PR or greater)
CCICCI
CELGENE PROPRIETARY INFORMATIONATATATAT
e progressedprogresse
ects with RRects with R
bjects with Rbjects with 
RA.RA.MA
YIRY
PREndpointsEndpoin
NaNaNEOverall reOverall reEN
LGecondaryecondaryELTARETAETRIETRIE
OPRROPRO
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 28 MEDI4736-MM- 005 Final: 03 Oct 2016Table 2: Study Endpoints (Continued)
Endpoint Name Description
Secondary Duration o f response (DOR) Time from the first docu mentation of r esponse
(PR or greater) to the first documentation of PD or death, 
whichever is earlier, based on the investigator 
assessments according to the IMWG Uniform Response 
Criteria.
Progression-free survival (PFS)Time from trea tment initiation to the first documentation 
of PD or death from any cause during study, whichever
occurs earlier
Overall survival (OS) Time from treatment initiation to death due to any cause
Secondary Pharmacokinetic (PK)
parametersTypical serum/plasma PK parameters for DURVA and 
DARA, such as maximum observed concentration
(Cmax), area under the concentration-time curve (AUC),
time to maximum concentration (Tmax), terminal
elimination half-life (t1/2), clearance (CL/F), and volume
of distribution (V z/F)
 
 
 
 
 
 
 
  
 
 
CCICCI
CELGENE PROPRIETARY INFORMATIONTtion ion
heveheve rrTTAT
e to any caue to any cauRMforforDUDURRUUUVAV
d dconcentratconcentr
ioon-n-timtimecuc
oon( Tn( Tmamax),),t
clearanceearance (C(R
Y
AR
IE
OP
PR
NE
GGGGELGELLL
CLRYARYTARETAIETRIEPRIPRPP
ENEEN
LLGE
CEL
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 29 MEDI4736-MM- 005 Final: 03 Oct 20163. OVERALL STUDY DESIGN
3.1. Study Design
This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the 
combination regimen of daratumumab plus durvalumab (D2). The study will consist of 2 parts; 
Part 1 has a 2-stage design while Part 2 consists of an expansion phase. Subjects will receive 
intravenous (IV) DARA at 16 mg/kg on the same dosing schedule (weekly [QW], every 2 weeks 
[Q2W]or every 4 weeks [Q4W] of each 28-day cycle) received on their last prior therapy containing DARA. The dosing schedule for DARA may be adjusted during the course of the 
study as outlined in Section 7.2.2.1 . Subjects will also receive IV DURVA at 1500 mg on Day 2 
(Cycle 1) and on Day 1 (Cycles â‰¥ 2) of each 28-day treatment cycle. The dosing schedule is 
outlined in Table 3 .
3.1.1. Part 1: Selected 2-Stage 
3.1.1.1. Stage 1
A cohort of 18 subjects will be enrolled to determine the preliminary efficacy of DARA plus 
DURVA. Once the 18 subjects have been enrolled, an interim analysis for futility purpose will be conducted to determine if the study can proceed to Stage 2.
3.1.1.1.1. Early Safety Monitoring
Once 6 subjects have been enrolled and completed the first treatment cycle in Stage 1 of this 
study, the enrollment continuity would depend on the availability of safety data from the on-
going Phase 2 study (MEDI4736-MM-003) of DARA and DURVA in previously DARA-naÃ¯ve 
patients.
!If MEDI4736-MM-003 safety data are available and the tolerability profile of DARA
plus DURVA has been determined to be adequate, then enrollment will continue as 
planned in Stage 1 without an early safety monitoring review of the data.
!If safety data are not available enrollment in this study will be paused for a review of 
the safety profile of DARA plus DURVA by a Dose Review Team (DRT), using the 
data from the first 6 patients.
âˆƒIf â‰¥ 1 of the first 6 patients experiences a dose-limiting toxicity (DLT) as outlined 
in Section 3.1.1.1.1.1 , the study will be halted for review and a change in the 
dosing regimen may be implemented.
âˆƒThe DRT will consist of the Celgene Medical Monitor, Celgene lead Safety 
Physician, Celgene biostatistician, other Celgene functional area representatives, as appropriate, and site investigator and/ or designees who have enrolled subjects 
to the study.
âˆƒAll available safety and, if applicable, PK/(  and 
preliminary efficacy data will be reviewed and can be considered in the DRTâ€™s 
decisions.
CCICCI CELGENE PROPRIETARY INFORMATIONhe e 
n Day 2 Day 2 
duleuleis is 
y efficacyefficacy oo
alysis for fysis for f
he first treate first tr
the availabthe availab
DARA andDARA an
y y data are data ar
etermined totermined
hout an earhout an e
ot availablot availab
le of DARAof DAR
e fifirst 6 patrst 6 pi
1 of the firsof the firs
SectiSecti onon3.3
dosingdosing regre
âˆƒâˆƒThThe eDD
PPhh
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 30 MEDI4736-MM- 005 Final: 03 Oct 2016âˆƒA DRT meeting w ill be held to review all d ata and make decisions regarding 
continuity of the study. 
3.1.1.1.1.1. Dose-limiting Toxicity
Dose-limiting toxicities (DLTs) may be evalu ated during the DLT evaluation period for the 
initial 6 patients in Part 1 of the study. The DLT evaluation period will be defined as the first 
treatment cycle. Subjects are considered evaluable for assessment of DLT if they:
!Receive at least 1 dose of study tr eatments and experience a DLT 
OR
!Receive 1 dose of DURVA, 4 doses of DARA and complete the safety follow-up 
through the end of the DLT evaluation peri od. 
Grading of DLTs will be according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI CTCAE) Version 4.03.
A DLT will be defined as below:
Hematologic DLT
a. Grade 4 neutropenia observed for greater than 5 days duration
b. Grade 3 neutropenia associated with fever ( â‰¥ 38.5 Â°C) of any duration.
c. Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding, or any 
requirement for platelets transfusion.
d. Any other Grade 4 hematologic toxicity that does not resolve to subjectâ€™s 
pretreatment baseline level within 72 hours
e. Grade 4 anemia, unexplained by underlying disease.
Non-hematologic DLT
a. Any nonhematological toxicity â‰¥ Grade 3 except for alopecia and nausea controlled 
by medical management
b. Any treatment interruption greater than 2 weeks due to an AE.
While the rules for adjudicating DLTs in the context of dose escalation are specified above, an 
AE not listed above may be defined as a DLT after consultation with the Sponsor and 
investigators, based on the emerging safety profile.
3.1.1.2. Stage 2
If 3 or more subjects achieved a response (PR or better) out of the 18 subjects at the end of Stage 
1, an additional 32 subjects will be enrolled to  evaluate the safety and efficacy of DARA plus 
DURVA. 
3.1.1.3. Part 2: Expansion
Upon completion of Part 1, if at least 9 subjects achieve a response (PR or better) out of a total of 
50 subjects and it is determined to further confirm the efficacy and safety of DARA plus 
DURVA, an additional 70 s ubjects may be enrolled. 
CCICELGitiiGENE PROPRIETARY INFORMATIONlow-up w-up 
Terminoermino lolo
ys duratys durat ion
5 Â°C) of an5 Â°C) of an
ocyocytopenitopeniyy a
that does nthat does 
hourshours
nderlying dnderlying d
iicicitytyiiâ‰¥ Graâ‰¥ 
nt
ruption greauption grea
atting DLTsing DLT
y be definedy be defin
n the emern the em
e 2e 2
subjects acsubjects a
onalonal 32 s32 sll
VA. VA. 
.1.1.3..1.1.3.
Upon cUpon c
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 31 MEDI4736-MM- 005 Final: 03 Oct 2016An Independent Response Adjudication Committee (IRAC) will be set up for this trial to review 
study data. The IRAC will determine tumor response to therapy and to confirm the time of 
disease progression (PD) (if disease progressed) at scheduled or unscheduled visits for each 
subject. 
The safety and efficacy of the study will be monitored by an independent Data Monitoring 
Committee (DMC) who are not involved in the trial conduct. The DMC will meet up and review 
study data at pre specified inte rvals throughout the trial. 
In the event that the trial is halted for early safety monitoring, as outlined in Section 3.1.1.1.1 , 
evaluation of the emerging safety data from the initial 6 patients enrolled in Part 1 will be 
performed by the Dose Review Team (DRT).  
Safety data will be monitored by the Celgen e Medical Monitor and Safety Physician on an 
ongoing basis throughout the study. S hould a significant safety issue be identified, the DMC will 
be convened to make a recommendation as to the future conduct of the st udy.
The decision to discontinue a subject, which will not be delayed or refused by the Sponsor, 
remains the responsibility of the treating physic ian. However, prior to discontinuing a subject, 
the Investigator may contact the Medical M onitor and forward appropriate supporting documents 
for review and discussion.
The study will be conducted in compliance wi th the International Council on Harmonisation 
(ICH) of Technical Requirements for Registr ation of Pharmaceu ticals for Human Use/G ood 
Clinical Practice (GCP) and applicable regulatory requirements.
Table 3: Dosing Schedules
IV DURVA 
(Dose: 1500 mg)IV DARA
(Dose: 16 mg/kg)
Cycle 1: Day 2 / 28-day cycle
Cycle â‰¥ 2: Day 1 / 28-day cycleSubjects should start study treatment on the same 
dosing schedule as their last DARA-containing 
regimen (QW, Q2W, or Q4W)
The dosing schedule should be modified, during the 
course of the study, as shown below, provided that the subject has a response of stable disease (SD) or 
better:
QW frequency (Days 1, 8, 15, and 22/ 28-day 
cycle): Weeks 1 to 8 then Q2W Weeks 9 to 24
Q2W frequency (Days 1, 15/ 28-day cycle): Weeks 
1 to 16 then Q4W
Q4W frequency (Day 1/28-day cycle): Week 1
onwards until disease progression
DARA= daratumumab; DURVA=durvalumab; IV= intravenous ly; QW=weekly; Q2W=every 2 weeks; Q4W=every 
4 weeks.
CCICELGENE PROPRIETARY INFORMATIONn on an n on an 
d, the DMCd, the DM
d byd by the Sthe Syy p
discontdiscont inuiinu
opririate supate sup
onal Counconal Coun
rmaceutmaceut icalical
irements.irements.
ETRIPRRR
CER
DARA= dDARA=
weekweek
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 32 MEDI4736-MM- 005 Final: 03 Oct 2016Figure 3: Overall Study Design
CCICELGENE PROPRIETARY INFORMATION

EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 33 MEDI4736-MM- 005 Final: 03 Oct 2016Figure 4: Study Schematic
3.2. Study Duration for Subjects 
The study will consist of the following consecutive phases: Screening, Treatment, and Follow-
up. The Screening Phase may not exceed a 28-da y window prior to start of study treatment 
(Cycle 1 Day 1). Subjects may continue on study treatment until PD or unacceptable toxicity. All 
subjects will have an End of Treatment (EOT) visit within 7 days after discontinuation of all 
study treatment. Subjects are to return to the study site 28 (+3) days after the EOT visit and 90 
(+3) days after the last dose of DURVA or DARA for safety follow-up visits. 
3.3. End of Trial
The End of Trial is defined as either the date of the last visit of the last subject to complete the post-treatment follow-up, or the date of receipt of the last data point from the last subject that is required for primary, secondary and/or exploratory analysis, as pre specified in the protocol, 
whichever is the later date.
CCICELGENE PROPRIETts ts 
onsecutonsecut ivei
eed a eed a 28-2d
tinue on stinue on st
eatment (Eeatment (E
e to return t to return t
se of DUse of D R
TrialTrial
al is definedal is defined
nt fnt fololffATION
loloww-u-u
or primaryprimary
ver ives the lthe l

EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 34 MEDI4736-MM- 005 Final: 03 Oct 20164. STUDY POPULATION
4.1. Number of Subjects 
Up to approximately 120 subjects with RRMM will be enrolled worldwide. 
!Part 1, Stage 1: Up to 18 subjects
!Part 1, Stage 2: Up to 32 subjects
!Part 2, Expansion: Up to 70 subjects
4.2. Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Subject received at least 3 prior anti-myeloma regimens including a PI and an 
immunomodulatory agent or is double-refractory to a PI and an immunomodulatory 
agent. 
!Induction, bone marrow transplant with or without maintenance therapy is 
considered one regimen.
!Refractory is defined as disease that is nonresponsive on therapy, or progresses 
within 60 days of last therapy. Nonresponsive disease is defined as either failure to achieve minimal response or development of progressive disease while on therapy.
!For subjects who received more than 1 regimen containing a PI their disease must be 
refractory to the most recent PI containing regimen.
!For subjects who received more than 1 regimen containing a immunomodulatory 
agent their disease must be refractory to the most recent immunomodulatory agent containing regimen.
2. All subjects must have failed DARA either as a single agent or in combination on last
MM therapy. Failure is defined as PD on DARA either as a single agent or in 
combination.
3. Subject has measurable disease defined as:
a. M-protein (serum protein electrophoresis (sPEP) or urine protein electrophoresis 
(uPEP): sPEP â‰¥0.5 g/dL or uPEP â‰¥ 200 mg/24 hours) and/or 
b. Light chain MM without measurable disease in the serum or the urine: serum 
immunoglobulin free light chain â‰¥10 mg/dL and abnormal serum 
immunoglobulin kappa lambda free light chain ratio
4. Subject achieved a response (minimal res ponse [MR] or better) to at least 1 prior 
treatment regimen.
5. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status score 
of 2 or less.
6. Subjectâ€™s toxicities resulting from previous  therapy (including peripheral neuropathy) 
have resolved or stabilized to â‰¤Grade 1.
CCICELGENE PROPRIETARY INFORMATIONand an nd an 
unomodulaunomodu
enance thernance the
sive ive onntherth
disease is deease is d
f progressivf progress
regimen coregimen co
aining regimaining regim
than 1 regithan 1 regi
fractory to fractory to
ed DARA DARA 
defined as defined as 
urable diseurable di
otein (serutein (seru
PEP): sPEPPEP): sPEP
LiLight chaight cha
immunimmun
immimm
..Subject Subject
treattrea
5..S
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 35 MEDI4736-MM- 005 Final: 03 Oct 20167. Subject is at least 18 years of age at th e time of signing the informed consent form (ICF). 
8. Subject must understand and voluntarily sign an ICF prior to any study-related 
assessments/procedures being conducted. 
9. Subject is willing and able to adhere to the study visit schedule and other protocol 
requirements.
10. Females of childbearing potential (FCBP1) must:
a. Have 2 negative pregnancy tests as verified by the investigator prior to starting 
study treatment. This app lies even if the subject practices true abstinence from 
heterosexual contact.
i. Negative serum pregnancy test at screening 
ii. Negative serum or urine pregnancy test (investigatorâ€™s discretion) within 
72 hours prior to starting study treatment (Cycle 1, Day 1), and before
beginning each subsequent cycle of treatment, and after end of study 
treatment. 
1. Note: Pregnancy testing does not need to be repeated prior to Cycle 1 if the 
serum pregnancy test for screening was performed within 72 hours of the first dose of study treatment.
b. Either practice true abstinence2from heterosexual contact (which must be 
reviewed on a monthly basis and source documented) or agree to use, and be able 
to comply with, effective contraception without interruption (eg, oral, injectable, 
or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier 
contraceptive with spermicide; true abs tinence; or vasectomized partner), 28 days 
prior to starting study treatment, during the study therapy (including dose 
interruptions), and for at least 90 days afte r discontinuation of study treatment. 
c. Agree to abstain from breastfeeding during study participation and for at least 90 
days after the last dose of DARA or DURVA, whichever is later.
d. Refrain from egg cell donation for at least 90 days after the final dose of DURVA 
or DARA, whichever is later.
11. Male subjects must:
a. Either practice true abstinence2(which must be reviewed on a monthly basis) or 
agree to use a condom during sexual contact with a pregnant female or a female 
of childbearing potential while participating in the study, during dose 
interruptions and for at least 90 days following study treatment discontinuation,
even if he has undergone a successful vasectomy. 
b. Refrain from sperm donation for at least 90 days after the final dose of DURVA 
or DARA, whichever is later.
                                               
1A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not 
undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea 
following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had 
menses at any time in the preceding 24 consecutive months).
2True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
CCICE                          CELGENE PROPRIETARY INFORMATIONom m
etion) withetion) with
), and befo), and befo
er end of ster end of st
ated pted p riorior to Cr toooo
med within 7med within 
al contact (wl contact (w
mented) or mented) o
thout interruhout interr
tubal ligattubal ligat i
bstinence; obstinence
uring the sturing the s
0days aftedays afte
feeding durfeeding dur
DARA or DARA or 
donation fordonation fo
er is later.is later.
ce true abse true ab
use a condouse a con
ldbearing pdbearing 
erruptirrupti ons aons a
even if he heven if he h
Refrain Refrain
or DAor DA
CE1A femaleA female
undergunderg
l
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 36 MEDI4736-MM- 005 Final: 03 Oct 20164.3. Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subject has had prior exposure to anti-CTLA-4, anti-PD-1, anti-PD-L1 mAbs, or cancer 
vaccines
2. Subject has received autol ogous stem cell transplantation ( ASCT) within 12 weeks before 
the date of rando mization.
3. History of organ or allogeneic stem cell transplantation
4. Subject received any of the following within the last 14 days of initiating study treatment:
a. Plasmapheresis
b. Major surgery (as defined by the investigator)
c. Radiation therapy other than local th erapy for myeloma associated bone lesions
d. Use of any systemic anti-myeloma drug therapy (except for DARA either alone or in 
combination with other agents given with it)
5. Subject received prior treatment with a monoclonal antibody within 5 half-lives of 
initiating study treatment, other than DARA.
6. Subject is receiving concurrent chemotherap y or biologic or hormonal therapy for cancer 
treatment. Note: Concurrent use of horm ones for noncancer-related conditions (eg, 
insulin for diabetes and hormone replacement therapy) is acceptable.
7. Subject has any of the following laboratory abnormalities:
a. Absolute neutrophil count (ANC) < 1,000/ Î¼L
b. Platelet c ount: < 75,000/ Î¼L (it is not permissible to transfuse a subject to reach 
this level)
c. Hemoglobin < 8 g/dL (< 4.9 mmol/L)(it is not permissible to transfuse a subject 
to reach this level)
d. Creatinine clearance (CrCl) < 45 mL/min (calculated using the Cockcroft-Gault 
formula or directly calculated from  the 24-hour uri ne co llection met hod)
e. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L)
f. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 
Ã— upper limit of normal (ULN)
g. Serum total bilirubin > 1.5 Ã— upper limit of normal (ULN) or > 3.0 mg/dL for 
subjects with documented Gilbertâ€™s syndrome 
8. Subject has clinical evidence of central nervous system (CNS) or pulmonary leukostasis, 
disseminated intravascular coagulation, or CNS MM
9. Subject has known chronic obstructive pulmonary disease (COPD) with a forced 
expiratory volume in 1 second (FEV1) 50% of predicted normal. Note that forced 
expiratory testing (FEV1)is required for subjects suspected of having COPD and subjects must be excluded if FEV1 is < 50% of predicted normal. 
10. Subject has known moderate or severe persistent asthma within the past 2 years (see 
Appendix F ) or uncontrolled asthma of any classification. Note that subjects who 
CCICELGENE PROtROPRIETARY INFORMATIONatmatment:ent:
one lone l esiesion
AAeieithtiier alr 
witwithin 5 halhin 5 ha
gigc or hormc or h
ncancercancer -rell
erapyapy) is ac) is yyy
bnormalibnormal tii
) < 1,000/ Î¼  < 1,000/Î¼
iis not perms not perm
4.94.9mmommo l/
ce (CrCe (Cr l) < ) <
ly calculatly calculat
um calciumum calci
artate aminartate a
r limit of nolimit of no
mtotaltotalm  bili bilill
ubjects wiubjects wi ththii
ect has cect has c linlin
sseminatedeminated
Subject hSubject 
expiraexpira
expexp
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 37 MEDI4736-MM- 005 Final: 03 Oct 2016currently have controlled intermittent asthma or controlled mild persistent asthma are 
allowed to participate in the study.
11. Subject has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome 
(polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis
12. Subject has nonsecretory MM
13. Subject has known allergy or hypersen sitivity to study drug formulations
14. Subject has active or prior documented autoimmune or inflammatory disorders (including 
inflammatory bowel disease [eg, colitis, Crohnâ€™s disease], diverticulitis, celiac disease, 
irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener syndrome; myasthenia gravis; 
Gravesâ€™ disease; rheumatoid ar thritis, hypophysitis, uveitis, etc) within the past 3 years 
prior to the start of treatment. The following are exceptions to this criterion: 
a. Subjects with vitiligo or alopecia.
b. Subjects with hypothyroidism (eg, foll owing Hashimotoâ€™s disease) stable on 
hormone replacement.
c. Psoriasis not requiring systemic treatment.
15. Subject has history of primary immunodeficiency
16. Subject is positive for human immunodef iciency virus (HIV-1), chronic or active 
hepatitis B or active hepatitis A or C.
17. Subject has received live, attenuated vaccine within 30 days prior to the first dose of 
DURVA (NOTE: Subjects, if enrolled, should not receive live vaccine during the study 
and through 30 days after the last dose of DURVA)
18. Subject is currently using or has used immunosuppressive medication within 14 days 
prior to the first study dose of study treatme nt. The following are exceptions to this 
criterion:
a. Intranasal, topical, inhaled, or local steroid injections (eg, intra-articular injection).
b. Systemic corticosteroids at physiologic dos es not to exceed 10 mg/day of prednisone 
or equivalent.
c. Steroids as premedication for hypersen sitivity reactions (eg, infusion-related 
reactions, computed tom ography [CT] scan premedication).
19. Subject has any one of the following:
a. Clinically significant abnormal ECG finding at screening
b. Congestive heart failure (New York Heart Association Class III or IV)
c. Myocardial infarction within 12 months prior to starting study treatment
d. Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina 
pectoris
20. Subject has prior history of malignancies, other than MM, unless the subject has been 
free of the disease for â‰¥ 5 years with the exception of the following noninvasive 
malignancies:
CCICELGENE PROPRIETARY INFORMATIONluding ding 
sease, ease, 
ociated ciated 
nia gravis; nia gravis
the past 3 yhe past 3
iterion: iterion
totoâ€™sâ€™sdiseasediseas
y virus (HIVy virus (HI
cine withincine within
d, should nod, should no
dose of ose of DURDU
as used s used immmm
of studyf study tretry
l,,inhaled, inhaled
costeroiterods 
nt.nt.
as prems prem edied
oons, ns, cocompumpu
ect hect h as anyas any
a.a.ClinClin
b.CC
c.c
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 38 MEDI4736-MM- 005 Final: 03 Oct 2016a. Basal cell carcinoma of the skin
b. Squamous cell carcinoma of the skin
c. Carcinoma in situ of the cervix
d. Carcinoma in situ of the breast
e. Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, 
nodes, metastasis] clinical staging system) or prostate cancer that is curative
21. Subject is a female who is pregnant, nursing, or breastfeeding, or who intends to become 
pregnant during the participation in the study. 
22. Subject has any significant medical condition, laboratory a bnormality, or psychiatric 
illness that would prevent the subject from participating in the study
23. Subject has any condition including the presence of laboratory abnormalities, which 
places the subject at unacceptable risk if he/she were to participate in the study
24. Subject has an y condition that confounds the ability to interpret data from the study
CCICELGENE PROPRIETARY INFORMATIONc 
s, which , which 
studystudy
fromfrom the stuthe stm
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 39 MEDI4736-MM- 005 Final: 03 Oct 20165. TABLE OF EVENTS
Table 4: Table of Events
Screening 
Period Treatment Period Follow-up Period
Events
-28 to -1C 1-2
(Â±3 days)C 3-6
(Â±3 days)â‰¥ C7 
(Â±3 
days)EOT (â‰¤7 days 
from trt 
discon 
decision)28 
days 
(+3) 
after 
EOT90 days (+3) 
after last 
DURVA/
DARA dose D1aD 2 D8D 
15 D 22 D 1 D 15 D 1
Informed consent X - - - - - - - - - - -
Inclusion/exclusion criteria X - - - - - - - - - - -
IRT registration X X - - - - - - - X - -
Complete medical history X - - - - - - - - - - -
Demographics X - - - - - - - - - - -
Prior disease history X - - - - - - - - - - -
Prior disease therapies X - - - - - - - - - - -
Forced expiratory volume test, 
(subjects with COPD)X- - - - - - - - - - -
Prior/concomitant medication 
evaluationX (-28 days 
from the date 
when ICF was 
signed)Continuous, until 90 days after last dose of DURVA or DARA, whichever is later
Blood Type, Rh, and IAT - X - - - - - - - - - -
Prior/concomitant procedures 
evaluationX (-28 days 
from the date 
when ICF was 
signed)Continuous, until 90 days after last dose of DURVA or DARA, whichever is later
AE evaluation Continuous starting after informed consent signat ure, until 90 days after last dose of DURVA or DARA, whichever is  later
Physical examination X X - - - - X - X X - -
CCICELGpriprietetGENE PROPRIETARY INFORMATIONe Corporae Corpora
ON
MAAAA
7 
(Â±3 (Â±3
days)days)EOEOORFO
155 D 1D1NFIN --YI NININYIN
--RYRYRYRY--ARYRYRYR
--A
E--EEETAE--IEEERE
----RRRIPR--PRPRPROPR
ContinuContinuRROOO
X-XEPEPEPNEEP days ays 
the date he date 
en ICF was n ICF was 
signedsigned ))NENENEEENE
ContinuContinuGELLLLGEELEE
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 40 MEDI4736-MM- 005 Final: 03 Oct 2016Table 4: Table of Events (Continued)
Screening 
Period Treatment Period Follow-up Period
Events
-28 to -1C 1-2
(Â±3 days)C 3-6
(Â±3 days)â‰¥ C7 (Â±3 
days)EOT (â‰¤7 days 
from trt 
discon 
decision)28 
days 
(+3) 
after 
EOT90 days 
(+3) after 
last 
DURVA/ 
DARA dose D1aD 2 D8D 
15 D 22 D 1 D 15 D 1
Vital signs X X X X X X X X X X X X
Height X - - - - - - - - - - -
Weight X X X X X X X X X X X X
12-lead ECG X C1 - - - - C6 - - X - -
Hepatitis and HIV-1 antibody
testingX- - - - - - - - - - -
Hematology X X X X X X X X X X X X
Coagulation parameters X X - - X - X - X X - -
Chemistry X X X X X X X X X X X X
Thyroid Function Tests
(TSH and free T3/T4 at Screening and 
Cycles 1-4; TSH for Cycle 5 onwards; 
reflex testing for free T3/T4 only if 
TSH is abnormal)XX - - - - X - X X - X
Renal Function (CrCl) X X X X X X X X X X X X
Urinalysis X if clinically indicated X X X
Pregnancy Testing (FCBP 
only)
Refer to Section 6.1XX - X - X X X X
CCICELGEpriprietetENEENE PROPRIETARY INFORMATIONe Corporae Corpora
ON
FolFoTIOAT
EOT (EOT â‰¤7 dayâ‰¤7 day
from trfrom t
discdi
deMAAA
OA
D 1D 1OOOXXFOOO
NO
--NNNFINXXINININYIN
--YYYRY--RYRYRYRY
XXTAE--EEETEXXRIEEE
PRE
---PRPRPR
ROPR
XXXRRROOO
PPRPPPRPRPR
XXEPEPEPNEE
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 41 MEDI4736-MM- 005 Final: 03 Oct 2016Table 4: Table of Events (Continued)
Screening 
Period Treatment Period Follow-up Period
Events
-28 to -1C 1-2
(Â±3 days)C 3-6
(Â±3 days)â‰¥ C7 
(Â±3 
days)EOT (â‰¤7 days 
from trt 
discon 
decision)28 
days 
(+3) 
after 
EOT90 days (+3) 
after last 
DURVA/ 
DARA dose D1aD 2 D8D 
15 D 22 D 1 D 15 D 1
Antiviral prophylaxis - Initiate within 1 week of starting DARA and continue for 3 months following last dose of DARA.
EFFICACY AND OTHER ASSESSMENTS
ECOG Performance status X X - - - - X - X X - -
Assessment of response 
(IMWG Uniform Response 
Criteria)b-C 2 - - - - X - X X - -
Serum and urine protein 
electrophoresisXX - - - - X - X X - -
Serum and urine 
immunofixationXX - - - - X - X X - -
Serum free light chains assay X X - - - - X - X X - -
Quantitative serum 
immunoglobulinXX - - - - X - X X - -
EMP clinical assessment X X - - - - X - X X - -
EMP radiological assessment 
(only required if history of or clinical indication of EMPs only assessable radiographically)X Day 1 starting at C3, then every 3 cycles thereafter X -
Skeletal Survey for bone 
lesionsX
(within 60 days 
prior to first 
dose is 
acceptable)Repeated during treatment if clinically indicated to confirm response or PD -
CCIpriprietetGENE PROPRIETARY INFORMATIONe Corporae Corpora
ON
FolFoTIOAT
EOT (EOT (â‰¤7 dayâ‰¤7 day
from trfrom t
discdi
deMAAA
OA
D 11OOFOe for 3 monthfor 3 mFOFOO
NF--INININYIN
--YYYRY
XXTAE--EEETRE
---RRRPR----OOOPPP
ROP
----RRROOO
PRO
DayD1 1yPRPRPR
NEXX
(within 60 day(within 60 day
prior to fiprior to 
dosedose
acceacENNN
ELELELELN
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 42 MEDI4736-MM- 005 Final: 03 Oct 2016Table 4: Table of Events (Continued)
Screening 
Period Treatment Period Follow-up Period
Events
-28 to -1C 1-2
(Â±3 days)C 3-6
(Â±3 days)â‰¥ C7 
(Â±3 
days)EOT (â‰¤7 days 
from trt 
discon 
decision)28 
days 
(+3) 
after 
EOT90 days 
(+3) after 
last 
DURVA/ 
DARA dose D1aD 2 D8D 
15 D 22 D 1 D 15 D 1
Bone marrow aspirate and/or 
biopsy sampling for 
cytogenetics, % plasma cells, X 
BMA and 
BMB 
cytogenetics, 
% plasma 
cells, - BMA and BMB at time of CR confirmation for % plasma cells 
 
Î²2-microglobulin X X - - - - X - X X - -
Pre- and post-DARA infusion 
medicationsc  (Refer to 
Section 7.2.1.2 )-X - X X XXX X - - -
DARA IV administration (QW, 
Q2W, or Q4W) Refer to 
Section 7.2.2- Xd-XdXdXdXdXdXd-- -
DURVA IV administration - C1D2
C2D1e-- - Xe-Xe-- -
Study treatment (DURVA, 
DARA) accountability/compliance-X X X X XXX X X - -
Blood sample for DURVA PK 
(Refer to Section 6.5.1 )-C 2 C 1 C 1 C 1 C1 C4,C6 - C10, 
C14-- -
Blood sample for DARA PK 
(Refer to Section 6.5.2 ) - C1 - C1 C1 C1 - - - X X X
CCICCICCI
CCICCI
CCI
CELGpriprietetLGENE PROPRIETARY XXARRRR
XXTAEXXdRIEEE
OPRE
----OOOPPP
PROP
XXXPRPRPREEPPR
C2C2EEEEENEE
--ENNN
LLGNY INFORMATIONe Corporae Corpora
ON
FolFoTIOAT
EOT (EOT (â‰¤7 dayâ‰¤7 day
from trfrom t
discdi
dedMAAA
OA
D 11OOFO asma cells asma cells FOFOOOFONF
YIOC
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 43 MEDI4736-MM- 005 Final: 03 Oct 2016Table 4: Table of Events (Continued)
Screening 
Period Treatment Period Follow-up Period
Events
-28 to -1C 1-2
(Â±3 days)C 3-6
(Â±3 days)â‰¥ C7 
(Â±3 
days)EOT (â‰¤7 days 
from trt 
discon 
decision)28 
days 
(+3) 
after 
EOT90 days (+3) 
after last 
DURVA/ 
DARA dose D1aD 2 D8D 
15 D 22 D 1 D 15 D 1
AE = adverse event; BMA = bone marrow aspirate; BMB = bone marrow biopsy; C = Cycle; COPD = chronic obstructive pulmonary disea se; CR = complete  response; CrCl = 
creatinine clearance; D= Day; DARA = daratumumab; DURVA= durvalumab; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncolo gy Group; eCRF= electronic case 
report form; EMP = extramedullary plasmacytomas; EOT = End of Treatment; FCBP = female of childbearing potential; HIV = human im munodeficiency virus; IAT = indirect 
antiglobulin test; IMWG = International Myeloma Working Group; IRT= Interactive Response Technology; IV = intravenous; PD = dis ease progression; PK = pharmacokinetics; 
QW = weekly; Q2W = every 2 weeks; Q4W = every 4 weeks; T SH= thyroid stimulating hormone; trt discon = treatment discontinuation .
aOn Cycle 1 Day 1 (C1D1), safety laboratory assessments must be performed locally (central confirmation is not required) to confir m subject continues to meet the required 
safety laboratory values prior to initiating study treatment.  However, if screening assessments were performed within 72 hours  of C1D1, safety laboratory and physical 
examinations need not be repeated at C1D1.
bPer IMWG Uniform Response Criteria all response categories and progressive disease require 2 consecutive assessments.
cPre infusion medications to be given before all daratumumab infusions (if necessary, oral pre infusion medications may be adminis tered at the subjectâ€™s home on the day of the 
infusion, provided they are given within 3 hours prior to the infusion); post infusion medications to be given on the first and second days following all daratumumab infusions. 
dEvery effort should be made to keep subjects on the planned dosing schedule (QW, Q2W, or Q4W) as detailed in Section 7.2.2 . However, doses given within 3 days of the 
scheduled dose are permitted, as long as the interval between doses is at least 5 days. Blood pressure is to be measured at the  following time points on C1D1 and C1D8: 
immediately before the start of the infusi on; at approximately 30 minutes, 1 hour, 90 minu tes, 2 hours, and 3 hours 30 minutes af ter the start of the infusion; at the end of the 
infusion; and 30 minutes and 1 hour (+/- 5 minutes) after the end of the infusion. For all other DARA infusions, blood pressure wi ll be measured immediately before the infusion 
start and at the end of the infusion.
eFirst DURVA infusion:  blood pressure and pulse will be monitored, as follows (based on a 60-minute infusion): Prior to the beginning of the infusion (measured once from 
approximately 30 minutes before up to 0 minutes [ie, the beginning of the infusion]); approximately 30 minutes during the infusio n (halfway through infusion); at the end of the 
infusion ( approximately 60 minutes Â±5 minutes). If the infusion takes longer than 60 minutes, then blood pressure and pulse meas urements should follow the principles as 
described above or be taken more frequently if clinically indicated.  For DURVA infusions on C2D1 onward, a +24 hour window is allowed and may be implemented per 
CCICCI
CEpriprietetELGENE PROPRIERIEEEE = Cycle; = Cycle; COPCOP
CG = electrocaG = electroc
FCBP = feFCBP = fe ma
teractive Ractive esR
roid stimulatinoid stimulat
rformed localrformed loc
ver, if screeniver, if screeni
ies and progrees and progr
mab infusionsmab infus
to the infusioto the infusio
e planned dosplanned do
erval between rval between 
at at approximateapproximat
 minutes)minutes afteaft
sure and pulsre and puls
up to 0 minutup to 0 minut
inutes Â±5 mininutes Â±5 m
more frequenmore frequenNFORMATIONe Corporae Corpora
ON
ATATATAT
s)EOT (EOT â‰¤
frRM
FOD 1D 1FOFONFONNNFN
IETARY INF
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 44 MEDI4736-MM- 005 Final: 03 Oct 2016investigator discretion.
Subsequent DURVA infusions: vital signs will be measured prior to the start of the infusion. Subjects should be carefully monitored and blood pressure and other vital signs 
should be measured during and post infusion as per institution standard and as clinically indicated. Any clinically significant  changes in vital signs should be entered onto an 
unscheduled vital signs eCRF page.
CCIpriprietetTIONe Corporae Corpora
ONure anure an d other vd other v
hould be enterould be ente
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 45 MEDI4736-MM- 005 Final: 03 Oct 20166. PROCEDURES
Any questions regarding the protocol should be directed to the Celgene Medical Monitor or 
designee.
6.1. Screening Period
The Screening Phase begins when the ICF is signed. Screening evaluations will be performed for all sub jects to determine study eligibility. These evalu ations must be completed within 28 days 
of first dosing unless noted otherwise below. 
Waivers to the protocol will not be granted during the conduct of this trial, under any 
circumstances.
Except for pregnancy tests, ECGs and urinalysis, all sa fety-related laboratory assessments will be 
performed centrally; however, tests that may result in dose interruption and/or modification may
also be performed locally to allow for treatment- related decisions during subject visits. All 
results from local laboratories used in treatment d ecisions or AE reporting must be entered as an 
unscheduled visit into the electronic case report form (eCRF).  
The following will be performed at screening as specified in Table 4 after informed consent has 
been obtained:
!Interactive Response Techno logy (IRT) registration
âˆƒNote: Subject may be enrolled in the IRT up to 3 days prior to initiating study 
treatment on Cycle 1 Day 1 (C1D1)
!Complete medical history (all  relevant medical conditions diagnosed/occurring prior 
to screening should also be included)
!Demographics (age, sex, race, and if allo wed by local regulations, ethnicity, and date 
of birth, will be collected in the eCRF and/or IRT system)
!Prior disease history (if available the date of initial diagnosis, staging at time of 
diagnosis [ Appendix D ], cytogenetics at diagnosis to be collected)
!Prior disease therapies (including surgery, radiation, systemic or any other therapy for 
the subjectâ€™s disease)
!Prior and concomitant medication ev aluation (including those taken â‰¤ 28 days before 
the date that the ICF was signed, except for those taken for disease)
!Prior and concomitant procedures evaluation (including all procedures occurring 
â‰¤28 days before the date that the ICF was signed)
!Adverse events 
!Physical examination, including assessment for potential venous thromboembolism 
events (VTEs) (can be source documented only) 
!Forced expiratory volume test (subjects with or suspected to have chronic obstructive 
pulmonary disease [COPD])
CCICELGENE PROPRIETARY INFORMATIONfor or 
ays ys 
assessmentssessmen
d/or modific/or modifi
g subject visubject
rting must rting must 
ableable 44afaterf
istrationistration
e IRT up toe IRT up to
D1)D1)
levant medevant med
ncluded)cluded)
race, and irace, and
ted in the eted in the 
oryory(if avail(if availyy
pendix Dndix D ], c
se e ththerapierap e
ectâ€™s diseaectâ€™s disea
or and concr and con
hhe date thae date tha
! PriPrioor anr a
â‰¤28â‰¤2
!!
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 46 MEDI4736-MM- 005 Final: 03 Oct 2016!Vital signs (including blood pressure, temperature, and heart rate)
!Height and weight 
!12-lead ECG (performed and reviewed locally)
!Hepatitis panel
!HIV-1 antibody test
!Hematology panel including complete blood count (CBC) with differential, including 
red blood cell (RBC) count, hemoglobin, hematocrit, white blood cell (WBC) count 
(with differential), platelet count, mean corpuscular volume 
!Coagulation parameters (prothrombin time/international normalized rati o, activated 
partial thromboplastin time, fibrinogen)
!Chemistry panel including sodium, potassium, calcium, corrected serum calcium
(refer to Section 6.4.1 ), chloride, blood urea nitrogen (BUN), creatinine, glucose, 
albumin, total protein, alkaline phosphatase (ALP), bilirubin (total, direct, and indirect), AST, ALT, lactate dehydrogenase (LDH), magnesium, bicarbonate, lipase, 
gamma-glu tamyl transferase (GGT), uric acid, triglycerides, cholesterol, and amylase.  
(NOTE: Tests for AST, ALT, ALP, direct bilirubin, indirect bilirubin, and total 
bilirubin must be conducted and assessed concurrently)
!Thyroid function tests (thyroid-stimulating hormone [TSH], free T4, free T3)
!Estimation of renal function will be assessed using the CrCl calculated based on the 
Cockcroft-Gault formula or the CrCl directly calculated from the 24-hour urine collection method.  Cockcroft-Gault formula: CrCl (mL/min) = (140 â€“ age) (weight 
[kg]) / 72 (serum creatinine [mg/dl]); for females, the formula is multiplied by 0.85.
!Urinalysis (color, appearance, specific gravi ty, pH, protein, glucose, ketones, blood, 
bilirubin)
!Females of childbearing potential (FCBP) should have two negative medically 
supervised pregnancy tests assessed locally  during screening. The subject may not 
receive any study treatment until the investigator has verified that the results of these 
pregnancy tests are negative.
oThe investigator will appraise a female subject as a FCBP according to the following 
definition (justification must be recorded in the eCRF and the source document):
FCBP is defined as a sexually mature woman who has not undergone a 
hysterectomy or bilateral oopherectomy or has not been naturally 
menopausal for at least 24 consecutive months (ie has had menses at any 
time in the preceeding 24 consecutive months). Amenorrhea following cancer therapy does not rule out childbearing potential.
oNegative serum pregnancy test (minimum sensitivity of 25mIU/ml) at screening
oNegative serum or urine pregnancy test (investigatorâ€™s discretion) within 72 hours 
prior to the start of study treatment (C1D1)
CCICELGENE PROPRIETARY INFORMATIONngng
unt unt 
, activated  activated 
serum calcserum calc
reatinine, geatinine, g
(total, dire(total, d
nesium, bicesium, bi
erides, cholides, chol
bin, indirebin, ind
currently)currently)
hormone [Thormone [
essed usingssed using
didirectrectiiily ly ca
ullt ft fllormormff ulaulammm
g/dl]); for fg/dl]); for f
ce, specificce, specific
aring potentring potent
ancyancy teststestyy
udyudtreatmtreay
tests are neests are ne
The investiThe investi
definitiodefini
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 47 MEDI4736-MM- 005 Final: 03 Oct 2016Note: Pregnancy testing does not need to be  repeated prior to C1D1 if the screening 
assessment (serum pregnancy test) was performed within 72 hours of the first dose of 
study treatment
Note: Pregnancy testing is not required for non-FCBP subjects. 
!Eastern Cooperative Oncology Group (ECOG) Performance Status (see Appendix C )
!Efficacy assessments / tumor evaluati ons per the IMWG criteria (See Section 6.4). 
!Î²2 microglobulin test
!Bone marrow aspiration/biopsy (for cy togenetics, percent plasma cells,  
6.2. Treatment Period
The subject will begin the treatment period upon confirmation of eligibility. The subject must 
start treatment within 28 days of signing the ICF. For all visits an administr ative window of Â± 3 
days is permitted. Safety laboratory testing at a local laboratory may be performed up to 3 days 
before the study treatment administration day. Resu lts of these laboratory tests must be evaluated 
before each study treatment administration. 
Treatment cycles are 28 days in duration, the treatment and schedule will be as described in 
Section 7.2.
The following evaluations will be performed at the frequency specified in Table 4 . The 
evaluations should be should be performed prior to dosing on the visit day, unless otherwise 
specified. 
!Interactive Response Techno logy (IRT) registration
!Concomitant medications evaluation
!Concomitant procedures evaluation
!Adverse event (continuously)
!Physical examination, including assessment for potential VTEs (can be source 
documented only) 
!Vital signs
!Weight 
!12-lead ECG (C1D1 and C6D1 immediately after DARA infusion)
!Blood Type, Rh, and indirect anti globulin test (IAT) should be done before the first 
dose of DARA. See Section 6.8for additional details.
!Hematology panel
!Coagulation parameters 
!Chemistry panel 
CCICCI
CELGENE PROPRIETARY INFORMATIONlity.y.The suThe
ministrativeministrative
ayy bye perfo perf
aboratoryabora
nd schedud sched
he frequence frequen
or to dosinor to dosin
olologygy (IRT(IRTyy
ns evaluatevaluat ii
dures evaludures eva
(continuouontinuou
xaminatxaminat ioin
ntednted onlyonly))yy
alal signs signsll
Weight Weight 
!!12--leal
!!B
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 48 MEDI4736-MM- 005 Final: 03 Oct 2016!Thyroid function tests:
âˆƒCycles 1 to 4: TSH, free T4, free T3
âˆƒCycle 5 onward: TSH, if TSH is abnormal, then reflex testing for free T4 and free 
T3 
!Renal function (CrCl) based on the Cockcroft-Gault formula or the CrCl directly 
calculated from the 24 hour urine collecti on method.  Cockcroft-Gault formula: CrCl 
(mL/min) = (140 â€“ age) (weight [kg]) / 72 (serum creatinine [mg/dl]); for females, the formula is multiplied by 0.85 (local laboratory).
!Urinalysis (only if clinically indicated)
!Urine (or serum) pregnancy test for FCBP (negative results required for study 
treatment [DURVA and/or DARA] administration) within 72 hours prior to dosing onD1 of every treatment cycle. The sub ject may not receive study treatment un til the 
investigator has verified that the result of the pregnancy test is negative.
!ECOG Performance Status 
!Antiviral prophylaxis
!Pre and post medication for DARA infusion (see Section 7.2.1.2 )
!Efficacy assessments (see Section 6.4)
!Î²2 microglobulin test on Day 1 of each cycle
!  
!Blood sampling for PK asse ssments (see Section 6.5)
!!Study treatment (DARA and DURVA) administration/accountability/compliance.
6.2.1. End of Treatment
An End of Treatment (EOT) evaluation will be performed for subjects who are withdrawn from 
treatment for any reason within 7 days after the decision to permanently discontinue treatment 
has been made. 
The following evaluations will be performed as specified in Table 4 .
!IRT registration
!Concomitant medications evaluation (monitored until 90 days after last dose of 
DURVA or DARA, whichever is later)
!Concomitant procedures evaluation (monit ored until 90 days after last dose of 
DURVA or DARA, whichever is later)
!Adverse event evaluation (monitored un til 90 days after last dose of DURVA or 
DARA, whichever is later)
CCICCI
CCI
CELGENE PROPRA and DURA and DU
entnt
EOTEOT))evaluval
son wion wi ththiinin
g evaluatiog evaluatio
IRT regiIRT reg
!ConConPRIEments (see ments (seeETARY INFORMATIONthe he 
studystudy
priprior to dosor to dos
atmatment untt un
negategative.ive.
SectionSection 7.27.
ycleycle
DDIET
OP
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 49 MEDI4736-MM- 005 Final: 03 Oct 2016!Physical examination, including assessment for potential VTEs (can be source
documented only) 
!Vital signs 
!Weight
!12-lead ECG
!Hematology panel
!Coagulation parameters 
!Chemistry panel
!Thyroid function tests (TSH, free T4, free T3)
!Renal function (CrCl) based on the Cockcroft-Gault formula or the CrCl directly 
calculated from the 24 hour urine collecti on method.  Cockcroft-Gault formula: CrCl 
(mL/min) = (140 â€“ age) (weight [kg]) / 72 (serum creatinine [mg/dl]); for females, the 
formula is multiplied by 0.85.
!Urinalysis
!Urine (or serum) pregnancy test for FCBP
!ECOG Performance Status
!Antiviral prophylaxis
!Efficacy assessments per the IMWG criteria will be performed according to the 
schedule defined in the Table of Events and do not need to be performed specifically 
for the EOT visit except as specified in Section 6.4.
!Î²2 microglobulin test
!!Blood sampling for DARA PK assessments (see Section 6.5)
!
!Study treatment (DARA and DURVA) accountability/compliance.
6.3. Follow-up Period
6.3.1. Safety Follow-up
All subjects will be followed for 90 days after the last dose of DURVA or DARA, whichever is 
later, for AEs, including adverse events of special interest (AESIs), reporting, as well as serious 
adverse events (SAEs) that had occurred within that time frame but were made known to the investigator at any time thereafter that are suspected of being related to study treatment 
(DURVA, DARA), as described in Section 10.1.
CCICCI
CCI
CELGENE PROPRIETARY INFORMATIONCrClCrCl didillrectreiii
Gault formGault form
mg/dl]); fomg/dl])
criteriariteria willwil
vents and dvents and d
cified in fied in SeSe
r DARA DARA PKP
tmtment (ent (DAD
owow-up Pup P
Safety FoSafety Fo
bjbjects will ects will 
er, r, fofor AEsr AEs
adverse evedverse ev
investignvestig
URROP
EP R
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 50 MEDI4736-MM- 005 Final: 03 Oct 2016Subjects are to return to the study site 28 (+3) days  after the EOT visit and 90 (+3) days after the 
last dose of DARA or DURVA, whichev er is later, for safety follow-up visits procedures as 
specified in Table 4 .
!Concomitant medications evaluation (monitored until 90 days after last dose of 
DURVA or DARA, whichever is later)
!Concomitant procedures evaluation (monitore d until 90 days after last dose of 
DURVA or DARA, whichever is later)
!Adverse event (including AESIs) evaluation (monitored until 90 days after last dose 
of DURVA or DARA, whichever is later)
!Vital signs
!Weight
!Hematology panel
!Chemistry panel
!Thyroid function tests (TSH, free T4, free T3)
!Renal function (CrCl) based on the Cockcroft-Gault formula or the CrCl directly 
calculated from the 24 hour urine collecti on method.  Cockcroft-Gault formula: CrCl 
(mL/min) = (140 â€“ age) (weight [kg]) / 72 (serum creatinine [mg/dl]); for females, the formula is multiplied by 0.85 (local laboratory).
!Urinalysis
!Urine (or serum) pregnancy test for FCBP
!Antiviral prophylaxis 
!Blood sampling for DARA PK assessments (see Section 6.5)
!
6.4. Efficacy Assessments
6.4.1. Laboratory Assessments for Efficacy Parameters
All laboratory assessments for efficacy will be performed centrally.If screening assessments are performed within 3 days of C1D1, efficacy laboratory assessments 
need not be repeated at C1D1:
!Serum protein electrophoresis (sPEP) and urine protein electrophoresis (uPEP) tests 
(performed on 24-hour urine co llection) are required at screeni ng, on Day 1 of each 
cycle, and at the EOT Visit. 
!Serum and urine immunofixation tests are required at screening, on Day 1 of each 
cycle, and at the EOT Visit.
CCICCI
CELGENE PROessmentssment ss
ry Assessmry Assess
sessments fessments f
assessmentsssessment
e repeated repeated OPRIETARY INFORMATIONdose ose 
formula orform
od.  od.  CockcCock
rum creatinum creatin
oryory).y
r FCBPr FCBP
A A PK assesPK as
!!Serumerum
(pe(peRO
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 51 MEDI4736-MM- 005 Final: 03 Oct 2016!Quantitative serum immunoglobulin assessment includes IgG, IgA, and IgM for all 
subjects, and IgE or IgD onl y for subjects with the respective MM subtype (IgE or 
IgD) and is required at screening, on Day 1 of each cycle, and at the EOT Visit.
!Serum free light chains assay is required at screening, on Day 1 of each cycle, and at 
the EOT Visit.
!Corrected serum calcium will be assessed as part of the safety serum chemistry 
assessments performed at screening, on Day 1 of each cycle, and at the EOT Visit.
6.4.2. Bone Marrow Aspiration and/or Biopsy
A bone marrow aspirate (BMA) and biopsy (BMB) is mandatory at the following time points:
!At screening, BMA and BMB for percent plasma cells, cytogenetics,  
!During treatment:
âˆƒâˆƒBMA and BMB at the time of complete response (CR) confirmation for percent 
plasma cells 
âˆƒ  
The analysis of bone marrow for percentage of plasma cells will be performed locally and at a 
central laboratory.  
6.4.3. Bone Lesion Assessment
Bone lesion assessment by x-ray (skeletal survey) or CT Scan will be performed at screening and 
when clinically indicated to confirm response or PD. The same method (x-ray or CT Scan) 
should be used throughout the study. All films will be analyzed locally by the site investigator/radiologist. If a bone lesion assessmen t by x-ray or CT Scan was performed within 
60 days prior to the start of Cycle 1, it ma y be used for the screening assessment.  
If assessment is done by x-ray, the following are the minimum plain radiological films required 
for the skeletal (bone) survey: 
!Lateral skull 
!Anteroposterior (AP) and lateral cervical spine 
!AP and lateral thoracic spine 
!AP and lateral lumbar spine 
!Posteroanterior chest 
!AP pelvis 
!AP upper extremities, shoulder to elbow 
CCICCI
CCI
CCI
CCI
CCI
CELGENE PROPRIEeletaleletal  surve surll
rm responsrm respon
studytudy. All f. All f
bone lesiobone les
of Cyof Cy cle 1,cle
e by xby x--rayrayt
one) surveyone) survey
teraleral skull  skullll
AnteropoAnteropo
!!AP aAP 
!!ATARma cells wima cells wRY INCR) confirmR) confirNFORMATIONpoints:points:
ORM
INF
ARY
ET
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 52 MEDI4736-MM- 005 Final: 03 Oct 2016!AP lower extremities, hip to knee.
Other radiological films may be necessary to  view symptomatic areas or known pre-existing 
lesions in skeletal regions not included in the films above. 
6.4.4. Extramedullary Plasmacytoma Assessments 
Clinical assessment for extramedullary plasmacytoma (EMP) assessments will be performed at 
screening, on Day 1 of every cycle, and at the EOT Visit. 
For EMPs that are only assessable radiographically  (by x-ray and/ or conventional [spiral] 
CT/magnetic resonance imaging [MRI] scan), scans are required at screening, at Cycle 3 Day 1, 
every 3 cycles thereafter (Cycle 6 Day 1, Cycle 9 Day 1, etc.) during treatment, at the EOT Visit, 
and when clinically indicated to confirm a response ( â‰¥ PR) or PD. The radiographic modality 
used at screening (eg, x-ray) will be repeated at each assessment time point throughout the study. 
All scans will be reviewed locally only. Celgene may request redacted copies of reports.
6.4.5. Assessment of Response
6.4.5.1. Investigator Assessment
Starting from Cycle 2, response will be assessed  by the investigators using the International 
Myeloma Working Group (IMWG) Uniform Response Criteria ( Rajkumar, 2011 )(Appendix B )
at every cycle on Day 1 and at the EOT Visit. Response must be based on the central laboratory 
data to ensure consistency across investigative sites. All treatment discontinuation decisions due to disease progression will be made by treating physicians based on response as assessed using 
results from central laboratories by the IMWG criteria, except for new or increase in bone lesions 
or soft tissue plasmacytomas.
6.4.5.2. Independent Response Adjudication Committee Assessment
An IRAC will be formed by a group of experts in the MM disease area to review efficacy data. 
For each subject, the IRAC will determine tumor response at scheduled or unscheduled visits, and the time of PD (if disease progressed). In addition, the IRAC will determine the best overall 
response of each subject up to time of the data cut off for interim and final analyses. 
The IRAC will adjudicate efficacy  data incrementally according to IRAC Charter during the 
study.  The IRAC adjudicated response data will be used for efficacy analysis in all interim and 
final analyses.  Primary efficacy analyses will be conducted in tumor response data, including 
progressive disease (PD) that are assessed by the IRAC according to the IMWG Uniform 
Response Criteria ( Appendix B ).
NOTE: Per IMWG Uniform Response Criteria all response categories and progressive disease 
require 2 consecutive assessments except for radiographic or bone marrow assessments
6.5. Pharmacokinetics
Serum samples will be collected to assay concentrations of DURVA and DARA. On PK 
sampling days, dosing and sample co llection i nformation including dosing d ate, dosing time (24 
hour clock), and actual PK blood sampling time (24 hour clock) should be accurately 
documented on the appropriate eCRF pages.
CCICELGENE PROPRIETARY INFORMATIONDayDay 1, 1, y
EOT Visit, EOT Visit
modalitmodalit y y
ughout the sghout the s
of reports.f reports
gators usingators u
eriaria((RajRakumku
must be must be basb
ll treatmenll treatmen
sicians bassicians ba
riteria, exceriteria, exce
udication Cudication
p of expertsof exper
determine tudetermine 
progressedprogresse
 to time oto time o f
ateateefficacyefficac
djudicated rudicated 
rimary efficrimary effic
sease (PD) ease (PD
ririteriteriiiia (a (ApAp
: Per IMWPer IMW
uire 2 conseuire 2 cons
6.5.6.5
rum
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 53 MEDI4736-MM- 005 Final: 03 Oct 20166.5.1. Pharmacokinetics of Durvalumab
All subjects enrolled in Part 1 Stage 1 will pa rticipate in the DURVA PK sample collections at 
the following time points: 
!C1D2: pre dose (-30 to -5 minutes prior to dose), end of infusion (EOI) (+5 minutes), 
!C1D8: 144 hours post C1D2 dose (Â± 1 hour)
!C1D15: 312 hours post C1D2 dose (Â± 1 hour),
!C1D22: 480 hours post C1D2 dose (Â± 1 hour).
!Additional DURVA PK samples to be collected  
 on C2D1, C4D1, C6D1, C10D1, and C14D1.
6.5.2. Pharmacokinetics of Daratumumab
DARA PK sample collections w ill occur at the following time points for subjects enrolled in Part 
1 Stage 1: 
!C1D1: predose (-30 to -5 minutes prior to dose), and EOI (+5 minutes)
!C1D8: predose (-30 to -5 minutes prior to dose), and EOI (+5 minutes)
!C1D15: predose (-30 to -5 minutes prior to dose), and EOI (+5 minutes)
!C1D22: predose (-30 to -5 minutes prior to dose), and EOI (+5 minutes)
!EOT
!28 days after EOT, 
!90 days after last DARA or DURVA dose
 
 
 
 
 
CCICCI
CCI
CELGENE PROPRIETARY INFORMATIONbjects enrobjects enro
((+5 minut+5 minut
EOI EOI (+5 m
),,and and EOI EOI 
dose), and dose), and E
RVA doseRVA doseMA
PROPREPNE ENGELGEELGCELC
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 54 MEDI4736-MM- 005 Final: 03 Oct 20166.8. Blood Type, Rh and Indirect Antiglobulin Test (IAT)
Blood type, Rh, and IAT should be done before the first dose of DARA for the reasons detailed 
below. Subject RBC phenotyping (standard or extended) is an alternative option to the IAT test, 
if locally required. Either method must be completed prior to first DARA i nfusion.
DARA interferes with the indirect antiglobulin test (IAT), which is a routine pre-transfusion test 
performed to identify a patientâ€™s antibodies to minor antigens so that suitable donor blood can be 
given for transfusion. DARA does not interfere with ABO/RhD typing. CD38 is expressed at 
very low levels on erythrocytes. DARA binds to the CD38 on erythrocytes, which results in a 
CCICCI
CELGEBlood TBlood T
ddttype, Rh,ype, Rh
lowow. Subje. Subje
if f lolcally rally 
ARAARAION
GENE PROPRIETARY INFORMATIO
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 55 MEDI4736-MM- 005 Final: 03 Oct 2016positive IAT (Indirect Coombs Test).  This positiv e result masks the detection of antibodies to 
minor antigens and may prevent or delay blood banks from issuing donor blood for 
transfusion. This effect occurs during DARA t reatment and for up to 6 months after treatment 
ends. Subjects will receive a patien t identification w allet card for the study that includes the 
blood profile (ABO, Rh, and IAT or phenotyping) determined before the first infusion of DARA
along with information on the IAT interference for healthcare providers/blood banks. Subjects 
are to carry this card throughout the treatment period and for at least 6 months after treatment ends. Blood banks can eliminate the DARA interfe rence with IAT by tr eating reagent RBCs 
with dithiothreitol (DTT) ( Chapuy, 2015 ).
Possible methods for blood banks to provide safe RBCs for transfusion to subjects receiving 
DARA include:
a. Providing ABO/RhD compatible, phenotypically  (standard or extended phenotyping) 
or genotypically matched units
b. Providing ABO/RhD compatible, K-negative units after ruling out or identifying 
alloantibodies using dithiothreital-treated reagent RBCs
Uncrossmatched, ABO/RhD compatible RBC units should be administered if transfusion is 
needed emergently as per local blood bank practice.
Despite DARA binding to CD38 on erythrocytes, no indication of clinically significant 
hemolysis has been observed in DARA studies. For additional details, refer to the DARA IB.
CCICELGENE PROPRIETARY INFORMATIONing ng 
phenotyphenoty pipyyy
ut or identut or ident if
stered if trastered if tra
n ofn ofclinicaclinff
nal details,al detail
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 56 MEDI4736-MM- 005 Final: 03 Oct 20167. DESCRIPTION OF STUDY TREATMENTS
7.1. Description of Investigational Product(s)
Investigational product supply will be managed by IRT. All IP must be stored in accordance with 
the product label in a secured area to prevent unauthorized access. 
United States:
Durvalumab (MEDI4736) will be supplied by Celgene and labeled appropriately as 
investigational material. Labels will bear C elgeneâ€™s name, telephone number and address, the 
protocol number, product name, dosage form and strength, medication identif ication kit/number, 
lot number, expiry date, dosing instructions, storage conditions, the quantity of IP contained, and 
required caution statements and/or regulatory statement as applicable. 
Daratumumab (Darzalex) will not be supplied by  Celgene; instead it will be obtained according 
to local clinical study agreement and in accord ance with local guidelines. Additional information 
may be included on the label as needed or applicable. 
Outside the United States:
Durvalumab (MEDI4736), and Daratumumab (Darzalex) will be supplied by Celgene and 
labeled appropriately as investigational material. Labels will bear Celgeneâ€™s name, telephone number and address, the protocol number, product name, dosage form and strength, medication 
identification kit/number, lot number, expiry d ate, dosing instructions, storage conditions, the 
quantity of IP contained, and required cauti on statements and/or re gulatory statement as 
applicable. 
7.1.1. Durvalumab (MEDI4736)
DURVA will be supplied by Celgene in single-use vials in single count cartons. Each  10 ml vial 
will be supplied as a vialed liquid solution containing 500 mg (nominal) of IP at a concentration 
of 50 mg/mL. DURVA should be stored in accordance with the product label. 
Sites are to supply the following:
!IV infusion bags of normal saline (0.9% [w /v] sodium chloride injection, 250 mL 
size). Saline bags must be latex-free and can be made of polypropylene, polyethylene, 
polyolefin copolymers, or polyvinyl chloride. Infusion lines should contain a 0.2- Î¼m 
in-line filter. 
!Since the compatibility of DURVA with other IV medications and solutions, other 
than normal saline, is not known, the DURVA solution should not be infused through 
an IV line in which other solutions or medications are being administered. 
For additional information on preparation and storage please refer to the pharmacy manual.
CCICELGENE PROPRIETARY INFORMATIONe e 
umber, umber, 
ained, and ained, and
ained ained accoac
dditddiioional l ini
suppliedupplied byby
ear Celgenear Celg
osage form sage form
g instructiinstruct o
ents and/or ents and/or
singlesingle --use vuse v
tioon contain contai
tored in accred in ac
g:g:
s of normaof norma
bags must bags mus
n copolymecopolym
filtfilter. er. 
nce the comce the com
thhan an normnorm
an IV lian IV l
addiaddititiiionalonalll
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 57 MEDI4736-MM- 005 Final: 03 Oct 20167.1.2. Daratumumab (Darzalex)
Daratumumab (Darzalexâ„¢) will be supplied by Celgene in single-use vials in single count 
cartons. Daratumumab is a colorless to pale yellow, preservative-free solution and will be 
supplied in 20 mL vials (20 m/mL) and/or 5 mL vials (20 mg/mL).
!Since the compatibility of DARA with other IV medications and solutions, other than 
normal saline, is not  known, the DARA solution should not be infused through an IV line 
in which other solutions or medications are being administered. 
For additional information on preparation and st orage please refer to the pharmacy manual. 
7.2. Treatment Administration and Schedule
The first day of study treatment dosing (DARA and/or DURVA) is considered Day 1 of a cy cle.
7.2.1. Treatment Administration
On days when DARA and DURVA are dosed on the same day, the DARA infusion should be 
administered first, followed by the DURVA infusion. Simultaneous infusion of DARA and 
DURVA is prohibited. 
!Since the compat ibility of DARA or DURVA with other IV medications and solutions, 
other than normal saline, is not known, the DARA or DURVA solution should not be 
infused through an IV line in which other solutions or medications are being 
administered.
!If DARA and DURVA will be infused through the same port, the port must be flushed 
with saline prior to attaching dedicated DARA IV line.
7.2.1.1. Durvalumab (MEDI4736)
7.2.1.1.1. Durvalumab Product Dose Preparation/Administration
The IV infusion for subjects will be approximately 1 hour in duration.For detailed information on DURVA dose preparation and administration please refer to the 
pharmacy manual. 
7.2.1.1.2. Monitoring During/After Durvalumab Infusion
7.2.1.1.2.1. First DURVA infusion
For the first DURVA infusion (C1D2), blood pressure and pulse will be monitored, as follows
(based on a 60-minute infusion):
!Prior to the beginning of the infusion (measured once from approximately 30 minutes 
before up to 0 minutes [ie, the beginning of the infusion])
!Approximately 30 minutes during the infusion (halfway through infusion) 
!At the end of the infusion ( approximately 60 minutes Â±5 minutes)
If the infusion takes longer than 60 minutes, then blood pressure and pulse measurements should 
follow the principles as described above or be taken more frequently if clinically indicated.
CCICELGENE PROPRIETARY INFORMATIONy 1 of a cyy 1 of a cy
RA infusioA infus n
fusiofusio n of Dn of D
er IV mIV m edic
r DURVAr DURVA
ns or medics or med
ugh the samugh the sam
DDARAARA IV lV
ose Preparose Prep
be approxibe approx
DURVADURVA dod
ing Duringng Durin
rstrstDURVADUR
t DURVA DURVA 
on a 60n a 60 -minmi
!! PriPri
bb
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 58 MEDI4736-MM- 005 Final: 03 Oct 20167.2.1.1.2.2. Subsequent DURVA infusions
For the subsequent DUR VA infusions, vital signs  will be measured prior to the start of the 
infusion. Subjects should be  carefully monitored and blood pressure and other vital signs should 
be measured during and post infusion as per inst itution standard and as clinically indicated. Any 
clinically significant changes in vital signs should be entered onto an unscheduled vital signs 
electronic case report form (eCRF) page. 
In the event of a â‰¤ Grade 2 infusion-related reaction, th e infusion rate of study drug may be 
decreased by 50% or interrupted until resolution of the event (up to 4 hours) and reinitiated at 
50% of the initial rate until completion of the infusion. For patients with a â‰¤ Grade 2 
infusion-rel ated reaction, subsequent infusions may be  administered at 50% of the initial rate. 
Acetaminophen/paracetamol and/or an antihistamine (eg, diphenhydramine) or equivalent 
medications per institutional standard may be administered at the discretion of the 
investigator. If the infusion-related reaction is â‰¥ Grade 3 or higher in se verity, study drug will be 
discontinued.
As with any antibody, allergic reactions to dose administration are possible. Appropriate drugs 
and medical equipment to treat acute anaphylactic reactions must be immediately available, and study personnel must be trained to recognize and treat anaphylaxis. The study site must have 
immediate access to emergency resuscitation teams and equipment in addition to the ability to 
admit patients to an intensive care unit if necessary.
7.2.1.2. Daratumumab (Darzalex)
Subjects should be carefully observed during DARA infusions. Refer to the full prescribing 
information for DARA ( Darzalex PI ).
Pre-infusion and post infusion medications for i nfusion reaction prophylaxis will be given as 
detailed in Table 6 for all sub jects.
7.2.1.2.1. Infusion-related Reactions of Grade 1 or Grade 2
If the investigator assesses an adverse event to be related to the infusion, then the infusion should 
be paused. When the subjectâ€™s condition is stable, the infusion may be restarted at the investigatorâ€™s discretion. Upon restart, the infusion rate should be half of that employed before 
the interruption. Subsequently, the infusion rate may be increased at the investigatorâ€™s discretion.
If the subject experiences a Grade 2 or higher event of laryngeal edema, or a Grade 2 or higher 
event of bronchospasm that does not respond to systemic therapy and does not resolve within 
6 hours from onset, then the subject must be withdrawn from daratumumab treatment. 
7.2.1.2.2. Infusion-related Reactions of Grade 3 or Higher
For infusion-related adverse events that are Grade 4, the infusion should be stopped and the 
subject withdrawn from DARA treatment. 
For infusion-related adverse events that are Grade 3, the infusion must be stopped and the subject 
must be observed carefully until resolution of the adverse event or until the intensity of the event 
decreases to Grade 1, at which point the infusion may be restarted at the investigatorâ€™s discretion. Upon restart, the infusion rate should be half of that employed before the interruption. 
CCICELGENE PROPRIETARY INFORMATIONl rate. ate.
valealentnt
studystudy  drugdruyy
ible. Approe. App
immediatelmmediatel
s. The studyThe stud
ment in addient in
AAinfusioninfusion
fofor infusir infusi ono
ons of Grons of Gr
adverse evedverse eve
tâ€™s conditâ€™s condit io
Upon restaUpon re
equentquent ly, thth
riences a Griences a G
hospasm thahospasm tha
m onset, them onset, the
2.2.Infusionfusi
infusioinfusio n-n-
subject witubject wit
or infor inf
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 59 MEDI4736-MM- 005 Final: 03 Oct 2016Subsequently, the infusion rate may be increased at the investigatorâ€™s discretion. If the intensity 
of the adverse event returns to Grade 3 after restart of the infusion, then the procedure described 
in this section should be repeated, or the sub ject may be withdrawn from treatment. Should the 
intensity of the adverse event increase to Grade 3 for a third time, then the subject must be withdrawn from DARA treatment.
Table 6: Daratumumab Pre Infusion and Post Infusion Medications
Time point Medication All Subjects
Pre infusion (~1 hr prior 
to every daratumumab 
(DARA)administration)Oral montelukast
(if approved and 
available)per investigator discretion prior to first 
infusion
Intravenous (IV)corticosteroid methylprednisolone 100 mg or equivalent dose 
of an intermediate-acting or long-acting 
corticosteroid ( Refer to Table 7 for conversion 
table). Following the second infusion, the dose of corticosteroid may be reduced 
(methylprednisolone 60 mg intravenously)
oral antipyretics acetaminophen 650 to 1000 mga
oral or IV antihistamine diphenhydramine 25 to 50 mg or equivalent
Post infusion Medication 
(1
stand 2ndday after 
every DARA 
administration)oral corticosteroidb20 mg methylprednisolone or equivalent dose 
of a corticosteroid in accordance with local 
standards 
aIf necessary, oral preinfusion medications may be administered at the subjectâ€™s home on the day of the infusion, 
provided they are given within 3 hours prior to the infusion
bFor subjects with a history of obstructive pulmonary disorder, consider prescribing post infusion medications such as short and long-acting bronchodilators, and inhaled corticosteroids. Following the first four infusions, if the patient experiences no major infusion reactions, these additional inhaled post infusion medications may be 
discontinued.
Table 7: Conversion Table for Glucocorticoid Dose
Generic Name Oral or Intravenous Dose (mg)
Dexamethasone 0.75
Hydrocortisone 20
Methylprednisolone 4
Prednisolone 5
Prednisone 5
CCICELGENE PROPRIETARY INFORMATIONTTTAT
quivalent doquivalent d
ongong--acting acting 
ble ble 7for coor co
cond infusioond infusio
y be reducedbe redu
one 60 mg inne 60 mg inRM
en 650 to 10650 to 10IN
dramine 25 dramine 2Y
mg methylpreg methylpre
a corticostea corticoste
sstandards tandardsRY
RIRIERII administereadministere
the infusionthe infusi
lmonary disolmonary diso
and inhaled and inhaled
reactions, thereactions, th
on Table fon Tabl
ENE
soneoneEN
prednisolonprednisolonG
dnisolonednisoloneLG
PrednisonPrednisonCECC
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 60 MEDI4736-MM- 005 Final: 03 Oct 20167.2.2. Treatment Schedule
7.2.2.1. Daratumumab Plus Durvalumab Treatment Schedule
See Section 3.1for dosing rules.
!Intravenous DARA on the same dosing schedule received on last MM Dara-
containing regimen
âˆƒ16 mg/kg starting at the same dosing schedule; QW, Q2W, or Q4W, as their last 
DARA-containing MM therapy. 
âˆƒDosing schedule should be adjusted as s hown below;  provided that th e patient has 
a response of stable disease (SD) or better:
!QW frequency (Days 1, 8, 15 and 22/28-day cycle): Weeks 1 to 8 then Q2W 
Weeks 9 to 24
!Q2W frequency(Days 1, 15 of a 28-day cycle): Weeks 1 to 16 then Q4W
!Q4W frequency (Day 1 of each 28-day cycle):Week 1 onwards until disease 
progression
!Intravenous DURVA:
âˆƒ1500 mg on Day 2 of Cycle 1, then Day 1 of Cycle â‰¥ 2 of a 28-day cycle.  
NOTE: For all DURVA infusions after Cycle 1, a +1 day window is allowed 
(subject may either receive the DURVA infusion on same day as the DARA infusion or on the next day per the investigatorâ€™s discretion; concomitant 
administration of DARA and DURVA is prohibited).
7.2.3. Overdose
Overdose, as defined for this protocol, refers to DURVA and DARA dosing only. On a per dose 
basis, an overdose is defined as the follo wing amount over the protocol-specified dose of 
DURVA and DARA assigned to a given subject, regardless of any associated AEs or sequelae.
!For IV, 10% over the protocol-specified dose
On a schedule or frequency basis, an overdose is defined as any am ount more frequent than the 
protocol-required schedule or frequency. On an infus ion rate basis, an overdose is defined as any 
rate faster than the protocol-specified rate. Complete data about drug administration, including 
any overdose, regardless of whether the overdose was accidental or intentional, should be 
reported in the eCRF. See Section 10.1 for the reporting of AEs associated with overdose.
7.2.4. Dose Modifications and Interruptions
Subjects will be evaluated for AEs at each visit with the NCI CTCAE Version 4.03 or higher as a 
guide for the grading of severity.  
If the treatment has been interrupted and the next cycle is delayed beyond Day 28 of the prior 
cycle, then Day 1 of the next cycle will be de fined as the first day that study treatment is 
resumed. 
CCICELGENE PROPRIETARY INFORMATIONatient has ent has
o 88ththen Qen Q
1 to 16 the1 to 16 the
k 1k 1onwardonward
of Cycle  Cycle fâ‰¥ â‰¥
Cycle 1, aCycle 1, a
RVA infusioRVA infusio
he investigae investig
DURVA is pDURVA is p
coll, ref, refers toers fff
he fohe fo llollowinwi
d to a givend to a given
over the prover the 
quencyuency bbyyasia
schedule orchedule or
the protocothe protoco
e, regardlese, regardle
n the eCRFthe eCRF
4.4. DosDos
Subjects wSubjects w
guiuide fde ff
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 61 MEDI4736-MM- 005 Final: 03 Oct 2016!If DURVA is permanently discontinued, then the subject must be permanently 
discontinued from all study treatments.
!If DARA is withheld or permanently discontinued, then DURVA dosing may be 
continued.
7.2.4.1. Dose Modification Instructions for Durvalumab
Refer to Appendix E for detailed instructions for DURVA dose modifications and toxicity
management.
7.2.4.2. Dose Modification Instructions for Daratumumab
For dose modification instructions for DARA, refer to the full prescribing information ( Darzalex
PI).
The criteria for a dose delay are:
!Grade 4 hematologic toxicity, or Grade 3 or higher thrombocytopenia with bleeding; 
!Febrile neutropenia of any grade;
!Neutropenia with infection, of any grade;
!Grade 3 or higher non-hematologic toxicities with the following exceptions: 
âˆƒGrade 3 nausea or Grade 3 vomiting that responds to antiemetic treatment, 
âˆƒGrade 3 diarrhea that responds to antidiarrheal treatment, 
âˆƒGrade 3 fatigue or asthenia that lasts for <7 days after the last administration of 
DARA.
DARA treatment should be resumed when  the toxicity has resolved to %Grade 2. If DARA 
administration does not commence within the pre-specified window ( Table 8 ) of the scheduled 
administration date, then the dose will be considered a missed dose. 
Administration may resume at the next planned dosing date. A missed dose will not be made up.
Table 8: Daratumumab-related Toxicity Management
CyclesDosing 
Frequency Dose Miss Dosing Resumption
1 and 2 Weekly (QW) >3 days next planned QW dosing date
3 to 6 Biweekly 
(Q2W)>7 days next planned Q2W dosing date
7+ Every 4 weeks 
(Q4W)>21 days next planned Q4W dosing date
Any dose delay of more than 28 days due to toxicity will result in permanent discontinuation of 
DARA. Dose delays of more than 28 days for other reasons should be discussed with the 
Sponsor. 
CCICELGENE PROPRIETARY INFORMATIONon on ((DarDarzalezale
ytopenitopeniy a w
hh th thhhe foe fllooRY t responds tresponds
tidiarrheal tidiarrheal
lasts for <asts for < 7
en the toxien the to
itithin the phin the
will be conwill be c
t the next pt the next p
mabab-r-relat
Dosing Dosing
FrequencFrequencEP
Weekly WeeklyENGEBiwBiw
((GEGEGEGE
ELGCE
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 62 MEDI4736-MM- 005 Final: 03 Oct 20167.2.4.2.1. Interruption or Missed Doses
A dose delay of 3 days or more from the planned date of administration for any reason other than 
toxicities suspected to be related to DARA s hould be brought to the attention of the Sponsor at 
the earliest possible time. 
Subjects missing â‰¥3 consecutive planned doses of DARA for  reasons other th an toxicit y should 
be withdrawn from treatment, unless, upon consu ltation with the Sponsor and the review of 
safety and efficacy, continuation is agreed upon.
7.3. Treatment Assignment
Celgene trial staff will review specific eligibility criteria for all screened subjects prior to 
initiation of study treatment via the IRT.
An IRT will be used to track subject assignments to the treatment stages and/or parts.
7.4. Packaging and Labeling
The label(s) for IP will include Sponsor name, address and telephone number, the protocol 
number, IP name, dosage form and strength (where applicable), amount of IP per container, lot number, expiry date (where applicable), medication identification/kit number, dosing 
instructions, storage conditions, and required caution statements and/or re gulatory statements as 
applicable. Additional information may be included on the label as applicable per local regulations.
7.5. Investigational Product Accountability and Disposal
Celgene (or designee) will review with the Investigator and relevant site personnel the process for investigational product return, disposal, and/or destruction including responsibilities for the site versus Celgene (or designee).
7.6. Investigational Product Compliance
Accurate recording of all study treatment ad ministration (DURVA and DARA) will be made in 
the appropriate section of the subjectâ€™s eCRF and source documents. The investigator or designee is responsible for accounting for all study-specific treatment (DURVA and DARA) 
either administered or in their custody during the course of the study. 
CCICELGENE PROPRIETARY INFORMATIONto to 
parts.parts.
number, thnumber, th
mount of IPmount of I
on/kit numbn/kit numb
ents and/or ents and/o
e label as ae label as a
ntability ntability
vestvestigator igator 
l, and/or del, and/or de
roduct Coroduct C
dydytreatmtreatyy en
the subjecte subject
for accounfor accou
or in their cr in their 
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 63 MEDI4736-MM- 005 Final: 03 Oct 20168. CONCOMITANT MEDICATIONS AND PROCEDURES
Over the course of this study, additional medications may be required to manage aspects of the 
disease state of the subjects, including side e ffects from trial treatments or disease progression. 
Supportive care, including but not limited to anti-emetic medications, may be administered at the 
discretion of the investigator.  
See Appendix E for additional details on DURVA toxicity management.
All concomitant treatments, including blood and blood products, used from 28 days prior to first 
dose of study treatment until 90 days after last dose of DURVA or DARA, whichever is later,must be reported on the eCRF. 
For information regarding other drugs that may interact with IP and affect its metabolism, PK, or 
excretion, please see the IBs and/or local package inserts.
8.1. Permitted Concomitant Medications and Procedures
Subjects with myeloma-associated bone diseas e may receive bisphosphonate therapy prior to 
study entry, unless such therapy is contraindicated.  The use of bisphosphonates is permitted 
throughout the study.
Platel et/RBC transfusions and hematopoietic growth factors are also permitted during the study.  
Concurrent use of hormones for noncancer-related conditions (eg, insulin for diabetes and 
hormone replacement ther apy) is acceptable.
8.2. Prohibited Concomitant Medications and Procedures
The following medications are prohibited (except for the outlined exceptions) during the study. 
The Sponsor must be notified if a subject receives any of these during the study.
1. Subjects who fail ANC, hemoglobin or pl atelet eligibility criteria at Screening should not 
be retested for the study after being treated with growth factors or platelet/RBC 
transfusion.
2. Any investigational anticancer therapy.
3. Any concurrent chemotherapy, radiotherapy (except palliative radiotherapy), 
immunotherapy, biologic or horm onal therapy for cancer treatment. 
4. Immunosuppressive medications including, but not limited to systemic corticosteroids at 
doses exceeding 10 mg/day of prednisone or equivalent, methotrexate, azathioprine, and 
tumor necrosis factor alpha (TNF- Î±) blockers. The following exceptions apply:
a. Pre and post infusion med ications as outlined in Table 6 andTable 7 for the 
management of infusion-rel ated reactions.
b. Use of immunosuppressive medications in subjects with contrast allergies (eg, CT 
scan contrast hypersensitivity) is acceptable. 
c. Use of inhaled, topical, or intranasal corticosteroids or local steroid injections (eg, 
intra-articular injection) is permitted. 
CCICELGENE PROPRIETARY INFORMATIONstt
err,,
lism, PK, olism, PK, 
s
onate therapate the
osphonatessphonate
re also permre also p
ons (eg, inons (eg, in
cations ancations a
xcept for thxcept for th
receives anreceives an
glglobin or pobin o
er being being tretr
anticancer anticance
chemotherchemothe
apypy, bi, biolologiog
suppressivesuppressiv
exceeding exceeding
mor necrosior necrosi
a.PPr
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 64 MEDI4736-MM- 005 Final: 03 Oct 2016d. Temporary uses of corticosteroids for concurrent illnesses (eg, food allergies) are 
acceptable upon discussion and agreement with the Medical Monitor. 
5. Live attenuated vaccines during the study t hrough 30 days after the last dose of DURVA. 
6. Herbal and natural remedies are to be avoided.7. Egg cell and sperm donation
8.3. Required Concomitant Medications and Procedures
!Infusion reaction prophylaxis: Pre infusion and post infusion med ications for 
infusion reaction prophylaxis will be given as detailed in Table 6 .
!Antiviral prophylaxis: All subjects must initiate antiviral prophylaxis to prevent 
herpes zoster reactivation within 1 week of starting DARA and continue for 3 months
following last dose of DARA.  
âˆƒAcceptable antiviral therapy includes acyclovir (eg, 400 mg given orally 3 times a 
day, or 800 mg given orally 2 times a day or per institutional standards), famciclovir (eg, 125 mg given orally, twice a day or per institutional standards), 
or valacyclovir (eg, 500 mg given orally, twice a day or per institutional 
standards), initiated within 1 week after the start of study drug.
CCICELGENE PROPRIETARY INFORMATIONo prevent o prevent 
nue for 3nue for 3 mm
g given orag given ora
ionalonal stand stanll
per inster inst itiut
day or per iy or per 
rt of rt of studystud
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 65 MEDI4736-MM- 005 Final: 03 Oct 20169. STATISTICAL CONSIDERATIONS
9.1. Overview
This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the 
combination regimen of DARA plus DURVA in subjects with RRMM who have progressed 
while on last MM treatment (DARA-containing regimen)
This section defines the subject populations for the statistical data analyses, the justifications of 
sample size, and the methodologies that will be used for the efficacy and safety analyses. All 
statist ical analyses sp ecified in the protocol will be conducted using SAS Version 9.2 or higher 
unless otherwise specified. 
9.2. Study Population Definitions
For the purpose of statistical analyses and data presentation, the study populations are defined as follows:
9.2.1. Full Analysis Set Population
The full analysis set population (FAS) will include all enrolled subjects. The primary efficacy 
analyses will be performed on the FAS population. 
9.2.2. Efficacy Evaluable Population
The supportive efficacy analyses will be perform ed on the efficacy evaluable (EE) population, 
which will include all enrolled subjects who take at least one dose of D
2and who have 
measureable disease at baseline and at least one post-baseline efficacy measurement. 
9.2.3. Safety Population
The safety population will include all subjects who take at least one dose of D2. All safety 
analyses will be based on this population.  
9.2.4. Pharmacokinetic Population
The PK population will include all subjects who received at least one dose of study treatment and 
who have at least one measureable plasma con centration. For subjects who are determined to be 
noncompliant with respect to ad ministration of IP, or for subjects with incomplete data, a 
decision as to their inclusion in the population w ill be made on a case-by-case basis prior to the 
analysis. 
9.3. Sample Size and Power Considerations
The study consists of 2 parts. In Part 1, a two-stage design with one interim analysis for futility 
at the end of Stage 1 is used. PASS software, Version 13.03 has been used to calculate the 
sample sizes. Setting the Type I error rate at 0.05, a total sample size of 50 subjects provides a power of at least 80% to reject the null hypothesis of ORR less than 10% with a target response 
rate of 25%. In Stage 1, 18 subjects will be enrolled and if there are at least 3 subjects out of 18 
who achieved a response (PR or above) by end of cycle 3, the study will continue to Stage 2. If 
there are 2 or less subjects who achieved a response out of 18 subjects in Stage 1, the study will 
CCICELGENE PROPRIETARY INFORMATIONigher igher 
tioinsnare dere de
ubjects. Thjects. Th
on the efficon the eff
at least oneat least on
e poste post --basebase
l subjects l subject w
ulatulatioin.   
c Populatioc Populati
include all include a
measureabmeasure
h respect to respect to 
eir inclusioeir inclusio
SaSampmp
e studystudy concony
at the end ot the end 
sample ample
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 66 MEDI4736-MM- 005 Final: 03 Oct 2016be terminated for futility and will not proceed to S tage 2. In Stage 2, an additional 32 subjects 
will be enro lled. If there are at least 9 subjects who achieved a response out of a total of 50 
subjects from Stages 1 and Stage 2, the null hypothesis will be rejected. If it is determined at the 
end of Part 1 to further evaluate the efficacy and safety of the combination regimen of DARA plus DURVA, then up to an additional 70 subjects will be enrolled in Part 2. This will bring the 
total number of subjects treated during the study up to approximately 120. The additional 
subjects will add to the certainty about the efficacy and safety of this combination therapy.  Table 9 shows the exact 95% CIs around the response rates observed based on different 
scenarios. For example, if the observed ORR is 25%, the lower limit of the 95% CI w ill be 
17.5%. If the observed ORR is 30%, the lower limit of the 95% CI w ill be 22.0%.  
Table 9: Estimated Overall Response Rate and 95% Confidence Interval Out of 120 
Subjects
Number of Responders in 120 Subjects ORR 95% Confidence Interval
30 25.0  % 17.5, 33.7
31 25.8 % 18.3, 34.6
32 26.7 % 19.0, 35.5
33 27.5 % 19.7, 36.4
34 28.3 % 20.5, 37.3
35 29.2 % 21.2, 38.2
36 30.0 % 22.0, 39.0
37 30.8 % 22.7, 39.9
38 31.7 % 23.5, 40.8
39 32.5 % 24.2, 41.7
40 33.3 % 25.0, 42.5
ORR=overall response rate
9.4. Background and Demographic Characteristics
Subjectsâ€™ age, height, weight, and baseline characteristics will be summarized using descriptive statistics, while gender, race and other categorical variables will be provided using frequency 
tabulations. Medical history data will be summar ized using frequency tabulations by system 
organ class (SOC) and preferred term (PT). 
9.5. Subject Disposition
Subject disposition (analysis population allocat ion, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent.  A summary of subjects enrolled by site will be provided. P rotocol deviations will be summarized using 
frequency tabulations.
CCICELGENE PROPRIETARY INFORMATIONut of 120 t of 120 
nfidence Innfidence OR17.5, 17.5, 33FO181NFINYYYYY
%%AR 29.2 %9.2 %TA 30.0 %30.0 ET303RIEPROPOPOPOPOPROOOO
PRO
ound andund an
eight, weighight, weigh
le gender, rgender, 
 MedicalMedical hh
ass (SOC) ass (SOC)
5. SuS
Subject dSubject d
ason
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 67 MEDI4736-MM- 005 Final: 03 Oct 20169.6. Efficacy Analysis
Primary efficacy analyses will be performed on the FAS population. Supportive efficacy 
analyses will also be performed using the EE population. 
9.6.1. Primary Efficacy Endpoint
The primary efficacy endpoint will be based on the tumor response, including PD, as assessed by 
an IRAC using the IMWG Uniform Response Criteria. 
The overall response rate (ORR) will be calculated as the number of responders (PR or better), 
divided by the number of subjects in the FAS population. The ORR together with the proportions 
in each category based on the IMWG criteria ( ie, stringent complete response [sCR], complete 
response [CR], very g ood partial response [VGPR], partial response [PR], stable disease [SD], 
and disease progression [PD] will be tabulated, together with the 2-sided exact 95% CI. 
This efficacy analysis will be conducted after the 18 subjects from Stage 1 have completed at 
least 3 cycles of treatment, Stage 2 of the Part 1 study and at the end of Part 2 of the study if the decision has been made to expand the study. 
9.6.2. Secondary Efficacy Endpoints
Time-to-res ponse (for responders only, per IMWG Uniform Response Criteria) is calculated as 
the time from treatment initiation of study tr eatment to the first date of documented response (PR 
or better). Time to response will be summarized using descriptive statistics.
Duration of response (for responders only, per IMWG criteria) is defined as t ime from the 
earliest date of documented response (PR or bette r) to the first documentation of PD or death, 
whichever is earlier. Duration of response will be analyzed using the Kaplan-Meier (KM) 
method. Median duration of response along with the two-sided CI will be provided. 
Progression-free survival is defined as t ime from tr eatment initiation to the first date of 
documented PD or death from any cause during th e study, whichever occurs earlier. Subjects 
who do not have a PFS event will be censored on the last adequate assessment date. PFS will be summarized using the KM method. 
Overall survival is defined as time from treatment in itiation to death due to any cause. Subjects 
who are alive or lost to follow-up will be censored on the last-known-alive date. The OS will be analyzed using the KM method. Median OS and the corresponding 95% CI will be provided. 
9.7. Safety Analysis
All subjects in the sa fety population w ho receive at least 1 dose of DARA plus DURVA, will be 
included in the safety analyses. Adverse events, vital sign measurements, physical exam findings, clinical laboratory data, ECG interpretations, pregnancy tests for FCBP, concomitant 
medications and procedures will be tabulated and summarized. 
Adverse events will be coded using the Me dical Dictionary for Regulatory Activities 
(MedDRA). Adverse event listings will include the verbatim term and the MedDRA preferred 
tem. Adverse events will be graded according to the CTCAE Version 4.03 criteria. 
CCICELGENE PROPRIETARY INFORMATIONr), r), 
portions ortions 
omomplete plete m
ease [SD],ease [SD]
5% % CICI. 
ave coave co mpmple
art 2 of the art 2 of the 
ResponseResponse C
 first date ofirst date 
descriptdescript ive ive
WG criteriaWG criteria
ter) to the ter) to the ff
ll be analyzll be analyz
g with the g with the 
time me from from
cause durinause duri
ll be censorll be censo
ethod. ethod. 
d as time frd as tim
fofollollow-up
KM methoM metho
afety Anaafety Ana
cts in thin the sae sa
ed in the sad in the sa
dings, clinicings, clinic
medicatmedicat ioionsn
AdAdversvers
d
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 68 MEDI4736-MM- 005 Final: 03 Oct 2016The frequency of AEs will be tabulated by MedDRA SOC and PT. In the by-subjects analysis, a 
subject having the same event more than once will be counted only once. Adverse events leading 
to discontinuation from treatment, leading to dose reduction/interruption/delay, classified as 
CTCAE Grade 3 or higher, DARA, DURVA-related events, and serious AEs will be tabulated and listed separately. By-subject listings of all AEs, serious AEs, and their attributes will be 
provided. 
Primary cause of death recorded on the eCRF death form will be coded according to MedDRA 
and summarized by SOC and PT. By-subject listing of death will also be provided. 
Clinical laboratory results will be summarized descript ively and will include a display of change 
from baseline. Laboratory values outside of the normal ranges will be identified. Laboratory data will be graded according to CTCAE Version 4.03 criteria for select analytes unless otherwise 
specified. The frequencies of the worst severity grade observed during treatment will be 
displayed in cross-tabulations by screening status. 
9.8. Interim Analysis
This study will be conducted in 2 parts. Part 1 and Part 2. Part 1 consists of one pre-planned 
interim analysis for futility purposes at the completion of Stage 1.
9.9. Other Topics
9.9.1. Pharmacokinetic Analysis
Noncompartmental PK parameters such as time to maximum concentration (T max), maximum 
observed concentration (C max), area under the curve (AUC), terminal elimination half-life (t 1/2), 
clearance (CL/F), and volume of distribution (V z/F) will be estimated from the plasma 
concentration-time profile. All concentration data and PK parameters will be summarized 
descriptively. 
 
 
 
 
 
 
 
CCICCI
CELGENE PROPRIETARY INFORMATIONhange hange 
atoryatory data datyy
therwise therwise 
will be ill be 
ists ofsts of oneone
maximum maximum
urve (AUC)rve (AUC
(V(Vzz/F) wil/F) wilzzz
ion data anion data an
RPROPREPNE ENEGENLGEELGCELEL
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 69 MEDI4736-MM- 005 Final: 03 Oct 2016 
 
 
 
9.10. Study Committees
9.10.1. Data Monitoring Committee 
An external and independent DMC with multidis ciplinary representation will be established to 
monitor the safety data regularly.
The DMC will review the safety and the efficacy data at the end of Stage 1. If the study is to 
proceed to Stage 2, the DMC will also review the safety and efficacy data at the end of Stage 2. 
The DMC chairman may convene formal DMC meetings if there are any unusual safety/efficacy 
concerns. The Sponsor can also request a DMC review of the safety data if unexpected safety 
concerns arise during the conduct of the trial. The DMC responsibilities, authorities, and 
procedures will be detailed in the DMC charter.  
9.10.2. Independent Review Adjudication Committee
An IRAC will be set up for this trial to  assess the response data for each subject using the 
IMWG Uniform Response Criteria. The IRAC will determine the tumor response to therapy and 
to confirm the time of disease progression (PD) (if disease progressed) at scheduled or 
unscheduled visits for each subject. 
CCIC
CI
ished to shed to 
he studyhe study iys
the end of the end o
y unusual saunusu
data if unexata if unex
ilitliies, authes, aut
ee
ponse onse data data ff
determine determine
(if di(if di sease psease 
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 70 MEDI4736-MM- 005 Final: 03 Oct 201610. ADVERSE EVENTS
10.1. Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study. It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomi tant impairment of the subjectâ€™s health, including 
laboratory test values (as specifi ed by the criteria in Section 10.3), regardless of etiology. Any 
worsening (ie, any clinically significant adverse change in the frequency or intensity of a 
preexisting conditio n) should be considered an AE. A diagnosis or syndrome should be recorded 
on the AE page of the case report form (eCRF) rather than the individual signs or symptoms of the diagnosis or syndrome. 
Abuse, withdrawal, sensitivity or toxicity to an IP should be reported as an AE. Overdose, 
accidental or intentional, whether or not it is associated with an AE should be reported on the overdose eCRF (see Section 7.2.3 for the definition of overdose). Any sequela of an accidental or 
intentional overdose of an IP should be reported as an AE on the AE CRF. If the sequela of an 
overdose is an SAE, then the sequela must be reported on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be identified as the cause of the event on the 
SAE report form and CRF but should not be reported as an SAE itself.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary. There is no known specific antidote for DURVA, or DARA, 
overdose. Actual treatment should depend on the severity of the clinical situation and the 
judgment and experience of the treating physician.
All subjects will be monitored for AEs during the study. Assessments may include monitoring of 
any or all of the following parameters: the subjectâ€™s clinical symptoms, laboratory, pathological, 
radiological or surgical findings, physical examin ation findings, or findings from other tests 
and/or procedures.
All AEs will be recorded by the Investigator from the time the subject signs informed consent 
until 90 days after the last dose of DURVA or DARA, whichever is later, as well as those SAEs made known to the Investigator at any time thereafter that are suspected of being related to study 
IPs (DARA, DURVA). Adverse events and SAEs will be recorded on the AE page of the CRF 
and in the subjectâ€™s source documents. All SAEs mu st be reported to Celgene Drug Safety within 
24 hours of the Investigatorâ€™s knowledge of the event by facsimile, or other appropriate method, 
using the SAE Report Form, or approved equivalent form. 
10.2. Evaluation of Adverse Events
A qualified Investigator will evaluate all AEs as to: 
10.2.1. Seriousness
An SAE is any AE occurring at any dose that:
!Results in death;
!Is life-threatening (ie, in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);
CCICELGENE PROPRIETARY INFORMATIONorded rded 
oms of ms of 
Overdose, erdose, 
reported oneported o
ela of an acela of an a
F. If the seq. If the
ort form anort form an
cause of tcause of
E itself. itsel
s appropriatappropriat
ecific antcific ant id
ritrity yofof the c the ff
the studyhe study . A.
ubjectâ€™s cliubjectâ€™s cli
l examinatil examinati
vestivestgator ato
 of DURVAof DURVA
ator at anyator at an
ddverse eveerse 
urce documurce docum
estigatorâ€™s igatorâ€™s 
Report FormReport Form
EvaluatiEvaluati
ified Invesified Inves
0.2.1.0.2.1. S
An SAEAn SA
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 71 MEDI4736-MM- 005 Final: 03 Oct 2016!Requires inpatient hospitalization or prolongation of ex isting hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);
!Results in persistent or significant disability/incapacity (a substantial disruption of the 
subjectâ€™s ability to conduct normal life functions);
!Is a congenital anomaly/birth defect;
!Constitutes an important medical event.
Important medical events are defined as those occurrences that may not be immediately life-
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above. 
Medical and scientific judgment should be exercised in deciding whether such an AE should be considered serious.
Events not considered to be SAEs are hospitalizations for:
!a standard procedure for protocol therapy administration.  However, hospitalization or 
prolonge d hospitalization for a complication of therapy administration will be 
reported as an SAE. 
!routine treatment or monitoring of the stud ied indication not associated with any 
deterioration in condition.
!the administration of blood or platelet transfusion as routine treatment of studied 
indication. However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.
!a procedure for protocol/disease-related investigations (eg, surgery, scans, endoscopy, 
sampling for laboratory tests, bone marrow  sampling). However, hospitalization or 
prolonge d hospitalization for a complication of such procedures remains a reportable 
SAE.
!hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.
!a procedure that is planned (ie, planned prior to start of treatment on study); must be 
documented in the source document and the CRF. Hospitalization or prolonged 
hospitalization for a complication remains a reportable SAE.
!an elective treatment of or an elective pro cedure for a pre-existing condition, 
unrelated to the studied indication, that has not worsened from baseline. 
!emergency outpatient treatment or observa tion that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form 
must be completed.
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to the IP, action taken regarding the IP, and outcome.
CCICELGENE PROPRIETARY INFORMATIONor 
ve. 
E should beE should be
wever, hospwever, hos
ministratiinistrati ono
ation not astion n
usioion nas rouas ro
olonged hoolonged 
e SAE.e SAE.
llated invesated inves
one mne m arrowarrow
a coma com plicplmmm
ongationgati on oon 
e of an AE.e of an AE
at is planneat is pla
d in the soud in the sou
zatiation fon for or fff
ectective treaive trea
nrelated to nrelated to
ememergenerge
unlesunl
f an AE if an AE i scs
must be cmust be c
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 72 MEDI4736-MM- 005 Final: 03 Oct 201610.2.2. Severity/Intensity
For both AEs and SAEs, the Investigator must a ssess the severity/ intensity of the event. 
The severity/intensity of AEs will be graded based upon the subjectâ€™s symptoms according to the 
current active minor version of the Common Terminol ogy Criteria for Adverse Events (CTCAE, 
Version 4.03 or higher); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Adverse events that are not defined in the CTCAE should be evaluated for severity/intensity 
according to the following scale:
!Grade 1 = Mild â€“ transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!Grade 2 = Moderate â€“ mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!Grade 3 = Severe â€“ marked limitation in activ ity, some assistance usually required; 
medical intervention/therapy required, hospitalization is possible
!Grade 4 = Life-threateningâ€“ extreme limi tation in activity, significant assistance 
required; significant medical intervention/therapy required, hospitalization or hospice care probable
!Grade 5 = Death - the event results in death.
The term â€œsevereâ€ is often used to describe th e intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is notthe same as â€œseriousâ€ which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subjectâ€™s life or functioning. 
Seriousness, not severity, serves as a guide for defining regulatory obligations.
10.2.3. Causality
The Investigator must determine the relationship between the administration of the IPs (DARA, 
DURVA) and the occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: A causal relationship of the AE to IPs (DARA, DURVA)
administration is unlikely or remote , or other medications, 
therapeutic interventions, or underlying conditions provide a sufficient 
explanation for the observed event.
Suspected: There is a reasonable possibility that the administration of IPs 
(DARA, DURVA) caused the AE. â€˜Reasonable possibilityâ€™ means 
there is evidence to suggest a causal relationship between the IP and the adverse event.
CCICELGENE PROPRIETARY INFORMATIONedicaldical
ssistance mssistance m
nce usuallynce usually
ssiblesible
itty,y significsignif
quiquired, hosrediii
sitity of a spy of a 
however, mhowever, 
criterioriterio n nis is 
ititerieria assoa asso
a guiguide fde for offf
rmine the rmine the 
rence of anrence of a
ed:d: A caA c
a
SuspecteSuspecte
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 73 MEDI4736-MM- 005 Final: 03 Oct 2016Causality s hould be a ssessed and provided for every AE/SAE based on currently available 
information. Causality is to be reassessed and provided as additional information becomes 
available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.
10.2.4. Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
10.2.5. Action Taken
The Investigator will report the action taken with IPs (DARA, DURVA) as a result of an AE or 
SAE, as applicable (eg, discontinuation, interruption, or dose reduction of IPs, as appropriate) and report if concomitant and/or addition al treatments were given for the event. 
10.2.6. Outcome
The Investigator will report the outcome of the event for both AEs and SAEs.
All SAEs that have not resolved upon discontinuation of the subjectâ€™s participation in the study 
must be followed until recovered (returned to baseline), recovered with sequelae, or death (due to 
the SAE).
10.3. Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!results in discontinuation from the study; or
!requires treatment, modification/ interrup tion of IPs (DARA, DURVA) dose, or any 
other therapeutic intervention; or
!is judged to be of significant clinical importance, eg, one that indicates a new disease 
process and/or organ toxicity, or is an exacerbation or worsening of an existing 
condition.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as an SAE.
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF. If the abnormality was not a part of a diagnosis or syndrome, then the labor atory abnormality should be recorded as the AE. If 
possible, the laboratory abnormality should be r ecorded as a medical term and not simply as an 
abnormal laboratory result (eg, record thrombocyt openia rather than decreased platelets).
10.4. Pregnancy
All pregnancies or suspected pregnancies occurring in either a female subject of childbearing 
potential or partner of childbearing potential of a male subject are immediately reportable events . 
CCICELGENE PROPRIETARY INFORMATIONft h e  he 
esult of an sult of an
Ps, as approPs, as appr
event. event. 
AEs and SAEs an
e subjectâ€™s subjectâ€™
recovered wecovered
s
to be an Ato be an 
om the studm the stu
ificaticioon/ in/ i
ervention; oervention; o
of significanf signific
or organ toxor organ t
veriterity y gradegrade
umented asumented 
toryoryabnormabnormy
rome shoulrome shou
of a diagnoof a diagn
ossible, theossible, the
abnormbnorm alal
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 74 MEDI4736-MM- 005 Final: 03 Oct 201610.4.1. Females of Childbearing Potential:
Pregnancies and suspected pregnancies (including elevated Î²-subunit human chorionic 
gonadotropin [ Î²-hCG]) or positive pregnancy test in a female subject of childbearing potential 
regardless of disease state) occurring while the sub ject is on study tr eatment, or within 90 days 
after last dose of DURVA / DARA, whichever occurs later are considered immediately reportable 
events. Investigational product is to be discontinued immediately and the subject instructed to 
return any unused portion the Investigator . The pregnancy, suspected pregnancy, or positive 
pregnancy test must be reported to Celgene Drug Safety immediately by email, phone or 
facsimile, or other appropriate method, using the Pregnancy Initial Report Form, or approved 
equivalent form. 
The female subject should be referred to an obstetrician-gynecologist, preferably one 
experienced in reproductive toxicity for further evaluation and counseling.
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow -up Report Form, or approved equivalent form.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the Investigator 
should report the abnormal outcome as an AE. If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by facsimile, or other appropriate 
method, within 24 hours of the Investigatorâ€™s knowledge of the event using the SAE Report Form, or approved equivalent form.
All neonatal deaths that occur within 28 days of birth should be reported, without regard to 
causality, as SAEs. In a ddition, any infant death after 28 days  that the Investigator suspects is 
related to the in utero exposure to the IPs (DARA, DURVA) should also be reported to Celgene 
Drug Safety by facsimile, or other appropriate method, within 24 hours of the Investigatorâ€™s 
knowledge of the event using the SAE Report Form, or approved equivalent form.
10.4.2. Male Subjects
If a female partner of a male subject taking IPs (DARA, DURVA) becomes pregnant, the male 
subject taking IPs (DARA, DURVA) should notify the Investigator, and the pregnant female 
partner should be advised to call their healthcare provider immediately.
10.5. Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the CRF. All SAEs must be reported to 
Celgene Drug Safety within 24 hours of the Investigatorâ€™s knowledge of the event by facsimile, 
or other appropriate method (eg, via email), using the SAE Report Form, or approved equivalent form. This instruction pertains to initial SAE reports as well as any follow-up reports.
The Investigator is required to ensure that the data on these forms are accurate and consistent. 
This requirement applies to all SAEs (regardless of relationship to IPs [DARA, DURVA]) that occur during the study (from the time the subject signs informed consent until 90 days after the 
last dose of DURVA or DARA, whichever is later) or any SAEs made known to the Investigator 
at any time thereafter that are suspected of being related to IPs (DARA, DURVA). Seriousadverse events occurring prior to treatment (after signing the ICF) will be captured.
CCICELGENE PROPRIETARY INFORMATIONd d 
ncyncy, and mnd my
cycy(ei(eiyyththiier er
proved equioved e
ortion), ion), ththe
utcome meecome me
yyby facsimby facsi
fththe event e even
h should beh should 
afterfter28 day28 da
RA, DURVRA, DURV
ate methodate metho
Report FormReport Fo
ubject takinbject takin
DURVA) sDURVA)
d to call theto call
ting of Seting of Se
meets any creets any 
being recorbeing recor
Drug Safetug Safet
er approprier appropri
mm. This ins. This ins
The InvesThe Inves
his rehis re
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 75 MEDI4736-MM- 005 Final: 03 Oct 2016The SAE report should provide a detailed description of the SAE and include a concise summary 
of hospital records and other relevant documents . If a subject died and an autopsy has been 
performed, copies of the autopsy report and d eath certificate are to be sent to Celgene Drug 
Safety as soon as these become available. Any follow-up data should be detailed in a subsequent SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the Institutional 
Review Board/Ethics Committee (IRB/EC) of the SAE and providing them with all relevant initial and follow-up information about the event. The Investigator must keep copies of all SAE 
information on file including correspondence with Celgene and the IRB/EC.
10.5.1. Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail. The response t ime is exp ected to be no more than five (5) business 
days. Urgent queries (eg, missing causality assessment) may be handled by phone.
10.6. Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of events suspected of being related to DUR VA and DARA based on their respective IBs.
In the United States, all suspected unexpected serious adverse reactions (SUSARs) will be 
reported in an expedited manner in accordance with 21 CFR 312.32.
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, SUSARs in accordance with Directive 2001/20/EC and the Detailed 
Guidance on collection, verification and presentation of adverse reaction reports arising from clinical trials on IPs for human use (ENTR/CT3) and also in accordance with country-specific 
requirements. 
Events of disease progression for the disease under study (including deaths due to disease 
progression for indications that are considered to be fatal) will be assessed as expected AEs and 
will not be reported as expedited safe ty reports to regulatory authorities.
Celgene or its authorized representative sh all notify the Investigator of the following 
information: 
!Any AE suspected of being related to the us e of IPs (DARA, DURVA) in this study 
or in other studies that is both serious and unexpected (ie, suspected unexpected serious adverse reaction [SUSAR]);
!Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copies of all pe rtinent safety information on file including 
correspondence with Celgene and the IRB/EC (See Section 14.3 for record retention 
information).
CCICELGENE PROPRIETARY INFORMATIONE 
e sie site vie viii a a
five (5) busive (5) b
phone.phone
determine tdetermine
ononththeeirres
rse reactionse reaction
CFR 312.32FR 312.
EEA), CelgEEA), Ce
to Regulatto Regula
e with Direwith Dire
esentation osentation o
TR/CT3) anTR/CT3) an
tthe diseasehe diseas
t are considare consid
dited safetdited safe
d d representrepresen
AE suspectAE suspec
in other stuin other st
seriserous adous ad
!!Any fny f
humhum
Where reqWhere req
hhese nese n
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 76 MEDI4736-MM- 005 Final: 03 Oct 2016Celgene Drug Safety Contact Information:
For Celgene Drug Safety  contact information, please refer to the Serious Adverse Event Report 
Form Completion Guidelines or to the Pr egnancy Report Form Completion Guidelines.
10.7. Adverse Events of Special Interest
An adverse event of special interest (AESI) is one of scientific and medical interest specific to 
understanding of DURVA(MEDI4736) and may require close monitoring and rapid 
communication by the Investigator to the Sponsor. An AESI may be serious or non-serious. The 
rapid reporting of AESIs allows ongoing surveillance of  these events in order to characterize and 
understand them in association with the use of durvalumab.
AESIs for durvalumab include but are not limited to events with a potential inflammatory or 
immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants and/or hormone replacement therapy. These 
AESIs are being closely monitored in clinical  studies with durvalumab monotherapy and 
combination therapy. An immune-related adverse event (irAE) is defined as an AE that is 
associated with drug exposure and is consis tent with an immune-mediated mechanism of action 
and where there is no clear alternate etiology. Se rologic, immunologic, and histologic (biopsy) 
data, as appropriate, should be used to support an irAE diagnosis. Appropriate efforts should be made to rule out neoplastic, infectious, metabolic, toxin, or other etiologic causes of the irAE.
If the Investigator has any questions in regards to an AE being an irAE, the Investigator should 
promptly contact the Medical Monitor.
Further information on these AESIs (eg, presenting symptoms) can be found in the current 
version of the DURVA IB (Section 5.5.2 Summary of Risks). 
CCICELGENE PROPRIETARY INFORMATIONhe e
ze and and 
matorymatory or or yy
and/or and/or 
ment therapyent therap
notherapynotherapy aayy
d as an as an AE
iated mechated mec
ogic, and hgic, and h
is. Approprs. App
other etioother etio lolo
being an ibeing an
ng symptomng sympto
mmarymary  of ofy Ri Riff
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 77 MEDI4736-MM- 005 Final: 03 Oct 201611. DISCONTINUATIONS
11.1. Treatment Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the 
investigational product(s):
!Adverse event
!Withdrawal by subject
!Pregnancy
!Death
!Lost to follow-up
!Other (to be specified on the CRF)
The reason for discontinuation of treatment should be recorded in the CRF and in the source 
documents.
The decision to discontinue a subject from treatment remains the responsibility of the treating 
physician, which will not be delayed or refused by the Sponsor.  However, prior to discontinuing 
a subject, the Investigator may contact the Medical Monitor and forward appropriate supporting 
documents for review and discussion.
11.2. Study Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
!Screen failure
!Adverse event
!Withdrawal by subject
!Pregnancy
!Death
!Lost to follow-up
!Other (to be specified on the CRF)
The reason for study discontinua tion should be r ecorded in the CRF and in the source 
documents.
CCICELGENE PROPRIETARY INFORMATIONF and in thF and i
responsibilisponsibil
.  However How
and forwarand forwa
reasons foreasons fo
ectct
fofollollow-upw-up
her (to be ser (to be 
n for studyfor study
ents.nt
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 78 MEDI4736-MM- 005 Final: 03 Oct 201612. EMERGENCY PROCEDURES
12.1. Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page). This global 
Emergency Call Center is available 24 hours a day and 7 days a week. The representatives are 
responsible for obtaining your call-back information and contacting the on-call Celgene/contract 
research organization Medical Monitor, who will then contact you promptly.
Note: The back-up 24-hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls. 
12.2. Emergency Identification of Investigational Products
This is an open-label study; therefore, IPs w ill be identified on the package lab eling.
CCICELGENE PROPRIETARY INFORMATIONe e 
on 
ves are ves are 
ene/ene/contracontra
bbe used if y used if 
r designee fdesignee f
ProductsProduct
n the packan the pac
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 79 MEDI4736-MM- 005 Final: 03 Oct 201613. REGULATORY CONSIDERATIONS
13.1. Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to en sure that Celgene, its authorized represent ative,
and Investigator abide by Good Clinical Practice (GCP), as described in International Council on 
Harmonisation (ICH) Guideline E6 and in accordance with the general ethical principles outlined in the Declaration of Helsinki. The study w ill receive approval from an IRB/EC prior to 
commencement. The Investigator will conduct all aspects of this study in accordance with 
applicable national, state, and local laws of the pertinent regulatory authorities.
13.2. Investigator Responsibilities
Investigator respons ibilities ar e set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all Investigators who in turn will select their staff.
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions, including obligations of confidentiality of Celgene information. The Investigator should maintain 
a list of Sub-investigators and other appropriately qualified persons to whom he or she has 
delegated significant study-related duties.
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
form (ICF) and are screened for entry into the study .  Subjects who fail screening must have the 
reason(s) recorded in the subjectâ€™s source documents.
The Investigator, or a designated member of the Investigatorâ€™s staff, must be available during 
monitoring visits to review data, resolve quer ies and allow direct access to subject records (eg, 
medical records, office charts, hospital charts, and study-related charts) for source data verification.  The Investigator must ensure timely and accurate completion of CRFs and queries.
The information contained in the protocol and amendments (with the exception of the 
information provided by Celgene on public registry websites) is considered Celgene confidential 
information.  Only information that is previously disclosed by Celgene on a public registry 
website may be freely disclosed by the Investigator or its institution, or as outlined in the Clinical 
Trial Agreement.  Celgene protocol, amendment a nd IB information is not to be made publicly 
available (for example on the Investigatorâ€™s or their institutionâ€™s website) without express written 
approval from Celgene.  Information proposed  for posting on the Investigatorâ€™s or their 
institutionâ€™s website must be submitted to Celgene for review and approval, providing at least 5 business days for review.
At the time results of this study are made available to the public, Celgene will provide 
Investigators with a summary of the results that is written for the lay pe rson. The Investigator is 
responsible for sharing these results with the subject and/or their caregiver as agreed by the 
subject.
CCICELGENE PROPRIETARY INFORMATIONPractice anPractice 
luate and aluate and a
dyyare adeqare adeq
y--related drelated d
. TheTheIInve
persons to persons to 
of all subjeof all sub
dydy.  Subjec.  Subje
ments.ments.
of the Invesf the Inve
e queries anqueries 
tal charts, aal charts
st ensure timst ensure 
the protocothe protoc
elgene on pgene on 
mmataion than th
y disclosedy disclose
CelCelgene prgene pr
xample on xample o
mm CelCelmm genegene
nâ€™s websitewebsite
ss days forss days for
 the time re the time r
Investnvest igatigat
esponsespon
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 80 MEDI4736-MM- 005 Final: 03 Oct 201613.3. Subject Information and Informed Consent
The Investigator must obtain informed consent of a subject and/or a subjectâ€™s legal representative 
prior to any study related procedures.
Documentation that informed consen t occurred prior to the study subjectâ€™s entry into the study 
and of the informed consent process should be recorded in the study subjectâ€™s source documents including the date.  The original ICF signed and dated by the study subject and by the person 
consenting the study subject prior to the study subjectâ€™s entry into the study, must be maintained 
in the Investigatorâ€™s study files and a copy given to  the study subject.  In addition, if a protocol is 
amended and it impacts on the content of the informed consent, the ICF must be revised.  Study 
subjects participating in the study when the amended protocol is implemented must be re-
consented with the revised version of the ICF.  The revised ICF signed and dated by the study subject and by the person consenting the study s ubject must be maintained in the Investigatorâ€™s 
study files and a copy given to the study subject.
13.4. Confidentiality
Celgene affirms the subject's right to protecti on against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent). Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in
accordance with local laws.
Should direct access to medical records require  a waiver or authorization separate from the 
subjectâ€™s signed ICF, it is the responsibility of the Investigator to obtain such permission in writing from the appropriate individual.
13.5. Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, protocol number, study title and amendment number(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
13.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protoc ol, ICF, and any other appropriate documents will 
be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is sought. If applicable, the documents will also be submitted to the authorities in accordance with 
local legal requirements.
IP can only be supplied to an Investigator by Celgene or its authorized representative after 
documentation on all ethical a nd legal requirements for starting the study has been received by 
CCICELGENE PROPRIETARY INFORMATIONol is ol is
Study Study 
re-
the studythe study
Investnvest igatoigato
privacyivacy andand
ost stringenst stringen
necessary, necessa
cords relevcords relev
iver or authver or au
InvestInve igatoiga
st be approvt be app
endments wndments 
ned beforened before
m m ththe IRB/e IRB E
tlle and ameand 
re do not ree do not re
poses.poses.
nstitutionnstitution
anand Appd App
e the  thestart oart o
submitted tubmitted t
dates of issdates of iss
sought. ought
al
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 81 MEDI4736-MM- 005 Final: 03 Oct 2016Celgene or its authorized represe ntative. This documentation must also include a list of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it  should be asked to issue 
a statement confirming that the composition of the committee is in accordance with GCP. For example, the IRB General Assurance Number may be accepted as a substitute for this list. 
Formal approval by the IRB/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other documents reviewed. It must mention the date on which the decision was made and must be 
officially signed by a commi ttee member. Be fore the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICF should also be revised.
The Investigator must keep a record of all comm unication with the IRB/EC  and, if applicable, 
between a Coordinating Investigator and the IRB /EC. This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.  
13.7. Ongoing Information for Institutional Review Board/ Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:
!Information on serious or unexpected AEs as soon as possible; 
!Periodic reports on the progress of the study;
!Deviations from the protocol or anything th at may involve added risk to subjects.
13.8. Termination of the Study
Celgene reserves the right to terminate this st udy prematurely at any time for reasonable medical 
or administrative reasons. Any premature discontinuation will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities, etc).
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!Unsatisfactory enrollment;
!GCP noncompliance;
!Inaccurate or incomplete data collection;
!Falsification of records;
!Failure to adhere to the study protocol.
CCICELGENE PROPRIETARY INFORMATIONotocol ocol 
aluated to aluated to 
also be revalso be rev
and, if appand, if app
o applies toapplie
r, if applicar, if applic
be reviewee revi
onal Revienal Revie
vestigator mestigator 
pected pected AEAE
gress of thegress of the
otocolotoco  or aorl
of the Stuof the S
ht to terminht to term
ons. ons. Any pAny
requirequi remenremeiii
e InvestInvest igaig
studytudy ffyyor mor mff
!!UnsatUnsat ii
!!GG
!
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 82 MEDI4736-MM- 005 Final: 03 Oct 201614. DATA HANDLING AND RECORDKEEPING
14.1. Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the IP are complete, accurate, filed and retained.  Examples of 
source documents include: hospital records; clinic and office charts; laboratory notes; 
memoranda; subjectâ€™s diaries or evaluation checklists; dispensing records; recorded data from automated instruments; copies or transcriptions certified after verification as being accurate 
copies; microfiche; x-ray film and reports; and records kept at the pharmacy, and the 
laboratories, as well as copies of CRFs or CD-ROM.
14.2. Data Management
Data will be collected via CRF and entered into the clinical database per Celgene SOPs. This data will be electronically verified through use of programmed edit checks specified by the clinical team.  Discrepancies in the data will be brought to the attention of the clinical team, and 
investigational site personnel, if necessary.  Resolutions to these issues will be reflected in the 
database.  An audit trail within the system will track all changes made to the data.
14.3. Record Retention
Essential documents must be retained by the Investigator according to the period of time outlined 
in the clinical trial agreement. The Investigator must retain these documents for the time period 
described above or according to local laws or requirements, whichever is longer. Essential documents include, but are not limited to, the following:
!Signed ICFs for all subjects;
!Subject identification code list, screening log (if applicable), and enrollment log;
!Record of all communications between the Investigator and the IRB/EC;
!Composition of the IRB/EC;
!Record of all communications between the Inve stigator, Celgene, a nd their authorized 
representative(s);
!List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;
!Copies of CRFs (if paper) and of documentation of corrections for all subjects;
!IP accountability records;
!Record of any body fluids or tissue samples retained;
!All other source documents (subject records, hospital records, laboratory records, 
etc.); 
!All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
CCICELGENE PROPRIETARY INFORMATIONene Sne SOPs. TOPs.
specified byspecified b
of the clinicf the cl
s will be res will be re
ade to the dade to the
accordingaccordin
retain theseetain these
rements, wrements, w
llolowing:wing:
ist, screenist, screen
atitions betwons bet
IRB/EC;RB/EC;
ommummu nicatnicat
ve(s);ve(s)
ubb--investinvest ii
ttigator hasigator ha
e studye study , cur cu
CopiCopi es oes o
!!IP acIP a
!!
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 83 MEDI4736-MM- 005 Final: 03 Oct 2016The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to r etain them for a specified period.  
The Investigator must obtain approval in writi ng from Celgene prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene for permission to make alternative arrang ements. Details of these arrangements should be 
documented. 
All study documents should be made available if required by relevant health authorities. The 
Investigator or institution should take measures to prevent accidental or premature destruction of 
these documents.
CCICELGENE PROPRIETARY INFORMATIONof of 
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 84 MEDI4736-MM- 005 Final: 03 Oct 201615. QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully moni tored by Celgene or its authorized representative
for compliance with applicable government regulations with respect to current GCP and SOPs.
15.1. Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after the study.  All aspects of the study are reviewed with the Investigator and the staff at a study initiation visit and/or at an Investigatorsâ€™ Meeting.  Prior to enrolling subjects into the study, a 
Celgene representative will review the protoc ol, CRFs, procedures for obtaining informed 
consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring will include on-site visits with the Investigat or and his/her staff as  well as any appropriate 
communications by mail, email, fax, or telephone.  During monitoring visits, the facilities, 
investigational product storage area, CRFs, subjectâ€™s source documents, and all other study documentation will be inspected/reviewed by the Celgene representative in accordance with the 
Study Monitoring Plan.
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the CRFs or via queries by the Investigator and/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
15.2. Audits and Inspections
In addition to the routine monitoring procedure s, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with Good Clinical Pract ice 
guidelines and regulations.
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, CRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/ECs, regulatory authorities (eg, FDA, EM A, Health Canada) and 
company authorized representatives.  The Investigator should make every effort to be available for the audits and/or inspections.  If the Inves tigator is contacted by any regulatory authority 
regarding an inspection, he/she should contact Celgene immediately.
CCICELGENE PROPRIETARY INFORMATIONa 
will will 
e e 
facilitcilities, ies, 
l other studother stu
accordanceaccordanc
t iis a s a didirecrecii
cumentationumentatio
/her staff.  /her sta
bybythe Invthe Invy
nts, adherents, adhe
ecording beecording b
ecific mecific m onion
cedures, cedures a GG
atives of thatives of th
ne SOPs toe SOPs to
to permit dto permi
and applicand app
by IRB/by IRB ECC
d representd represent
d/or inspecd/or inspec
inspectnspect ioon, n,
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 85 MEDI4736-MM- 005 Final: 03 Oct 201616. PUBLICATIONS
As described in Section 13.2, all protocol- and amendment-related information, with the 
exception of the information provided by Celgene on public registry websites, is considered 
Celgene confidential information and is not to be used in any publications.  Celgene protocol-
related information proposed for use in a publication must be submitted to Celgene for review 
and approval, and should not be utilized in a publication without express written approval from 
Celgene, or as described in the Clinical Trial Agreement.  
Celgene will ensure Celgene-sponsored studies are considered for publication in the scientific 
literature in a peer-reviewed journal, irrespective of the results.  At a minimum, this applies to 
results from all Phase 3 clinical studies, and any other study results of significant medical 
importance.  This also includes results relating to investigational medicines whose development programs have been discontinued.
Study results may also be presented at one or more medical congresses, and may be used for 
scientific exchange and teaching purposes.  Additionally, this study and its results may be submitted for inclusion in all appropriate health authority study registries, as well as publication 
on health authority study registry websites, as required by local health authority regulations.  
Eligibility for external authorship, as well as  selection of firs t authorship, will be based on 
several considerations, including, but not limited to, contribution to protocol development, study 
recruitment, data quality, participation in data analysis, participation in study steering committee 
(when applicable) and contribution to abstract, presentation and/or publication development.
CCICELGENE PROPRIETARY INFORMATIONes to s to 
al 
evelopmenevelopmen
maymay byye usedused
resulresul ts mts ml
es, as well aes, as we
h authorityh authority
thorship, wthorship, w
tion to protion to pro
rticipation icipation
tion and/ortion and/o
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 86 MEDI4736-MM- 005 Final: 03 Oct 201617. REFERENCES
Carlino M, Gowrishankar K, Saunders C, Pupo G, Snoyman S, Zhang XD, et al. 
Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition 
following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther. 
2013;12(7):1332-42.
Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, BladÃ© J, et al. International 
Myeloma Working Group consensus approach to th e treatment of multiple myeloma patients 
who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063â€“73.
Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T et al. Functional 
interaction of plasmacytoid dendritic cells with multiple myeloma cells: a novel therapeutic 
target. Cancer Cell. 2009;16(4):309â€“23.
Ciardello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, et al. Cetuximab 
continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a 
randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann  Oncol. 2016;27:1055-61.
Chapuy, C, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving 
the daratumumab interference with blood comp atibility testi ng. Transfusion. 2015; 55:1545-54.
Darzalex
â„¢[Prescribing Information]. Horsham, PA: Janssen Biotech, Inc; November 2015. 
https://www.darzalex.com/shared/product/darzalex/darzalex-prescribing-information.pdf.
de Weers M, Tai YT, van der Veer MS, Bakker JM,  Vink T, Jacobs DC, et al. Daratumumab, a 
novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and 
other hematological tumors. J Immunol. 2011;186(3):1840-8.
Dimopoulos MA, Oriol A, Nahi H, San Miguel J,  Bahlis NJ, Rabin N, et al. An open-label, 
randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus 
lenalidomide and dexamethasone (Rd) in rela psed or refractory multiple myeloma (RRMM): 
POLLUX. Abstract LB2238. Presented at the EHA 21st Congress, June 10, 2016; Copenhagen, Denmark.
Durie BG, Salmon SE.  A clinical staging system for multiple myeloma. Correlation of measured 
myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54.
Global Burden of Disease Cancer Collaboration (GBD), Fitzmaurice C, Dicker D, Pain A, 
Hamavid H, Moradi-Lakeh M, et al.  The Global Burden of Ca ncer 2013. JAMA Oncol. 2015 
Jul;1(4):505-27. 
Greipp P, San Miquel J, Durie BG, Crowley JJ, Barl ogie B, Blade J, et al.  International staging 
system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates 
of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-7.
CCICELGENE PROPRIETARY INFORMATIONoonal nal 
peuteutic ic 
CetuximabCetuxim
GOIM): a GOIM): a 
Ann  OncoAnn  On l
chardson Pchardson 
TransfusioTrans
en Biotech,n Biotech
alexalex--prescrpres
 Vink T, JaVink T, 
bodyody, induc, induc
;186(3):184;186(3):184
Miguel J, BaMiguel J, Ba
mab, lenalimab, lenal
dd) in rel) in rel apa
sented at thsented at t
clinical stainical sta
h presentinh presentin
f Df Disease isease C
Moradioradi -LakLa
055--27. 27. 
p P, San Mp P, San M
temem ffmor mor mfff ummm
Hanahan DHanahan 
rbsb
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 87 MEDI4736-MM- 005 Final: 03 Oct 2016Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2009 
(Vintage 2009 Populations) [Internet]. Bethesda, MD: National Cancer Institute; based on 
November 2011 SEER data submission, posted to the SEER web site, April 2012. Available 
from: http://seer.cancer.gov/csr/1975_2009_pops09/.
Ishibashi M, Tamura H, Sunakawa M, Kondo-Onodera A, Okuyama N, Hamada Y, et al. 
myeloma drug resistance induced by binding of myeloma B7-H1. Cancer Immunol Res. 2016;4
(9):779-788.
Jackisch C, Welslau M, Schoenegg W, Selbach J, Harich HD, Schroder J, et al.  Impact of 
trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on 
survival results from a prospective, observational study in Germany. Breast. 2014; 23(5):603-8.
Jansen JHM, Boross P, Overdijk MB, Lammerts van Bueren JJ, Parren PWHI, Leusen JHW. 
Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc 
receptor-mediated cro sslinking. Blood. 2012;120 (21) :2974 [abstract].
Krejcik J, Casneuf T, Nijhof I, Verbist B, Bald J, Plesner T, et al. I mmunomodulatory Effects 
and Adaptive Immune Response to Daratumumab in Multiple Myeloma [abstract]. Blood. 2015.
Krejcik J, Casneuf T, Nijhof IS, Verbist B, Ba ld J, Plesner T, et al. Daratumumab depletes 
CD38+ immune regulatory cells, promotes T- cell expansion, and skews T-cell repertoire in 
multiple myeloma.  Blood. 2016; DOI 10.1182/blood-2015-12-687749.
Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, et al. 
Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies 
MOR03087, SAR650984 and Ab79. 56th ASH Annual Meeti ng and Exposition; San Francisco, 
CA, USA; Dec 6â€“9, 2014.Abstract 3474.
Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, et al. Management of relapsed 
multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia.
2016, 30(5):1005â€“17. 
Masi, G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, et al. Continuation or 
reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal 
cancer: final results of the randomized BEBYP trial. Ann Oncol. 2015; 26 (4):724-30.
Meyer S, Leusen JH, Boross P. Regulation of complement and modulation of its activity in 
monoclonal antibody therapy of cancer.  MAbs. 2014; 6(5): 1133-44.
Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of 
diffuse large B-cell ly mphoma identifies robust subtypes including one characterized by host 
inflammatory response. Blood. 2005;105(5):1851-61.
Morrissey KM, Yuraszack TM, Li C-C, Zhang Y, Kasichayanula S. Immunotherapy and Novel 
Combinations in Oncology: Current Landscape, Challenges, and Opportunities.  Clin Transll Sci.
2016; 9: 89-104. 
NCCN Clinical Practice Guidelines in Oncology â€“ (NCCN GuidelinesÂ®): Multiple Myeloma, 
Version 3.2016. Â©National Comprehensive Cancer Network, Inc. 2015. All rights reserved. 
Available from: http://www.nccn.org/Accessed on 24 Feb 2016. 
CCIn 
):603):603 -8.8.
sen sen JJHWHW.
ls via Fc ls via Fc 
omomodulduatort
a [absta [abst ractrac
DaratumDaratum um
d d sskews Tke
2-687749.2-687749
a M, HiddiM, Hid
ogate analoogate analo
nnual Meetnual Meet i
on Gn G,,Caersaers
the Internathe Interna
upakis F, Cupakis F, 
beyobeyo nd prnd pr
andomized andomize
oross P. Reoross P. R
y therapytherapyy ooyy
KJ, KutokKJ, Kutok
B-cellcell lymplymll
oryryresponsresponsy
sseyseyKM, YKM, Yyy
mmbinatbinatmm ioions ns 
2016; 9: 89016; 9: 89
NCCN NCCN
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 88 MEDI4736-MM- 005 Final: 03 Oct 2016Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al.  CD38 expression and 
complement inhibitors affect response and resistance to daratumumab therapy in myeloma.  
Blood. 2016; 128 (7): 959-70. doi 10.1182/blood-2016-03-703439.
Oganesyan V, Damschroder  MM, Leach W, Wu H, Dall'Acqua WF. Structural characterization 
of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol. 2008;45(7):1872-82.
Overdijk MB, Verploegen S, Bogels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, et 
al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic 
antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311â€“21.
Palumbo, A, Chanan â€‘Khan, A, Weisel, K, Nooka, AK, Masszi T, Becsak M, et al.  
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.  N Engl J Med 2016; 
375 (8): 754-66.
Phipps C, Chen Y, Gopalakrishnan S, Tan D. Daratumumab and its po tential in th e treatment 
of multiple myeloma: overview of the preclinical and clinical development. Ther Adv 
Hematol. 2015; 6: 120-7.
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus 
recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117(18):4691-5.
Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D, Anderson KC, et al. Targeting
PD1â€“ PDL1 immune checkpoint in plasmacytoid dendri tic cell interactions with T cells, natural 
killer cells and multiple myeloma cells. Leukemia 2015; 29,1441â€“44.
Riely GJ, Kris MJ, Zhao B, Akhurst T, Milton DT, Moore E, et al. Prospective assessment of 
discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007;13(17):  
5150-57.
Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of lymphoidlike stroma 
and immune escape by tumors that express the chemokine CCL21. Science. 
2010;328(5979):749-52.
Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. Marrow stromal 
cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in 
multiple myeloma. Leukemia 2013;27:464â€“72.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
activity, a nd immune correlates of anti-PD-1 an tibody in cancer. N Engl J Med. 
2012;366(26):2443-54.
Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy of 
daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple 
myeloma.  Bl ood. 2016; 128(1):37-44.
Vollbrecht T, Brackmann H, Henrich N, Roeling J, Seybold U, Bogner JR, et al. Impact of 
changes in antigen level on CD38/PD-1 co-expressi on on HIV-specific CD8 T cells in chronic, 
untreated HIV-1 infection. J Med Virol. 2010 Mar;82(3):358-70.
CCICELGENE PROPRIETARY INFORMATIONdd2016; 2016; 
in thein the treatr
ent. ent. Ther ATher
M,M,KylKyleR ,eR ,
t of the Inteof the In
han D, Andan D, An
icccellcell intine
15; 29,15; 29, 144144
T, Moore ET, Moore E
ggefitefitinib ininib in
on ofn of e effverovero
Roberts JMRoberts J
at express tat express
Yamashita Tmashita T
ressioressio n on on
Leukemia 2eukemia 2
odi FS, Braodi FS, Bra
mmune commune co
26):24436):2443 -5-5
ni SZ, Weisni SZ, Wei
atumtumumab umab mm
myelomyelo ma.ma.
VollbreVollbr
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 89 MEDI4736-MM- 005 Final: 03 Oct 2016von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, et al. 
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III 
study in HER2-positive breast cancer. Eur J Cancer 2011;47(15): 2273-81. 
CCICELGENE PROPRIETARY INFORMATION
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 90 MEDI4736-MM- 005 Final: 03 Oct 201618. APPENDICES
Appendix A: Table of Abbreviations
Table 10: Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term Explanation
ADCC Antibody-dependent cell-mediated cytotoxicity
ADL Activity of daily life
AE Adverse event
AESI Adverse event of special interest
ALP Alkaline phosphatase
ALT Alanine aminotransferase 
ANC Absolute neutrophil count
ASCT Autologous stem cell transplantation
AST Aspartate aminotransferase 
AUC Area under the curve
BM Bone ma rrow
Î²-hCG Î²-subunit of human chorionic gonadotropin
BMA Bone ma rrow aspirate
BMB Bone ma rrow biopsy
BUN Blood urea nitrogen
C Cycle
CBC Complete blood count
CD Cluster of differentiation
CDC Complement-dependent cytotoxicity
CIs Confidence intervals
CIPs Complementary-inhibitory proteins
CL/F Clearance
Cmax Maximum observed concentration 
CNS Central nervous system
COPD Chronic obstructive pulmonary disease
CR Complete response
CrCl Creatinine clearance
CT Computed tomography
CCICELGENE PROPRIETARY INFORMATIONTTTTATATATATATMARMORFONFINYIRYARionic gonadonic gonadTA
teET
opsyopsyRInitrogennitrogenPROPmplete bloomplete bloROCluster of Cluster ofPRECompCoEEEPNECCNENENENEENGELGNSNSELCOPDCOPDCEC
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 91 MEDI4736-MM- 005 Final: 03 Oct 2016Table 10: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
CTCAE Common Terminology Criteria for Adverse Events
DD a y
D2Daratumumab plus durvalumab
DARA Daratumumab
DURVA Durvalumab
DLT Dose-limiting toxicity
DMC Data Monitoring Committee
DNA Deoxyribonucleic acid
DOR Duration of response
DRT Dose Review Team
EC Ethics Committee
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic case report form
EE Efficacy evaluable
EEA European Economic Area
EMP Extramedullary plasmacytoma
EOI End of infusion
EOT End of Treatment
EU European Union
FAS Full analysis set
Fc Fragment crystallizable
FCBP Females of childbearing potential
FDA Food and Drug Administration
FEV Forced expiratory volume
GCP Good Clinical Practice
GLP Good Laboratory Practice
HIV Human immunodeficiency virus
IAT Indirect antiglobulin test
IB Investigatorâ€™s Brochure
CCIIVIVCEGLPGLPCELGENE PFull anall anPROPRIETARY INFORMATIONTTTATATATATMARMORFONFIN
RYGrouproupARTAET ic Areaic AreaIE
ry plasmacyty plasmacR
fusionusionOPf f TTrereatmenatmenROEuropean UnEuropean RPEFragFraEEENENENENENEENGELG
CEC
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 92 MEDI4736-MM- 005 Final: 03 Oct 2016Table 10: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
ICF Informed c onsent form
ICH International Council on Harmonisation
IFNÎ³ Interferon gamma
Ig Immunoglobulin
ILD Interstitial lung disease
IMWG International Myeloma Working Group
IMiD Immunomodulatory drug
IND Investigational New Drug
IP Investigational product
IRAC Independent Response Adjudication Committee
irAE Immune related adverse events
IRB Institutional Review Board
IRT Interactive Res ponse Technology
ITT Intent to treat
IV Intravenous
KM Kaplan-Meier
mAb Monoclonal antibody
MedDRA Medical Dictionary for Regulatory Activities
MM Multiple myeloma
MR Minimal response
MRI Magnetic resonance imaging
NCCN National Comprehensive Cancer Network
NCI National Cancer Institute
NK Natural killer cells
NOAEL No obs erved adverse effect level
ORR Overall response rate
OS Overall survival
PD Disease progression
CCICCI
CC
ICELGENE PROPRIETARY INFORMATIONTTTATATATATMARMORFOteeeeNFIN
RYgyyARTAETIE
ntibodyntibodyR
Dictionary foictionaryOPiple myelomple myelomROMinimaMinima l respl rR
MagnetiagnePEEEENENENENENEENGE
AELAELLG
ORRORRCESSCE 
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 93 MEDI4736-MM- 005 Final: 03 Oct 2016Table 10: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
PD-1 Programmed cell death-1
PD-L1 Programmed death-ligand 1
PFS Progression-free survival
PI Proteasome inhibitor
PI Prescribing Information
PK Pharmacokinetics
PR Partial response
PT Preferred term
QW Weekly
Q2W Every 2 weeks
Q4W Every 4 weeks
RBC Red blood cell 
RECIST Response Evaluation Criteria in Solid Tumors
RNA Ribonucleic acid
RRMM Relapsed and refractory multiple myeloma
SAE Serious adverse event
sCR Stringent complete response
SD Stable disease
SmPC Summary of Product Characteristics
SOC System organ class
SOP Standard operating procedure
sPD-L1 Soluble programmed death-ligand 1
sPEP Serum protein electrophoresis
SUSAR Suspected unexpected serious adverse reaction
t1/2 Terminal elimination half-life
Tmax Time to maximum concentration
TCR T-cell receptor
TSH Thyroid stimulating hormone
Tregs Regulatory t-cells
TTR Time-to-response
CCICELGENE PROPRIETARY INFORMATIONTTTATATATATMARMORFONFIN
RYSolid TumSolid TuARTA y multiple my multiple mET ententIE
plete responplete respR
easeeaseOPmary of Prodmary of ProROSystem orgaSystem orR
StandardndaPESoluSolEEENENENENENEENGELG
TCRTCRCESHSHC
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 94 MEDI4736-MM- 005 Final: 03 Oct 2016Table 10: Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
ULN Upper limit of normal
uPEP Urine protein electrophoresis
USA United States of America
VGPR Very good pa rtial response
VTE Venous thromboembolism
Vz/F Volume of distribution
WBC White blood cell 
CCICELGENE PROPRIETARY INFORMATIONTTTATATATATMARMOR
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 95 MEDI4736-MM- 005 Final: 03 Oct 2016Appendix B: International Myeloma Working Group Uniform Response 
Criteria
Response CategoryaResponse Criteria
Stringent Complete 
Response (sCR)Complete response (CR) as defined below, plus
Normal serum free light chain (FLC) ratio and
Absence of clonal plasma cells by immunohistochemistry or 2- to 4-color 
flow cytometry
Complete Response 
(CR)Negative immunofixation of serum and urine and
Disappearance of any soft tissue plasmacytomas and
â‰¤ 5% plasma cells in bone marrow
In patients in whom the only measurable disease is by serum FLC levels: 
CR in such patients indicates a normal FLC ratio of 0.26 to 1.65 in 
addition to CR criteria listed above. 
Very Good Partial Response (VGPR)Serum and urine M-protein detectable by immunofixation but not on 
electrophoresis or
90% or greater reduction in serum M-pro tein plus urine M-protein level 
<100 mg per 24 hours
In patients in whom the only measurable disease is by serum FLC levels: 
VGPR in such patients requires a > 90% decrease in the difference 
between involved and uninvolved FLC levels.
Partial Response (PR) â‰¥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-
protein by â‰¥ 90% or to < 200 mg per 24 hours
If the serum and urine M-protein are not measurable, a â‰¥ 50% decrease in 
the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.
If serum and urine M-protein are unmeasurable, and the serum free light 
chain assay is also unmeasurable, a â‰¥ 50% reduction in plasma cells is 
required in place of M-protein, provided baseline bone marrow plasma 
cell percentage was â‰¥ 30%
In addition to the above, if present at baseline a â‰¥ 50% reduction in the 
size of soft tissue plasmacytomas is also required.
Stable Disease (SD) Not meeting criteria for CR, VGPR, PR, or progressive disease (PD)
CCICELGENE PROPRtion of serumion of ser
â‰¥ â‰¥ 90% or t90% o
erum and uerum and
difference bdifference b
place of the place of th
If serum f ser
chain chain
reqreqPRIETARY INFORMATIONor 
AT
s by serum s by ser
tio of 0.26 toio of 0.26 MAAA
by immunofby immunof
m Mm M -protein-protein
e only measuonly meas
nts requires nts requires
and uninvoand uninvoYI N
PR
E
Disease (SDDisease (SG
ELG
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 96 MEDI4736-MM- 005 Final: 03 Oct 2016Appendix B: International Myeloma Working Group Uniform Response 
Criteria (Continued)
Response CategoryaResponse Criteria
Progressive disease (PD) Requires only one of the following:
Increase of 25% from lowest response value in any of the
following:
!Serum M-component (absolute increase must be â‰¥ 0.5 g/dL), 
and/or
!Urine M-component (absolute increase must be â‰¥ 200 mg/24 h), 
and/or
Only in patients without measurable serum and urine M-protein levels: the 
difference between involved and uninvolved FLC levels (absolute increase must be â‰¥ 10 mg/dL)
Only in patients without measurable serum and urine M protein levels and 
without measurable disease by FLC levels, bone marrow plasma cell 
percentage (absolute percentage must be â‰¥ 10%)
Definite development of new bone lesions or soft tissue plasmacytomas or 
definite increase in the size of existing bone lesions or soft tissue plasmacytomas
Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL) 
that can be attributed solely to the plasma cell proliferative disorder
Additional Response Criteria
Molecular Complete 
ResponseCR plus negative allele-specific oligonucleotide polymerase chain 
reaction (ASO-PCR), sensitivity 10-5
Immunophenotypic Complete Response Stringent CR plus
Absence of phenotypically aberrant plasma cells (clonal) in bone marrow 
(BM) with a minimum of 1 million total BM cells analyzed by multiparametric flow cytometry (with > 4 colors)
Minimal Response (MR)
in patients with relapsed 
refractory myeloma 
adopted from the European 
Group for Blood and Marrow Transplantation (EBMT) criteriaâ‰¥ 25% but â‰¤ 49% reduction of serum M-protein and reduction in 24-hour 
urine M-protein by 50%-89%
In addition to the above criteria, if present at baseline, 25%-49% 
reduction in the size of soft tissue plasmacytomas is also required
No increase in size or number of lytic bone lesions (development of 
compression fracture does not exclude response)
aAll response categories (CR, sCR, VGPR, PR, and PD) require 2 consecutive assessments made at any time before 
the institution of any new therapy; CR, sCR, VGPR, PR, and SD categories also require no known evidence of 
progressive or new bone lesions if radiographic studies were performed. VGPR and CR categories require serum and urine studies regardless of whether disease at baseline was measurable on serum, urine, both, or neither. Radiographic studies are not required to satisfy these response requirements. Bone marrow assessments need not be confirmed. For PD, serum M-component increases of more than or equal to 1 g/dL are sufficient to define relapse if the starting M-component is â‰¥ 5 g/dL.
CCICELGENE PROPRIETARY INFORMATION), ), 
0 mg/24 h),0 mg/24 h)
M-protein leprotein le
evels (absoluevels (absol
nd urine M pnd urine M p
, bone marrobone mar
e e â‰¥ 10%)â‰¥ 1
esions or soesions or s
isting bone isting bone
emia (correemia (corr
lely to the plely to the AT
E
ive alleleve allele -sp
SOO--PCR), sPCR), sRI
nt CR nt C pluslus
sence of pheence of phe
BMBM))with awith
multiparamultiparaOP
EMR)MR)
psed psed 
mma a mmm
the Europeahe Europea
Blood and lood and 
Transplantansplant
MT) criteriMT) criteri aâ‰¥ 25%â‰¥ 2
ururEEEP
ELE
All response cresponse c
the institutithe institut
progressprogre
nd ud
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 97 MEDI4736-MM- 005 Final: 03 Oct 2016Appendix C: ECOG Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status
Grade ECOG Performance Status
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up 
and about more than 50% of waking hours
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5D e a d
Eastern Cooperative Oncology Group, Robert Comis, MD, Group Chair.
CCICELGENE PROPRIETARY INFORMATIONa a 
ATes. Up  UpATATAT
% of waking of wakingRM
ned to bed oned to bed oO
NFIN
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 98 MEDI4736-MM- 005 Final: 03 Oct 2016Appendix D: Staging Systems for Multiple Myeloma
Table 11: Staging Systems for Multiple Myeloma 
Stage Durie-Salmon CriteriaaInternational Staging
System (ISS) Criteriab
I All of the following:
Hemoglobin value > 10 g/dL
Serum calcium value normal or <  12 mg/dL
Bone x-ray, normal bone structure (scale 0), or 
solitary bone plasmacytoma only
Low M-component production rates
IgG value < 5 g/dL; 
IgA value < 3 g/dLUrine light chain M-component onelectrophoresis < 4 g/24hSerum beta-2 microglobulin < 3.5 
mg/L
Serum albumin â‰¥ 3.5 g/dL
II Neither Stage I nor Stage II Neither Stage I nor Stage II
III One or more of the following:
Hemoglobin value < 8.5 g/dL
Serum calcium value normal or > 12 mg/dL
Advanced lytic bone lesions (scale 3)
High M-component production rates
IgG value > 7 g/dL; IgA value > 5 g/dLUrine light chain M-component on
electrophoresis > 12 g/24hSerum beta-2 microglobulin â‰¥ 5.5 
mg/L
Subclassification Criteria
A  Normal renal function (serum creatinine value < 2.0 
mg/dL)
B  Abnormal renal function (serum creatinine value â‰¥ 2.0 
mg/dL)Not applicable
aDurie, 1975.
bGreipp, 2005.
CCICELGENE PROPRIETAponent onponent on
g/24hg/24hTARY INFORMATIONAT
either Stage ither YI Serum betSerum bet
mg/Lmg/LRY
TA
serum creatium creati
unction (serunction (serRO
EN5..
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 99 MEDI4736-MM- 005 Final: 03 Oct 2016Appendix E: Durvalumab Treatment Modification and Toxicity Management Guidelines
Note: The toxicity management guidelines in Appendix E-1, E- 2, and E-3 prepared by the Sponsor are to assist the 
investigator in the exercise of his/her clinical judgment in treating these types of toxicities and should be applied to 
management of adverse events related to study treatment and not ANY adverse event.
Appendix E-1: Durvalumab Treatment Modification and Toxicity Management Guidelines for Immune-related Adverse 
Events
Immune-Mediated Reactions
Dose Modifications Toxicity Management
Immune-related 
Adverse Events 
(Overall Management For toxicities not 
noted below)Drug administration modifications of study drug/study regimen will 
be made to manage potential immune-related AEs based on severity 
of treatment-emergent toxicities graded per NCI CTCAE v4.03.
In addition to the criteria for permanent discontinuation of study 
drug/regimen based on CTC grade/severity (table below),
permanently discontinue study drug/study regimen for the following 
conditions: 
!Inability to reduce corticosteroid to a dose of â‰¤10 mg of 
prednisone per day (or equivalent) within 12 weeks after last 
dose of study drug/regimen
!Recurrence of a previously experienced Grade 3 treatment-
related AE following resumption of dosing.It is recommended that management of irAEs follow the 
guidelines presented in this table
-Patients should be thoroughly evaluated to rule out any 
alternative etiology (eg, disease progression, concomitant medications, infections, etc.)
-In the absence of a clear alternative etiology, all events 
should be considered potentially immune related.
-Symptomatic and topical therapy should be considered 
for low-grade (Grade 1 or 2, unless otherwise specified) events 
-For persistent (greater than 3 to 5 days) low-grade 
(Grade 2)  or severe (Grade â‰¥3) events promptly start 
prednisone PO 1-2mg/kg/day PO or IV equivalent 
-If symptoms recur or worsen during corticosteroid 
tapering 28 days of taper), increase the corticosteroid dose (prednisone dose [eg, up to 2-4mg/kg/day PO or IV equivalent]) until stabilization or improvement of symptoms, then resume corticosteroid tapering at a slower rate (> 28 days of taper)
-More potent immunosuppressives such as TNF 
inhibitors (eg, infliximab) â€“ (also refer to the individual sections of the immune related adverse event for specific type of immunosuppressive) should be considered for events not responding to systemic Grade 1 No dose modification
Grade 2 Hold study drug/study regimen dose until Grade 2 
resolution to â‰¤ Grade 1
â€¢ If toxicity worsens then treat as Grade 3 or 
Grade 4
Study drug/study treatment can be resumed at the 
next scheduled dose once event stabilizes to Grade â‰¤1 after completion of steroid taper
Patients with endocrinopathies who may require 
prolonged or continued steroid replacement 
CCICELpriprietetELGENE PROPRIETARY INFORMATIONe Corporae Corpora
ON
o assist theassist th
be appliedbe applied
for Immunfor Immu
FOToxToNF
wing wing 
10 mg of 10 mg of 
2 weeks2 week afteafte
nced Grade 3 nced Grad
n of dosing.f dosingommended thommended
elines presenelines presen
--PatiPa
aIN
TA
tionionRO drug/studyug/stud rey
to toâ‰¤ Grade rad
toxicity toxicity wow
Grade 4Grade 4
Study Study drug/drug/
next next
GGrr
PaPa
EL
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 100 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
can be retreated with study drug/study regimen 
on the following conditions: 1) the event stabilizes and is controlled, 2) the patient is clinically stable as per Investigator or treating physicianâ€™s clinical judgement, and 3) doses of prednisone are at less than or equal to 10mg/day or equivalent.steroids.  
-Discontinuation of study drug is not mandated for 
Grade 3 / Grade 4 inflammatory reactions attributed to local tumour response (eg, inflammatory reaction at sites of metastatic disease, lymph nodes etc.). Continuation of study drug in this situation should be based upon a benefit/risk analysis for that patient 
Grade 3 Depending on the individual toxicity, may 
permanently discontinue study drug/study 
regimen. Please refer to guidelines below
Grade 4 Permanently discontinue study drug/study 
regimen 
Note:  For Grade 3 and above asymptomatic amylase or lipase levels hold study drug/regimen and if complete work up shows no evidence 
of pancreatitis, may continue or resume study drug/regimen
Pneumonitis/ILDGrade of 
Pneumonitis 
(CTCAE version 
4.03) General Guidance -Monitor patients for signs and symptoms of 
pneumonitis or ILD (new onset or worsening shortness 
of breath or cough).  Patients should be evaluated with 
imaging and pulmonary function tests including other diagnostic procedures as described below
-Initial work-up may include clinical evaluation, 
monitoring of oxygenation via pulse oximetry (resting 
and exertion), laboratory work-up and high-resolution 
CT scan. 
Grade 1 
(Asymptomatic, 
clinical or diagnostic observations only, 
intervention not 
indicated)No dose modification required. However, 
consider holding study drug/study regimen 
dosing as clinically appropriate and during 
diagnostic work-up for other etiologiesFor Grade 1 (Radiographic Changes Only)
-Monitor and closely follow up in 2-4 days for clinical 
symptoms, pulse oximetry (resting and exertion) and laboratory work-up and then as clinically indicated
-Consider pulmonary and infectious disease consult
CCICELGpriprietetLGEnly, nly, 
not ot
)GENE PROPRIETARY INFORMATIONe Corporae Corpora
ONO
mententTIO
dy drug is noty drug is n
flammatory flammatory
onse (onse ( eg,eg,infinf
atic disease, atic disease, 
n of study drof study d
on a benefit/on a benefitAT
Als 
dence dencATAET
ose modificaose modifica
onsider holdinsider holdi
dosing as cdosing as c
diagnosdiagnoEP
LGGE
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 101 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
Grade 2 
(Symptomatic, 
medical intervention indicated, limiting instrumental ADL) Hold study drug/study regimen dose until 
Grade 2 resolution to â‰¤ Grade 1
â€¢ If toxicity worsens then treat as Grade 3 or 
Grade 4 
â€¢ If toxicity improves to â‰¤Grade 1 then the 
decision to reinitiate study drug/regimen will be based upon treating physicianâ€™s clinical judgment and after completion of steroid taper.For Grade 2 (Mild to Moderate New Symptoms)
-Monitor symptoms daily and consider hospitalization
-Promptly start systemic steroids (eg, prednisone 1-
2mg/kg/day PO or IV equivalent)
-Reimaging as clinically indicated
-If no improvement within 3-5 days, additional workup 
should be considered and prompt treatment with IV 
methylprednisolone 2-4mg/kg/day started 
-If still no improvement within 3-5 days despite IV 
methylprednisone at 2-4/g/kg/day, promptly start immunosuppressive therapy such as TNF inhibitors (eg, infliximab at 5 mg/kg every 2 weeks). Caution: Important to rule out sepsis and refer to infliximab 
label for general guidance before using infliximab 
-Once improving, gradually taper steroids over â‰¥28 
days and consider prophylactic antibiotics, antifungal or anti PCP treatment (refe r to current NCCN 
guidelines for treatment of cancer-related infections 
(Category 2B recommendation)
a, b
-Consider pulmonary and infectious disease consult
-Consider as necessary discussing with study physician
Grade 3 or 4 
(Grade 3: Severe 
symptoms; limiting self-care ADL; 
oxygen indicated; 
Grade 4: life 
threatening respiratorycompromise, urgent intervention Permanently discontinue study drug/study 
regimenFor Grade 3 or 4 (severe or new symptoms, new/worsening 
hypoxia, life threatening 
-Promptly initiate empiric IV methylprednisolone 1 to 4 
mg/kg/day or equivalent
-Obtain pulmonary and infectious disease consult
-Hospitalize the patient
-Supportive Care (oxygen, etc.)
-If no improvement within 3-5 days, additional workup 
should be considered and prompt treatment with 
CCICELpriprietetELGEmise, urgent mise, urgent 
ventioventio n noooELGENE PROPRIETARY INFORMATIONe Corporae Corpora
ONO
mententTIO w Symptomsw Symptom
ily and ly and consicon
emic steroidsemic steroid
orr IV equiva IV equiva
as clinically iclinically
provement wprovement w
d be considebe con
ethyethylprednlprednyy isois
If still no itill no 
methym lpy
immim
(AT
TA
discodisco ntinue sntinue RO
GE
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 102 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
indicated [eg, 
tracheostomy or intubation]) additional immunosuppressive therapy such as TNF 
inhibitors (eg, infliximab at 5 mg/kg every 2 weeks dose) started. Caution: rule out sepsis and refer to infliximab label for general guidance before using 
infliximab 
-Once improving, gradually taper steroids over â‰¥28 days 
and consider prophylactic antibiotics, antifungals and in particular, anti PCP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections (Category 2B recommendation)
a
Diarrhea/ 
EnterocolitisGrade of Diarrhea 
(CTCAE version 4.03)General Guidance -Monitor for symptoms that may be related to 
diarrhea/enterocolitis (abdominal pain, cramping, or changes in bowel habits such as increased frequency 
over baseline or blood in stool) or related to bowel 
perforation (such as sepsis, peritoneal signs and ileus)
-Patients should be thoroughly evaluated to rule out any 
alternative etiology (eg, disease progression, other medications, infections including testing for clostridium difficile toxin, etc.)
-Steroids should be considered in the absence of clear 
alternative etiology, even for low grade events, in order to prevent potential progression to higher grade event
-Use analgesics carefully; they can mask symptoms of 
perforation and peritonitis
Grade 1 diarrhea  
(stool frequency of 
<4 over baseline per day) No dose modification For Grade 1 diarrhea : 
-Close monitoring for worsening symptoms
-Consider symptomatic treatment including hydration, 
electrolyte replacement, dietary changes (eg, American Dietetic Association colitis diet), and loperamide. Use of probiotics as per treating physicianâ€™s clinical judgment.
Grade 2 diarrhea 
(stool frequency of Hold study drug/study regimen until resolution 
to â‰¤ Grade 1For Grade 2 diarrhea: 
-Consider symptomatic treatment including hydration, 
CCICEpriprietetELGENE PROPRIETARY INFORMATIONe Corporae Corpora
ONO
mententTIO sive therapy sive therapy 
b at 5at 5mg/kgmg/
on: rule out sn: rule out s
for general gor general g
roving, gradroving, gra
nsider prophnsider proph
articulararticular , , anta
NCCN guidelCCN guide
infections ectionsAT
--MonitM
diadiaYI
TA
modificationodificationPR
GEdiarrhea diarrhea 
l frequency ofrequency oLGGG
EG
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 103 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
4-6 over baseline 
per day) â€¢ If toxicity worsens then treat as Grade 3 or 
Grade 4
â€¢ If toxicity improves to â‰¤Grade 1 then 
study drug/study regimen can be resumed after completion of steroid taper electrolyte replacement, dietary changes (eg, American 
Dietetic Association colitis diet), and loperamide and/or budesonide 
-Promptly start prednisone 1 to 2  mg/kg/day PO or IV 
equivalent 
-If event is not responsive within 3-5 days or worsens 
despite prednisone at 1-2 mg/kg/day PO or IV 
equivalent, GI consult should be obtained for 
consideration of further workup such as imaging and/or colonoscopy to confirm colitis and rule out perforation, and prompt treatment with IV methylprednisolone 2-4mg/kg/day started. 
-If still no improvement within 3-5 days despite 2-
4mg/kg IV methylprednisolone, promptly start 
immunosuppressives such as (infliximab at 5 mg/kg once every 2 weeks
3). Caution : Important to rule out 
bowel perforation and refer to infliximab label for general guidance before using infliximab  
-Consult study physician if no resolution to â‰¤ Grade 1 in 
3-4 days
-Once improving, gradually taper steroids over â‰¥28 days 
and consider prophylactic antibiotics, antifungals and anti PCP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation])
3ASCO Educational Book 2015 Michael Postow MD â€œManaging Immune Checkpoint Blocking Antibody Side Effects.
CCICEpriprietetELGENE PROPRIETARY INFORMATetary changeetary change
itis diet), ands diet), 
ednisone 1 toednisone 1 to
not responsivnot responsiv
prednisone aprednisone a
valent, GI conlent, G
nsideration onsideration ATIONe Corporae Corpora
ONO
mententTIO
cololonoscopyonosco
and promprom
4mg/k4
--If sfAT
PRTA
ELGook 2015 Miok 2015 Mi
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 104 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
Grade 3 or 4 
diarrhea 
(Grade 3: stool 
frequency of â‰¥7 
over baseline per day; 
Grade 4: life 
threatening consequences)Permanently discontinue study drug/study 
regimenFor Grade 3 or 4 diarrhea:
-Promptly initiate empiric IV methylprednisolone 2 to 4 
mg/kg/day or equivalent
-Monitor stool frequency and volume and maintain 
hydration 
-Urgent GI consult and imaging and/or colonoscopy as 
appropriate
-If still no improvement within 3-5 days of IV 
methylprednisolone 2 to 4mg/kg/day or equivalent, promptly start further immunosuppressives (eg, infliximab at 5 mg/kg once every 2 weeks).  
-Caution: Ensure GI consult to rule out bowel 
perforation and refer to infliximab label for general guidance before using infliximab. 
-Once improving, gradually taper steroids over â‰¥28 days
and consider prophylactic antibiotics, antifungals and 
anti PCP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation])
Hepatitis 
(Elevated LFTs)
Infliximab 
should not be used for management of Immune Related
HepatitisGrade of Liver 
Function Test 
Elevation (CTCAE version 4.03)
Any Grade-Monitor and evaluate liver function test: AST, ALT, 
ALP and total bilirubin 
-Evaluate for alternative etiologies (eg, viral hepatitis, 
disease progression, concomitant medications) 
Grade 1 
(AST or ALT > to 
3 times ULN 
and/or TB > to 1.5 
times ULN)No dose modification
If it worsens, treat as Grade 2 eventFor Grade 1 AST or ALT and/or TB elevation
-Continue LFT monitoring per protocol 
CCIpriprietetE PROPRIETARY INFORMATric IV methyric IV meth
valentvalent
frequency andfrequency an
GI consult anGI consult an
priateriate
still no imprstill no impr
methyethyATIONe Corporae Corpora
ONO
mententTIO
lprednlprey
promptlypromptl
inflixiin
-- CaCAT
TA
PR
e modificatioe modific
t worsens, trt worsens, 
GEGEGEGE
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 105 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
Grade 2 
(AST or ALT > 3 
to 5 times ULN and/or TB >1.5- 3.0 
times ULN)Hold Study drug/study regimen dose until 
grade 2 resolution to â‰¤ Grade 1
â€¢ If toxicity worsens then treat as Grade 3 or 
Grade 4
â€¢ If toxicity improves to â‰¤Grade 1 or 
baseline resume study drug/study regimen after completion of steroid taper For Grade 2 AST or ALT and or TB elevation : 
-Regular and frequent checking of LFTs (eg, every 1-2 
days) until elevations of these are improving or 
resolved.  
-If no resolution to â‰¤ Grade 1 in 1-2 days, discuss with 
study physician.
-If event is persistent (> 3-5 days) or worsens, promptly 
start prednisone 1-2mg/kg/day PO or IV equivalent. 
-If still no improvement within 3-5 days despite 1-
2mg/kg/day of prednisone PO or IV equivalent, 
consider additional workup and prompt treatment with IV methylprednisolone 2-4mg/kg/day started.
-If still no improvement within 3-5 days despite 2-4mg/kg/day of IV methylprednisolone, promptly start immunosuppressives (mycophenolate mofetil)
4.
Discuss with study physician if mycophenolate mofetil 
is not available.  Infliximab should NOT be used .
-Once improving, gradually taper steroids over â‰¥28 days 
and consider prophylactic antibiotics, antifungals and 
anti PCP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections 
[Category 2B recommendation])
Grade 3
(AST or ALT >5-
20 times ULN and/or TB > 3.0-10 times ULNFor elevations in transaminases â‰¤ 8 Ã— ULN, or 
elevations in bilirubin â‰¤ 5 Ã— ULN 
-Hold study drug/study regimen dose until 
resolution to â‰¤ Grade 1 or baseline 
-Resume study drug/study regimen if 
elevations downgrade â‰¤ Grade 1 or For Grade 3 or 4 AST or ALT and/or TB elevation:
-Promptly initiate empiric IV methylprednisolone at 1 to 
4 mg/kg/day or equivalent 
-If still no improvement within 3-5 days despite 1 to 4 
mg/kg/day methylprednisolone IV or equivalent,
4ASCO Educational Book 2015 â€œManaging Immune Checkpoint Blocking Antibody Side Effectsâ€, by Michael Postow MD.
CCICELGENE PROPRIETARY INFORMATIONe Corporae Corpora
ON
priprietetO
mententTIO B elevation :B elevation
checking of Lhecking of
ons of these aons of these 
tion to onâ‰¤ Graâ‰¤ Gra
hysician.ysician.
vent is persistt is pers
tart prednisoart predniso
If still no ill no 
2mg/k2
cononAT
TA
0 0 elevations inlevations in
elevations elevations 
-Hold sHold s
resoreEP
LGGE
ELGook 2015ok 2015 â€œMâ€œM
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 106 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
baseline within 14 days and after 
completion with steroid taper.
Permanently discontinue study drug/study 
regimen if the elevations do not downgrade to â‰¤ Grade 1 or baseline within 14 days 
For elevations in transaminases > 8 Ã— ULN or 
elevations in bilirubin > 5 Ã— ULN, 
discontinue study drug/study regimen 
Permanently discontinue study drug/study 
regimen for any case meeting Hyâ€™s law criteria (AST and/or ALT > 3x ULN + bilirubin > 2x ULN without initial findings of cholestasis (ie, elevated alkaline P04) 
and in the absence of any alternative cause
ivpromptly start treatment with immunosuppressive 
therapy (mycophenolate mofetil)  Discuss with study 
physician if mycophenolate is not available. Infliximab 
should NOT be used.
-Hepatology consult, abdominal workup, and imaging 
as appropriate.
-Once improving, gradually taper steroids over â‰¥28 days 
and consider prophylactic antibiotics, antifungals and 
anti PCP treatment (please refer to current NCCN 
guidelines for treatment of cancer-related infections [Category 2B recommendation])
Grade 4 
(AST or ALT > 20 
times ULN and/or 
TB > 10 times 
ULN)Permanently discontinue study drug/study 
regimen 
Nephritis or 
Renal Dysfunction (Elevated Serum Creatinine) Grade of Elevated 
Serum Creatinine 
(CTCAE version 4.03)
Any Grade General Guidance-Consult with Nephrologist
-Monitor for signs and symptoms that may be related to 
changes in renal function (eg, routine urinalysis, elevated serum BUN and creatinine, decreased creatinine clearance, electrolyte imbalance, decrease in 
urine output, proteinuria, etc.) 
-Patients should be thoroughly evaluated to rule out any 
alternative etiology (eg, disease progression, infections etc.)
-Steroids should be considered in the absence of clear 
alternative etiology even for low grade events (Grade 2), in order to prevent potential progression to higher grade event
CCIpriprietetLGELGGENE PROPRIETARY INFORMATwith immunoswith immuno
te mofetil)  Dte mofetil) 
henolate is nhenolate is 
used.used.
gy consult, agy consult, 
propriate.ropriate
Once impronce impATIONe Corporae Corpora
ONO
mententTIO
and consand con
anti Pant
gAT
AyyAATA
al Guidancel GuidancPR
GE
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 107 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
Grade 1 [Serum 
Creatinine > 1-1.5
X baseline; > ULN to 1.5 X ULN]No dose modification For Grade 1 elevated creatinine: 
-Monitor serum creatinine weekly and any 
accompanying symptom
!If creatinine returns to baseline, resume its 
regular monitoring per study protocol.
!If it worsens, depending on the severity, treat 
as Grade 2 or Grade 3 or 4 
-Consider symptomatic treatment including hydration, 
electrolyte replacement, diuretics, etc.
Grade 2 [Serum Creatinine>1.5-3.0X baseline; >1.5 X-3.0 X ULN]Hold study drug/study regimen until resolution 
to â‰¤ Grade 1 or baseline
â€¢ If toxicity worsens then treat as Grade 3 or 
Grade 4
â€¢ If toxicity improves to â‰¤Grade 1 or
baseline then resume study drug/study 
regimen after completion of steroid taper.  For Grade 2 elevated creatinine: 
-Consider symptomatic treatment including hydration, 
electrolyte replacement, diuretics, etc. 
-Carefully monitor serum creatinine every 2-3 days and 
as clinically warranted
-Consult Nephrologist and consider renal biopsy if 
clinically indicated
-If event is persistent (> 3-5 days) or worsens, promptly 
start prednisone 1 to 2 mg/kg/day PO or IV equivalent 
-If event is not responsive within 3-5 days or worsens 
despite prednisone at 1-2 mg/kg/day PO or IV 
equivalent, additional workup should be considered and prompt treatment with IV methylprednisolone at 2-4mg/kg/day started. 
-Once improving gradually taper steroids over â‰¥28 days
and consider prophylactic antibiotics, antifungals and 
anti PCP treatment (please refer to current NCCN 
guidelines for treatment of cancer-related infections [Category 2B recommendation]). 
-When event returns to baseline, resume study 
drug/study regimen and routine serum creatinine monitoring per study protocol.
CCICELGENE PROPRIETApriprietetstudy tudy
eroid tapereroid taper
LGGETARY INFORMATIONe Corporae Corpora
ONO
mententTIO
ine weekly aine weekly 
ptomptom
tinine returnsnine returns
ular monitorilar monito
If it worsensIf it worsens
as Grade 2as Gr
onsider sympnsider symp
electrolyectroly te rete ryyAT
Grade 2 elevde 2 elev
--ConCo
e
--YI N
TA
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 108 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
Grade 3 or 4 
(Grade 3:  Serum 
Creatinine > 3.0 X baseline; >3.0- 6.0 
X ULN
Grade 4: Serum 
Creatinine > 6.0 X 
ULN) Permanently discontinue study drug/study 
regimen-Carefully monitor serum creatinine on d aily basis
-Consult Nephrologist and consider renal biopsy if 
clinically indicated
-Promptly start prednisone 1 to 2  mg/kg/day PO or IV 
equivalent 
-If event is not responsive within 3-5 days or worsens 
despite prednisone at 1-2 mg/kg/day PO or IV equivalent, additional workup should be considered and 
prompt treatment with IV methylprednisolone 2-
4mg/kg/day started. 
-Once improving, gradually taper steroids over â‰¥28 days 
and consider prophylactic antibiotics, antifungals and 
anti PCP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections 
[Category 2B recommendation] 
Rash (excluding 
Bullous skin 
formations)Grade of Skin Rash 
(Please refer to 
NCI CTCAE version 4.03 for definition of severity/grade depending on type of skin rash)General Guidance Monitor for signs and symptoms of dermatitis (rash and 
pruritus) 
**IF THERE IS ANY BULLOUS FORMATION, THE 
STUDY PHYSICIAN SHOULD BE CONTACTED 
AND 
STUDY DRUG DISCONTINUED **
Grade 1 No dose modification For Grade 1:
-Consider symptomatic treatment including oral 
antipruritics (eg, diphenhydramine or hydroxyzine) and topical therapy (eg, urea cream)
Grade 2 For persistent (> 1- 2 weeks) Grade 2 events, 
hold scheduled study drug/study regimen For Grade 2 :
-Obtain dermatology consult 
CCICELpriprietetELGENE PROPRIETARY INFORMATIONe Corporae Corpora
ONO
mententTIO creatininreatinin e eonon
and consider and conside
prednisone 1 ednisone 1 
is not respons not respon
te prednisone predn
quivalent, adquivalent, ad
prompt trempt tr
4mg/kg4mg/kg
--OncOnAT
TA
RIE
ose modificaose modificEP
GEGGG
ELG
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 109 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
until resolution to â‰¤ Grade 1 or baseline 
!If toxicity worsens then treat as Grade 
3 
!If toxicity improves to â‰¤Grade 1 or 
baseline then re sume study drug/study 
regimen after completion of steroid taper.  -Consider symptomatic treatment including oral 
antipruritics (eg, diphenhydramine or hydroxyzine) and topical therapy (eg, urea cream)
-Consider moderate-strength topical steroid 
-If no improvement of rash/skin lesions occurs within 3-
5 days or is worsening despite symptomatic treatment and/or use of moderate strength topical steroid, discuss 
with study physician and promptly start systemic 
steroids prednisone 1-2 mg/kg/day PO or IV equivalent 
-Consider skin biopsy if persistent for >1-2 weeks or 
recurs
Grade 3 Hold study drug/study regimen until resolution 
to â‰¤ Grade 1 or baseline
If temporarily holding the study drug/study 
regimen does not provide improvement of the Grade 3 skin rash to â‰¤ Grade 1 or 
baseline within 30 days, then permanently discontinue Study drug/study regimen For Grade 3 or 4:
-Consult dermatology 
- Promptly initiate empiric IV methylprednisolone 1 to 4 
mg/kg/day or equivalent
-Consider hospitalization
-Monitor extent of rash [Rule of Nines]
-Consider skin biopsy (preferably more than 1) as 
clinically feasible.
-Once improving, gradually taper steroids over â‰¥28 days 
and consider prophylactic antibiotics, antifungals and anti PCP treatment (please refer to current NCCN guidelines for treatment of cancer-related infections [Category 2B recommendation])
-Discuss with Study PhysicianGrade 4 Permanently discontinue study drug/study 
regimen 
CCICELGENE PpriprietetE PROPRIETARY INFORMATIONe Corporae Corpora
ONO
mententTIO tment includtment includ
hydramine odramin
rea cream)ea cream)
ee--strength tostrength to
ment of rashment of ra
s worsening ds worsening 
se of moderase of modera
study physicudy ph
eroids prednieroids predni
Consider sknsider 
recursrAT
nt of nt of 
or or 
rmanently rmanently 
regimen regimen For Grade 3 For Grade 3
-Y
TA
dy drug/studdy drug/studRI
EP
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 110 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
Endocrinopathy 
(eg, 
hyperthyroidism, hypothyroidism, hypopituitarism, adrenal insufficiency, 
etc.)Any Grade 
(Depending on the 
type of endocrinopathy, refer to NCI CTCAE version 4.03 for defining 
the CTC 
grade/severity) General Guidance-Consult Endocrinologist
-Monitor patients for signs and symptoms of 
endocrinopathies.  Non-specific symptoms include headache, fatigue, behavior changes, changed mental status, vertigo, abdominal pain, unusual bowel habits, hypotension and weakness.
-Patients should be thoroughly evaluated to rule out any 
alternative etiology (eg, disease progression including 
brain metastases, infections, etc.)
-Monitor and evaluate thyroid function tests: TSH, free 
T
3and free T 4 and other relevant endocrine labs 
depending on suspected endocrinopathy. 
-If a patient experiences an AE that is thought to be 
possibly of autoimmune nature (eg, thyroiditis, pancreatitis, hypophysitis, diabetes insipidus), the investigator should send a blood sample for appropriate autoimmune antibody testing 
Grade 1
(Depending on the 
type of endocrinopathy, refer to NCI CTCAE version 4.03 for defining the CTC grade 1)No dose modification For Grade 1: (including those with asymptomatic TSH 
elevation)
-Monitor patient with appropriate endocrine function 
tests
-If TSH < 0.5 X LLN, or TSH >2X ULN or consistently 
out of range in 2 subsequent measurements, include FT4 at subsequent cycles as clinically indicated and consider endocrinology consult.
CCIpriprietetPROPRIETARY INFORMATgns and sympgns and sym
Nonon--specific sspecific 
, behavior ch, behavior ch
abdominal pabdominal p
n and weakneand weakn
should be thshould be th
native etiologtive eti
ain metastaseain metastas
Monitor anonitor a
TT3and frdf
dependeATIONe Corporae Corpora
ONO
mententTIO
--IfAT
TAET
P
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 111 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
Grade 2 
(Depending on the 
type of endocrinopathy, refer to NCI CTCAE version 4.03 for defining 
the CTC 
grade/severity 2)For Grade 2 endocrinopathy other than 
hypothyroidism, hold study drug/study 
regimen dose until subject is clinically stable
â€¢ If toxicity worsens then treat as Grade 3 or 
Grade 4 
Study drug/study regimen can be resumed once 
event stabilizes and after completion of steroid taper
   Patients with endocrinopathies who may 
require prolonged or continued steroid replacement can be retreated with study drug/study regimen on the following conditions: 1) the event stabilizes and is controlled, 2) the patient is clinically stable as per Investigator or treating physicianâ€™s clinical judgement, and 3) doses of prednisone are at less than or equal to 10mg/day or equivalent.For Grade 2: (including those with symptomatic 
endocrinopathy)
-Isolated hypothyroidism may be treated with 
replacement therapy without treatment interruption and 
without corticosteroids
-Initiate hormone replacement as needed for 
management
-Evaluate endocrine function, and as clinically indicated, consider pituitary scan
-For patients with abnormal endocrine work up, except 
for those with isolated hypothyroidism, consider short-
term, corticosteroids (eg, 1-2mg/kg/day methylprednisolone or IV equivalent) and prompt 
initiation of treatment with relevant hormone 
replacement (eg, Levothyroxine, hydrocortisone, or sex hormones). -
-Once improving, gradually taper steroids over â‰¥28 days 
and consider prophylactic antibiotics, antifungals and anti PCP treatment (please refer to current NCCN 
guidelines for treatment of cancer-related infections 
[Category 2B recommendation])
-For patients with normal endocrine work up (lab or 
MRI scans), repeat labs/MRI as clinically indicated.
CCICELGENE priprietetE PROPRIETAable able
anâ€™s anâ€™s 
f f 
qual to 10ual to 10
ETARY INFORMATsymptomaticsymptomat
idism may bidism may b
erapy withourapy withou
icosteroidscosteroids
hormone replhormone rep
agementement
valuate endovaluate endo
indicatedicated
-For patFATIONe Corporae Corpora
ONO
mententTIO
for forAT
TA
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 112 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
Grade 3 or 4
(Depending on the 
type of endocrinopathy, refer to NCI CTCAE version 4.03 for defining 
the CTC 
grade/severity 3 or 4) For Grade 3 or 4 endocrinopathy other than 
hypothyroidism, hold study drug/study 
regimen dose until endocrinopathy symptom(s) are controlled
Study drug/study regimen can be resumed once 
event stabilizes and after completion of steroid taper For Grade 3 or 4:
-Consult endocrinologist
-Isolated hypothyroidism may be treated with 
replacement therapy without treatment interruption and 
without corticosteroids
-Promptly initiate empiric IV methylprednisolone 1 to 2 
mg/kg/day or equivalent
-Administer hormone replacement therapy as necessary.
-For adrenal crisis, severe dehydration, hypotension, or 
shock: immediately initiate intravenous corticosteroids 
with mineralocorticoid activity
-Once improving, gradually taper immunosuppressive 
steroids over â‰¥28 days and consider prophylactic 
antibiotics, antifungals and anti PCP treatment (please refer to current NCCN guidelines for treatment of 
cancer-related infections [Category 2B 
recommendation])
-Discuss with study physician
Immune mediated 
Neurotoxicity (to 
include but not limited to limbic encephalitis.autonomic neuropathy,excluding
Myasthenia 
Gravis and 
Guillain-Barre)  Grade of 
Neurotoxicity 
Depending on the 
type of 
neurotoxicity, refer to NCI CTCAE version 4.03 for defining the CTC grade/severity
Any Grade General Guidance -Patients should be evaluated to rule out any altern ative etiology (eg, 
disease progression, infections, metabolic syndromes and 
medications, etc.) 
CCICELpriprietetELGENE PROPRIETARY INFORMATistst
oidism may boidism may b
erapy withouerapy withou
ticosteroidscosteroids
ly initiate emy initiate em
kg/day or equday or 
Administer hdminister hATIONe Corporae Corpora
ONO
mententTIO
For adrenadren
shock:sh
witwi
-AT
TA
OP
GEGeGeGEGEGE
ELGE
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 113 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
-Monitor patient for general symptoms (headache, nausea, vertigo, 
behavior change, or weakness)
-Consider appropriate diagnostic tes ting (eg, electro myogram and 
nerve conduction investigations)
-Symptomatic treatment with neurological consult as appropriate
Grade 1 No dose modifications See â€œAny Gradeâ€ recommendations above.
Grade 2 !For acute motor 
neuropathies or 
neurotoxicity, hold study drug/study regimen dose until resolution to â‰¤ 
Grade 1
!For sensory 
neuropathy/neuropathic pain, consider holding study drug/study regimen dose until resolution to â‰¤ 
Grade 1.
oIf toxicity worsens 
then treat as Grade 3 
or Grade 4 
!Study drug/study regimen
can be resumed once event improves to â‰¤
Grade 1 stabilizes after completion of steroid 
taper -Discuss with the study physician 
-Obtain Neurology Consult 
-Sensory neuropathy/neuropathic pain may be managed by 
appropriate medications (eg, gabapentin, duloxetine, etc.)
-Promptly start systemic steroids prednisone 1-2mg/kg/day PO or IV 
equivalent 
-If no improvement within 3-5 days despite 1-2mg/kg/day 
prednisone PO or IV equivalent consider additional workup and promptly treat with additional immunosuppressive therapy (eg, IVIG)
Grade 3 !Hold Study drug/study 
regimen dose until 
resolution to â‰¤ Grade 1For Grade 3 or 4:
-Discuss with study physician
CCICEpriprietetELGENE PROPRIen 
to to â‰¤ â‰¤
ity worsens ty worse
treat as Gradeat as Grad
r Grade 4  Grade 4 
udy udy drug/studrug/s
can be resumn be r
event ev im
GradGrad
coRIETARY INFORMATIONe Corporae Corpora
ONO
mententTIO (headache, naheadache, n
testing (testing ( eg, eg, e
ns)ns)
ith neurologith neurolAT
mmendationmmendatioOR
study physicudy phy
ology Consulogy Consu
neuropathy/nuropathy/n
priate medicariate m
omptly start somptly start 
equivalent equivalent 
If no impIf no imp
prednired
propr
IFO
GERI
GEGEGE
EGE
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 114 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
!Permanently discontinue 
Study drug/study regimen if Grade 3 irAE does not resolve to â‰¤ Grade 1 
within 30 days.-Obtain Neurology Consult
-Consider hospitalization
-Promptly initiate empiric IV methylprednisolone 1 to 2 mg/kg/day 
or equivalent
-If no improvement within 3-5 days despite IV corticosteroids, 
consider additional workup and promptly treat with additional immunosuppressants (eg, IVIG)
-Once stable, gradually taper steroids over â‰¥28 days
Grade 4 !Permanently discontinue 
study drug/study regimen
Immune-
mediated 
peripheral neuromotor syndromes, such as Guillain-Barre and Myasthenia 
GravisGeneral Guidance -The prompt diagnosis of immune-mediated peripheral neuromotor 
syndromes is important, since certain patients may unpredictably 
experience acute decompensations which can result in substantial morbidity or in the worst case, death. Special care should be taken for certain sentinel symptoms which may predict a more severe outcome, such as prominent dysphagia, rapidly progressive weakness, and signs of respiratory insufficiency or autonomic instability
-Patients should be evaluated to rule out any alternative etiology (eg, 
disease progression, infections, metabolic syndromes and medications, etc.). It should be noted that the diagnosis of immune-mediated peripheral neuromotor syndromes can be particularly challenging in patients with underlying cancer, due to the multiple potential confounding effects of cancer (and its treatments) throughout the neuraxis. Given the importance of prompt and accurate diagnosis, it is essential to have a low threshold to obtain a neurological consult
-Neurophysiologic diagnostic testi ng (eg, electromyogram and nerve 
conduction investigations, and â€œrepetitive stimulationâ€ if myasthenia is suspected) are routinely indicated upon suspicion of such conditions and may be best facilitated by means of a neurology consultation 
Important to consider that the use of steroids as the primary 
treatment of Guillain-Barre is not typically considered effective. Patients requiring treatment should be started with IVIG and followed by plasmapheresis if not responsive to IVIG
CCICELpriprietetELGENE PROPRIELGERIETARY INFORMATIONe Corporae Corpora
ONO
mententTIO
thylprednisothylpredniso
n 33--5 days de5 days d
rkup and prorkup and p
ts((eg, eg, IVIGIVIG ))
dually taper dually tapeAT
t diagnosis ofdiagnosis
es is importais import
ience acute dence acu
rbidity or in rbidity or in
for certain sefor certain se
outcome, outcome
weaknewea
instainst
-PN
RI
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 115 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
Grade 1 No dose modification -Discuss with the study physician
-Care should be taken to monitor patients for sentinel symptoms of a 
potential decompensation as described above
-Obtain a neurology consult unless the symptoms are very minor and 
stable
Grade 2 Hold study drug/study regimen 
dose until resolution to â‰¤ Grade 
1
Permanently discontinue study 
drug/study regimen if it does not resolve to â‰¤ Grade 1 within 
30 days or if there are signs of respiratory insufficiency or autonomic instabilityGrade 2 
-Discuss with the study physician 
-Care should be taken to monitor patients for sentinel symptoms of a 
potential decompensation as described above
-Obtain a Neurology Consult 
-Sensory neuropathy/neuropathic pain may be managed by 
appropriate medications (eg, gabapentin, duloxetine, etc.)
!MYASTHENIA GRAVIS
oSteroids may be successfully used to treat Myasthenia 
Gravis. Important to consid er that steroid therapy 
(especially with high doses) may result in transient worsening of myasthenia and should typically be administered in a monitored setting under supervision of a consulting neurologist.
oPatients unable to tolerate s teroids may be candidates for 
treatment with plasmapheresis or IVIG. Such decisions are best made in consultation with a neurologist, taking intoaccount the unique needs of each patient.
oIf Myasthenia Gravis-like neurotoxicity present, consider 
starting acetylcholine esterase (AChE) inhibitor therapy in 
addition to steroids. Such therapy, if successful, can also 
serve to reinforce the diagnosis.
!GUILLAIN-BARRE: 
oImportant to consider here that the use of steroids as the 
primary treatment of Guillain-Ba rre is not typically 
considered effective. Patients requiring treatment should be started with IVIG and followed by plasmapheresis if not responsive to IVIG.
CCIpriprietetELGECEGENE PROPRIETARY INFOstudy physicudy phy
e taken to me taken to m
ecompensatioecompensaORMATIONe Corporae Corpora
ONO
mententTIO
atients for senatients for s
scribed abovecribed above
unless the symless the syAT
a Neurologya Neurology
nsory neuropasory neurop
appropriate mpropriate m
!!MYAMYA
oO
GERI
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 116 MEDI4736-MM- 005 Final: 03 Oct 2016Immune-Mediated Reactions
Dose Modifications Toxicity Management
Grade 3 Hold study drug/study regimen 
dose until resolution to â‰¤ Grade 
1
Permanently discontinue Study 
drug/study regimen if Grade 3 irAE does not resolve to â‰¤ 
Grade 1 within 30 days or if 
there are signs of respiratory 
insufficiency or autonomic instabilityFor severe or life threatening (Grade 3 or 4) events: 
-Discuss with study physician
-Recommend hospitalization
-Monitor symptoms and obtain neurological consult
!MYASTHENIA GRAVIS
oSteroids may be successfully used to treat Myasthenia 
Gravis.  It should typically be administered in a monitored setting under supervision of a consulting neurologist.
oPatients unable to tolerate steroids may be candidates for 
treatment with plasmapheresis or IVIG.
oIf Myasthenia Gravis-like neurotoxicity present, consider 
starting acetylcholine esterase (AChE) inhibitor therapy in addition to steroids. Such therapy, if successful, can also 
serve to reinforce the diagnosis.
!GUILLAIN-BARRE : 
!Important to consider here that the use of steroids as the 
primary treatment of Guillain-B arre is not typically 
considered effective. Patients requiring treatment should be started with IVIG and followed by plasmapheresis if not responsive to IVIGGrade 4 Permanently discontinue study 
drug/study regimen 
aASCO Educational Book 2015 â€œManaging Immune Checkpoint Blocking Antibody Side Effectsâ€ by Michael Postow MD.
bNCI CTCAE version 4.03.
FDA Liver Guidance Document 2009 Guidance for Industry: Drug Induced Liver Injury â€“ Premarketing Clinical Evaluation.
CCICELGENE PRpriprietetROPRIETARY INFORMATnts: nts: 
in neurologicneurologi
VISVIS
y be successy be success
It should typishould
g under superunder supe
tients unabletients unab
treatment wieatment w
oIf MyIf My asty
startinstartin
adddd
!GATIONe Corporae Corpora
ONO
mententTIOAT
OPRI
t Blocking ABlocking A
y: Drug Indu: Drug Ind
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 117 MEDI4736-MM- 005 Final: 03 Oct 2016Appendix E-2: Durvalumab Treatment Modification and Toxicity Management Guidelines for Infusion-related Reactions
Infusion-Related Reactions
Severity 
Grade Dose Modifications Toxicity Management
Any Grade General Guidance -Management per institutional standard at the discretion of investigator
-Monitor patients for signs and symptoms of infusion-related reactions 
(eg, fever and/or shaking chills, flushing and/or itching, alterations in heart rate and blood pressure, dyspnea or chest discomfort, skin rashes 
etc.) and anaphylaxis (eg, generalized urticaria, angioedema, wheezing, 
hypotension, tachycardia, etc.)
Grade 1 The infusion rate of study drug/study regimen may be 
decreased by 50% or temporarily interrupted until resolution of the eventFor Grade 1 or Grade 2:
-Acetaminophen and/or antihistamines may be administered per 
institutional standard at the discretion of the investigator
-Consider premedication per institutional standard prior to subsequent 
doses
-Steroids should not be used for routine premedication of 
â‰¤Grade 2 
infusion reactions.Grade 2The infusion rate of study drug/study regimen may be 
decreased 50% or temporarily interrupted until 
resolution of the event 
Subsequent infusions may be given at 50% of the initial 
infusion rate
Grade 3/4
Permanently discontinue study drug/study regimenFor Grade 3 or 4:
Manage severe infusion-related reactions per institutional standards (eg, IM epinephrine, followed by IV diphenhydramine and ranitidine, and IV glucocorticoid)
CCICELGENE PROpriprietetROPRIETARY INFORMATIONe Corporae Corpora
ONted Reactited Reac
AT
nagementnagementMA
l standard at standard 
s and symptos and sympt
ing chills, flung chills, flu
d pressure, dyd pressure, 
laxis (axis ( egeg, genge
tachycardia, achycardiaOR
de 2:de 2:
minophen anminophen an
titutional stanitutional stan
Consider preConsider pr
dosesdoses
-Steroero
infinYI
PRenFor FPRPRPR
ROPR
EDMS Doc. Number: Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 118 MEDI4736-MM- 005 Final: 03 Oct 2016Appendix E-3: Durvalumab Treatment Modification and Toxicity Management Guidelines for Non-immune-mediated 
Reactions
Non-immune Mediated Reactions
(Note:  As applicable, for early phase studies, the following sentence may be added: â€œAny event greater than or equal to Grade 2, please discuss with Study Physicianâ€
Severity
Grade of the Event 
(NCI CTCAE 
version 4.03) Dose Modification Toxicity Management
Any Grade Note: dose modifications are not required for adverse events not deemed to be related to 
study treatment (ie, events due to underlying disease) or for laboratory abnormalities not deemed to be clinically significant.Treat accordingly as per institutional 
standard 
1 No dose adjustment Treat accordingly as per institutional 
standard 
2 Hold study drug/study regimen until resolution to â‰¤Grade 1 or baseline Treat accordingly as per institutional 
standard 
3 Hold study drug/study regimen until resolution to â‰¤Grade 1 or baseline
For AEs that downgrade to â‰¤Grade 2 within 7 days or resolve to â‰¤Grade 1 or baseline 
within 14 days, resume study drug/study regimen administration. Otherwise, discontinue study drug/study regimenTreat accordingly as per institutional 
standard 
4 Discontinue Study drug/study regimen (Note for Grade 4 labs, decision to discontinue 
would be based on accompanying clinical signs/symptoms and as per Investigatorâ€™s 
clinical judgment and in consultation with the Sponsor) Treat accordingly as per institutional 
standard 
AChE = acetylcholine esterase; ADA = American Dietetic Association; ADL= activity of daily life; AE = adverse event; ALP = alka line phosphatase; ALT = 
alanine aminotransferase; AST = aspartate aminotransferase; BUN= blood urea nitrogen; CT = computed tomography; CTC= common term inology criteria; GI = 
gastrointestinal; FT4= free T4; ILD = interstitial lung disease; IM = intramuscular; irAE = immune-related adverse event; IV = intravenous; LFT= liver function 
tests; LLN= lower level normal; MRI=magnetic resonance imaging; NCI CTCAE = National Cancer Institute Common Terminology Criter ia for Adverse 
Events; PO = by mouth; TB= total bilirubin; TNF = tumor necrosis factor; TSH = thyroid stimulating hormone; ULN = upper limit o f normal.
CCICELGENE priprietetEP R O P Rfor Grade 4 lfor Grade 
signs/symptosigns/symptoRIETARY INFORMATIONe Corporae Corpora
ON-mediatedmediate
ase discuss wie discuss wiAT
TMA
FOto to 
es not not TreTreFFOFOFOIN
neneRY
or baselineor baselin
esolve to solve â‰¤â‰¤GG
ministration. Onistration. TA
th the h the SponsSponR
ROssociation; sociation; AA
se; ;BUN= bloBUN= b
sease; IM = sease; IM =
nance imaginnance im
= tumor necr= tumor nec
EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 119 MEDI4736-MM- 005 Final: 03 Oct 2016Appendix F: Guideline for Asthma Eligibility Criteria
CCICELGENE PROPRIETARY INFORMATION

EDMS Doc. Number:Durvalumab (MEDI4736)
Protocol MEDI4736-MM-005 Celgene Corporation
Confidential and Propri etary 120 MEDI4736-MM- 005 Final: 03 Oct 2016Appendix F: Guideline for Asthma Eligibility Criteria (Continued)
CCI

EDMS Doc. Number:
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature policies and procedures.
8VHU1DPH
7LWOH'DWH0RQGD\2FWREHU30(DVWHUQ'D\OLJKW7LPH0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
8VHU1DPH
7LWOH'DWH0RQGD\2FWREHU30(DVWHUQ'D\OLJKW7LPH0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
CCIPPD
PPD
PPD
PPD
'D\OLJKW7LPD\OLJKW7L
               